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AMREE	American Medical Research Expedition to Mt Everest
AMS		Acute mountain sickness
AP		Action potential
ARVD		Arrhythmogenic right ventricular dysplasia
CPAP		Continuous positive airway pressure
CXE		Caudwell Xtreme Everest Expedition to Mt Everest
DaO2		Delivery of arterial oxygen
DHF		Diastolic heart failure
DL		Diffusion capacity of the lung
2,3-DPG	2,3 diphosphoglycerate
EAD		Early afterdepolarisation
E/A ratio	Ratio of the early (E) and late (A) ventricular filling velocities
EBC		Mt Everest Base Camp 
ECG		Electrocardiogram
FIO2		Fraction of inspired oxygen
H	Huffner’s Constant is the volume of oxygen that is bound to 1g of haemoglobin (1.34mls)
HACE	High altitude cerebral edema
HAPE	High altitude pulmonary edema
[Hb]		Concentration of haemoglobin in whole blood
HCVR		Hypercapnic ventilatory response




kPa		Kilopascal (1000Pa = 1kPa)
LVEDV	Left ventricular end diastolic volume
LVESV	Left ventricular end systolic volume
LVH		Left ventricular hypertrophy
MPAP		Mean pulmonary artery pressure
OEII		Operation Everest II
OSA		Obstructive sleep apnoea
P50		PaO2 at which 50% of the haemoglobin molecules are saturated
PaO2		Partial pressure of arterial oxygen
PAO2		Partial pressure of alveolar oxygen
PACO2		Partial pressure of alveolar carbon dioxide
PASP		Pulmonary artery systolic pressure
PB		Barometric pressure
PH		Pulmonary hypertension
PIO2		Partial pressure of inspired oxygen




QTc		QT interval corrected using Bazett’s formula unless otherwise specified
R		Respiratory exchange ratio
RVH		Right ventricular hypertrophy
RVOT		Right ventricular outflow tract
SaO2		Arterial oxygen saturation
SCD		Sudden cardiac death
SVR		Systemic vascular resistance 



















Objective: This thesis sets out to identify the rate, rhythm and morphological changes that occur in the ECG’s of healthy lowland residents who are exposed to hypoxic conditions at sea level and high altitude.
Methods: Three separate ECG studies were performed on healthy lowland residents. The first was conducted on 16 members of the Caudwell Xtreme Everest Expedition (CXE) during a stay at Mt Everest Base Camp (EBC) (5300m). The second was conducted on 37 members of the Team Everest Expedition (TE) during an ascent to EBC. Finally, a group of 10 participants were studied whilst breathing a range of hypoxic gas mixtures (12-18% oxygen) at sea level (AHS).    
Results: Rate - CXE - The median resting heart rate increased following ascent to Mt Everest Base Camp (EBC) (5300m) (P<0.05). TE - The mean resting heart rate of male and female participants increased following ascent to Namche Bazaar (3500m) (P<0.05). Rhythm – CXE, TE and AHS: No significant difference was observed in the incidence of atrial or ventricular ectopics following ascent to Mt Everest Base Camp (5300m). Morphology – CXE: The sum of P wave amplitudes in II, III and aVF increased at EBC (P<0.05). The T wave amplitude in V1 decreased at EBC (P<0.05). QTc (Bazett’s and Fridericia’s) increased on arrival at EBC (P<0.05). TE: QTc (Bazett’s and Fridericia’s) increased on ascent to high altitude. QTc (Bazett’s) increased following ascent from Namche Bazaar (3500m) to Gorak Shep (5200m) (P<0.05). AHS: QTc (Bazett’s and Fridericia’s) increased in hypoxia (P<0.05).
Conclusion: Significant changes in rate, rhythm and morphology occur in healthy lowland residents who are exposed to hypoxic conditions.
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CHAPTER 1 – INTRODUCTION
1.1	The high altitude environment

The highest of mountains is capable of severity, a severity so awful and so fatal that the wiser sorts of men do well to think and tremble even on the threshold of their high endeavour.
[Mallory, 1921]

The physiological and psychological demands placed upon those who venture to high altitude are considerable [Houston, 1996]. Whilst a wide range of environmental factors play their part, it is the fall in barometric pressure (PB) and consequently, the reduction in the partial pressure of oxygen (PO2), that has the greatest impact upon human physiology [Ward et al, 2000]. A reduction in the oxygen available to the body’s tissues is commonly referred to as hypoxia. As Peter Wagner, a leading high altitude physiologist once stated, “the essence of high altitude is hypoxia” [Wagner, 2001].
Historically, the PB at any given altitude has been determined by using a model atmosphere calculation [West, 1996]. Modern altimeters, including those used on wrist watches, are calibrated using the United States Standard Atmosphere (USSA). To obtain a PB for any given altitude, the USSA assumes a sea level temperature of 15 degrees C and a linear decrease in temperature (6.5 degrees C / km) up to an altitude of 11 km. This has the tendency to underestimate altitude [West, 1996]. More recently the eminent physiologist John West has used a quadratic equation “of best fit” to determine PB. Provided that the height above sea level in kilometres (h) is known, this equation gives an estimate of PB with, “minimal errors over a large range of altitudes” [West, 1999]. Therefore the quadratic equation “of best fit” is used throughout this thesis:
PB (mmHg) = e(6.63268-0.1112h-0.00149hh)
According to Dalton’s Law, each of the gaseous components in air exerts a pressure according to its own concentration. Therefore, any fall in PB will result in a proportional reduction in the partial pressure of oxygen (PO2).  If we assume that oxygen comprises 20.93% of the atmosphere, the PO2 can be calculated across a range of different altitudes (Figure 1.1). 


Figure 1.1: Barometric pressure (PB) (dark grey) and partial pressure of oxygen (PO2) (light grey) calculated between 1km and 10km in 1km increments using West’s quadratic equation [West, 1996].

Since the relationship between PB and altitude is linked by a quadratic equation, the PO2 declines rapidly at altitudes commonly occupied by human populations (Table 1.1).

	0m	1000m	2000m	3000m	4000m	5000m
Barometric Pressure (PB) (kPa)	101.3	90.5	80.6	71.6	63.4	56.0
Partial Pressure of Oxygen (PO2) (kPa)	21.2	18.9	26.6	15.0	13.3	11.7
PO2 as a percentage of sea level PO2 (%)	100.0	88.8	79.5	70.6	62.5	55.2

Table 1.1: The calculated barometric pressure (PB) and partial pressure of oxygen (PO2) between sea level and 5000m.

At what point does the fall in PO2 have a significant effect upon the human body? Whilst minor changes in organ function and physical performance have been reported at modest heights of 1000 to 2000m, the most significant adaptations occur at greater altitude. The exact point at which this occurs varies from individual to individual. For the benefit of this thesis, an altitude of 3000m above sea level has been chosen. This is consistent with the work of West who wrote,















1.2	The high altitude population

Lack of oxygen dulls the mind and judgement, slows the reflexes, weakens the muscles, and takes away our higher faculties. The higher one goes, the more serious are these effects. Too many people forget this exactly at a time when they should be most responsive to the danger.
[Houston, 1996]

A significant fall in PO2 affects a significant proportion of the world’s population. According to studies conducted by the World Health Organisation, more than 400 million people live in mountainous regions [WHO, 2008]. Whilst the majority of these individuals live in valleys, significant numbers reside at high altitude. According to the WHO, 89.3 million live above 2500m, 25.9 million above 3500m and 5.4 million above 4500m [WHO, 2008]. Of the highest capital cities in each continent, four are situated above 2000m. In La Paz, the world’s highest capital, approximately 2.4 million residents live at altitudes of up to 4100m. Many of these residents are exposed to a PO2 that is approximately two thirds of that found at sea level (Table 1.2).
The high altitude population is often increased by tourists, religious pilgrims and economic migrants. Whilst their numbers are difficult to quantify there is evidence to suggest that these are increasing. The amount of trekkers visiting Nepal rose by 330% from 1982 to 1994 and by 450% from 1994 to 2000 [Gaillard, 2004]. In the last decade the number of trekkers visiting Nepal’s Sagarmatha National Park has also risen sharply. Despite enormous political unrest, those walking in the foothills of the world’s highest mountain have risen by 60.5% (Figure 1.2).








Table 1.2: The barometric pressure and partial pressure of oxygen at the highest capital cities of each continent. 


Figure 1.2: The number of visitors who entered Sagamartha National Park from 1998 to 2011. 
The value for 2011 did not include visitors during November and December. Data points were displayed at the entrance of the Sagamartha National Park in October 2011.

The numbers of mountaineers venturing above 6000 m have also increased. In the 40 years between 1950 and 1990, 19810 climbers attempted the highest peaks in Nepal compared to 30141 between 1990 and 2006 [Salisbury and Hawley, 2008]. At these altitudes, the PO2 is approximately one half of that found at sea level. Despite this fall, large numbers of mountaineers go even higher. Between 1990 and 2006, 20145 mountaineers made attempts on the fourteen 8000m peaks and therefore exposed themselves to the lowest barometric pressures found on the planet [Salisbury and Hawley, 2006]. Over the last thirty years, two PB recordings have been obtained from the summit of Mt Everest. On October 24th 1981 Chris Pizzo recorded 253mmg, whilst on May 23rd 1997, the mountaineer and film-maker, David Breashers obtained a PB of 252.5mmHg [West et/al, 1983, West, 1999]. Whilst these two single measurements should be interpreted with caution, their closeness to West’s calculated value (253mmHg) means that they are likely to represent the true barometric pressures encountered by Pizzo and Breashers on the summit of the world’s highest mountain [Ward et/al 2000]. These correspond to PO2 values of just 7.1 and 6.8kPa. Compared to sea level, this represents a fall of more than two thirds in the partial pressure of oxygen available to those standing on the summit of Mt Everest. 












1.3	The impact of the high altitude environment upon tissue oxygenation

That sunny dome! Those caves of ice!
And all who heard should see them there,
And all should cry, Beware! Beware!

Excerpt from “Kubla Khan” by Samuel Taylor Coleridge
	
Historically, when measuring the impact of hypoxia upon tissue oxygenation, high altitude physiologists have focused upon the reduction in the delivery of arterial oxygen (DaO2). This is determined by multiplying cardiac output (Q) with the oxygen content of arterial blood (CaO2):
DaO2 = Q x CaO2
CaO2 is calculated by adding the amount of oxygen bound to haemoglobin to that dissolved in plasma:
CaO2 = Volume of oxygen dissolved in plasma + Volume of oxygen bound to haemoglobin
(PaO2 x 0.03) + ([Hb] x 10 x SaO2 x H) = mls O2 per litre of blood
Where:
[Hb] - concentration of haemoglobin in whole blood (g/dl).
SaO2 - arterial oxygen saturation given as a proportion (ie 99% is 0.99).
H- Huffner’s Constant is the volume of oxygen that is bound to 1g of haemoglobin (1.34mls)
Three factors are therefore necessary to calculate CaO2: the partial pressure of arterial oxygen (PaO2), the arterial oxygen saturation (SaO2) and the haemoglobin concentration [Hb]. A fall in any one of these can reduce tissue oxygenation and impair normal cell function. This state is commonly referred to as hypoxia. Following a period spent at high altitude, the PaO2, SaO2 and [Hb] are subject to changes that increase CaO2 and therefore alleviate hypoxia. These changes are described in more detail below:
1.3.1	The partial pressure of arterial oxygen (PaO2)
Once inspired, the partial pressure of oxygen (PO2) falls in three steps before reaching the arterial circulation. These steps are commonly referred to as the “Oxygen Cascade” and can be determined at all altitudes (Figure 1.3) [West et/al 1983].


Figure 1.3: The Oxygen Cascade. The partial pressures of oxygen in the ambient air, inspired into the upper airways, alveoli and arterial circulation at sea level and on the summit of Mt Everest [West et al 1983].

-Ambient to Inspired 
As air passes through the nose, mouth, larynx and trachea a process of heating and humidification occurs. This results in water vapour displacing inhaled gas molecules and reducing the partial pressure of inspired oxygen (PIO2). The PIO2 can be determined by subtracting the saturated water vapour pressure (SWVP) measured at body temperature (6.3kPa) from PB and multiplying the difference by the fraction of inspired oxygen (FIO2):
PIO2 = (PB – 6.3) x 0.2093
Since the barometric pressure and duration of stay at altitude has no effect upon SWVP, PIO2 remains constant at all altitudes.
-Inspired to Alveolar
As inspired gases enter the alveoli the PIO2 falls further still. This is largely the result of the addition of carbon dioxide (CO2) and the uptake of oxygen by the body’s tissues. The alveolar partial pressure of oxygen (PAO2) can be measured directly from samples of expired gas or calculated by using the Alveolar Gas Equation. To use this equation it is therefore necessary to know the PIO2, the partial pressure of carbon dioxide (PAO2) and the respiratory exchange ratio (R):
PAO2 = PIO2 – PACO2 / R
From Figure 1.3 it can be seen that the difference between the PIO2 and PAO2 is far lower on Everest’s summit (0.8kPa) than that found at sea level (6.0kPa). This is due to the combined effects of two physiological phenomena that occur following prolonged exposure to high altitude – the Hypoxic Ventilatory Response (HVR) and the Hypercapnic Ventilatory Response (HCVR) [Rahn and Otis, 1949] [Kellogg, 1963]. When PAO2 falls below approximately 8kPa (equivalent to an altitude of approximately 3000m) the peripheral chemoreceptors in the carotid and aortic bodies are stimulated, prompting neurotransmitter release along the carotid sinus and stimulation of higher centres responsible for ventilation (HVR) [Rahn and Otis, 1949]. However any increase in the rate or depth of breathing normally leads to a fall in PACO2 and a subsequent reduction in ventilation. Why? A fall in PCO2 results in a leftward shift in the carbonic acid / bicarbonate buffer system (CO2 + H2O – H2CO3 – H+ + HCO3-) and a fall in [H+] concentration in the cerebrospinal fluid. Central chemoreceptors within the medulla oblongata are sensitive to [H+] and trigger a reduction in higher centre activity when exposed to a lower concentration (HCVR) [Nattie 2002]. The relationship between [H+], PCO2 and [HCO3-] is described by the Henderson Hasselbalch equation:
[H+] = PCO2 / [HCO3-]












Table 1.3: The predicted alveolar gas measurements in unacclimatized and acclimatized mountaineers at 8400m. 
A sea level PACO2 and R were assumed (5.1kPa and 0.85). The PIO2 at 8400m was calculated using West’s quadratic equation. PACO2 and R values of acclimatized mountaineers were obtained from [Grocott et/al, 2009].
According to Table 1.3, if sea level ventilation is maintained at 8400m the PAO2 would be just 0.3KPa. This is clearly incompatible with life! However following a period of acclimatisation the level of ventilation increases and the PaCO2 falls. At 8400m the mean measurements of four Everest summiteers revealed a PACO2 of 1.6KPa and a PAO2 of 4.0KPa [Grocott et al, 2009]. At this PAO2 it is possible for small numbers of mountaineers to reach the summit of the world’s highest mountains and return safely.
-Alveolar to Arterial 
The final step in the Oxygen Cascade occurs at the alveolar capillary membrane. The fall in PO2 that occurs at this site is commonly referred to as the alveolar-arterial PO2 difference (A-a)PO2. At sea level the (A-a)PO2 is caused largely by the imbalance that exists between alveolar ventilation (V) and pulmonary capillary blood flow (Q). In the ideal lung model, ventilation is distributed equally to all parts of the lung and matched by a similar distribution of blood flow (V:Q=1). However in healthy individuals at sea level this does not occur and V:Q ratios vary widely throughout the lung. An infinite V:Q ratio is found in parts of the lung that are not in contact with the alveolar capillary membrane, whilst a V:Q ratio of 0 occurs when only perfusion takes place. This is commonly referred to as “shunt” and occurs in healthy individuals when deoxygenated blood from bronchial and Thebesian vessels enters the pulmonary veins and passes into the arterial circulation. Shunt can also occur in a number of extrapulmonary (eg congenital heart disease, pulmonary embolism) and intrapulmonary (eg atelectasis, infection) diseases. 
At heights of up to 4500m, changes in the matching of alveolar ventilation to capillary blood flow means that V:Q ratio often improves and (A-a)PO2 is significantly reduced [Dawson, 1972]. Amongst four naval volunteers placed in a small hypobaric chamber for 32 days, the (A-a)PO2 was less than 1.3KPa in the vast majority of measurements obtained at simulated altitudes of up to 15000 feet (4500m) [Houston and Riley, 1947].  However at higher altitudes, especially during exercise, the (A-a)PO2 rises and the proportion of (A-a)PO2 to PAO2 begins to increase [Wagner et al 1987]. During the Silver Hut Expedition, volunteers at 5600m experienced a (A-a)PO2 of 3.5KPa during maximal exercise [West et al, 1962]. At altitudes of more than 6300m, AMREE researchers found that (A-a)PO2 ranged between 1.1 and 2.8KPa, representing 23 and 40% of PAO2 respectively [West et al, 1983]. Whilst mismatches in ventilation and blood flow might explain (A-a)PO2 at sea level and altitudes up to 4500m, at higher elevations the (A-a)PO2 is influenced by changes in the ability of oxygen to diffuse across the alveolar capillary membrane [Wagner, 2001]. According to Fick’s Law of diffusion, the volume of gas (V) transferred through a sheet of tissue is proportional to the area of tissue (A) and the difference in gas partial pressures between the two sides (P1-P2), whilst being inversely proportional to tissue thickness (T). Therefore, if D is the diffusion constant:
V = A x D x (P1-P2) / T
As AD/T is the diffusion capacity of the lung (DL) the equation can be rewritten:
V = DL x (P1-P2)
Since oxygen extraction is largely unchanged during rest and sub-maximal exercise at altitude, the difference between the partial pressures of oxygen in the alveolus (P1) and venous blood (P2) falls. Therefore the volume of oxygen transferred across the alveolar capillary membrane is reduced and the (A-a)PO2 increases. However to accurately calculate the rate of oxygen transferred into the blood, it is necessary to take into account the way in which oxygen binds to haemoglobin. As we will see in the next section, the affinity of haemoglobin for oxygen is not constant and depends instead upon the number of oxygen receptor sites that are occupied on the haemoglobin molecule. The relationship linking the partial pressure of oxygen and the saturation of haemoglobin molecules is described by the Oxyhaemoglobin Dissociation Curve (Figure 1.5). In order to calculate the transfer of oxygen from the lungs to the haemoglobin (V), the slope of the curve (β) and cardiac output (Q) must be taken into account:
V = (P1 – P2) x β x Q x (1 – e-DL/(Q x β))
Given that humans at high altitude often occupy the steepest parts of the curve, 1 - e-DL/(Q x β) will tend towards zero and cause V to fall sharply.  As we reach higher elevations diffusion limitation therefore appears to play an increasing role in determining (A-a)PO2. 
So far we have assumed that DL remains constant throughout an ascent to altitude. However in some individuals the alveolar capillary membrane is damaged and DL is reduced. High Altitude Pulmonary Edema (HAPE) is a life threatening disease that occurs in 0.2-15% of healthy individuals who ascend to altitudes between 2500 and 5000m [Luks and Swenson, 2007]. HAPE results from a breakdown of the alveolar capillary membrane and the accumulation of a protein rich fluid in the respiratory tract. Whilst the causes of HAPE are not completely understood, it is thought that the alveolar capillary membrane is damaged by a rise in pulmonary artery pressure. As we shall see later, hypoxic pulmonary vascoconstriction (HPVR) is a normal physiological response that is seen in humans at altitude. However for reasons that are as yet unknown, an increase in pulmonary artery pressure can prove fatal in some individuals. In recent years small amounts of edema (otherwise known as, “sub-clinical pulmonary edema”) have been found in the lungs of large numbers who ascend to altitude [Cremona et al, 2002] [Pratali et al, 2010]. During a Himalayan trek to Gorak Shep (5130m), 15/18 at 3440m and 18/18 trekkers at 4790m had ultrasonic evidence of subclinical pulmonary edema [Pratali et al, 2010]. Meanwhile in a larger study of 262 climbers ascending Monte Rosa (4559m), three quarters were found to have radiographic evidence of edema following a stay of 24 hours in a hut on the summit [Cremona et al, 2007]. Given that the thickness of the alveolar capillary membrane is less than 0.3mm in places, small volumes of edema may represent a significant additional barrier to gas exchange and contribute to the relative increase in (A-a)PO2 seen at high altitudes [Wagner, 2001]. 

1.3.2	The arterial oxygen saturation (SaO2)
The arterial oxygen saturation (SaO2) is the percentage of haemoglobin molecules that are saturated with oxygen. Therefore:
SaO2 = (Oxygen Content of Haemoglobin / Oxygen Capacity of Haemoglobin) x 100
The relationship between SaO2 and PaO2 is described by the Oxyhaemoglobin Dissociation Curve (Figure 1.5). 


Figure 1.5: The Oxyhaemoglobin Dissociation Curve.

The sigmoidal shape of the curve is due to changes in oxygen affinity that occur as binding sites are occupied. As oxygen molecules attach to haemoglobin, the affinity for the gas increases. This is reflected by the sharp fall in SaO2 that occurs at high altitude. Whilst PaO2 falls rapidly on ascent, the SaO2 is at first preserved. At 3000m the PaO2 typically falls by a third - from 12.7 to 8.7kPa. However the reduction in SaO2 tends to be in the region of just 5 to 15 percentage points [Grover and Bartsch, 2001]. With further ascent the affinity for oxygen falls and the decline in SaO2 becomes more precipitous. During OEII the mean SaO2 fell to 76% at 6100m, 68% at 7620m and 59% at 8840m [Reeves et al, 1987]. Whilst at 8400m on Mt Everest, the SaO2 of four CXE mountaineers ranged from 34% to 68% [Grocott et al, 2009]. Although the shape of the curve does not change at high altitude, shifts along the x axis are common. A movement to the left is caused by an increase in pH and decreases in temperature, PaCO2 and the concentration of circulating 2,3 diphosphoglycerate (2,3-DPG), whilst a shift to the right is the result of a decrease in pH and increases in temperature, PaCO2 and 2,3-DPG. The PaO2 at which 50% of the haemoglobin molecules are saturated is known as P50. At sea level P50 is approximately 3.6KPa. A shift of the curve to either the left or the right will affect this value. On first exposure to high altitude, the increase in ventilation causes hypocapnia and respiratory alkalosis. This results in a leftward shift of the Oxyhaemoglobin Dissociation Curve and a reduction in P50. Whilst movement to the left encourages oxygen to bind to haemoglobin, this can limit its release into the tissues. Therefore the body makes efforts to ensure that P50 is maintained at a value that ensures a balance between the binding and release of the oxygen. This is achieved by two processes:
-Increase in Bicarbonate Excretion
 	As we have already seen, in order to maintain high levels of ventilation at altitude the human body excretes bicarbonate. Unfortunately metabolic compensation is slow to occur and is often incomplete. At altitudes of between 3000 and 4000m pH values tend towards the upper limits of the normal range (7.35-7.45) [Lenfant et al, 1971] [Severinghaus et al, 1963]. At higher elevations pH values tend to stray even further. Despite long periods of acclimatisation at 5800m, residents of the Silver Hut were found to have pH measurements of between 7.41 and 7.46 [West et al, 1962]. Amongst AMREE members stationed at 6300m the mean pH was found to be 7.47 [Winslow et al 1984]. At 8400m on Mt Everest the arterial pH of four summiteers ranged from 7.45 to 7.60, whilst the calculated pH of two AMREE members breathing a PIO2 equivalent to the summit was found to be 7.72 and 7.78 respectively [Grocott et al, 2009] [Winslow et al, 1984]. Although the kidneys are capable of restoring normal pH values up to an altitude of 4000m, at greater elevations metabolic compensation becomes increasingly inadequate. To restore sea level P50 a further adaptive process is therefore required. 
-Increase in Circulating 2,3 Diphosphoglycerate (2,3-DPG)
Under hypoxic conditions cells rely increasingly upon anaerobic metabolism to satisfy their energy requirements. Using anaerobic glycolysis, cells are able to generate small quantities of adenosine triphosphate (ATP) from glucose without the need for oxygen. Unlike other cells, the erythrocyte has an additional step in the glycolytic pathway. Instead of converting 1,3-diphosphoglycerate directly into 3-phosphoglyerate, 2,3-diphosphoglycerate (2,3-DPG) is first produced.  On an ascent to altitude the concentration of circulating 2,3-DPG increases. During OEII, concentrations of 2,3-DPG were found to rise with increasing hypoxia  from 1.7mmol/l at sea level to 3.8mmol/l at a simulated altitude of 8848m [Wagner et/al 2007]. Since 2,3-DPG is known to increase P50, the rise in 2,3-DPG ensures that the Oxyhaemoglobin Dissociation Curve is shifted back towards the right. Whether this is enough to restore sea level P50 is unclear. At altitudes of up to 6300m P50 tends towards normal values provided individuals are healthy and well acclimatized [Winslow et al, 1984] [Wagner et al 2007]. However above these heights the P50 appears to depend upon the degree of respiratory alkalosis present. The pH and PACO2 of Chris Pizzo on the summit of Mt Everest was found to be 7.75 and 1kPa respectively, leading the AMREE team to calculate a P50 value of 2.5kPa. However in a recent analysis of OEII results, Wagner and colleagues found that P50 remained between 3.5 and 3.6kPa in all five sedentary participants exposed to a simulated altitude equivalent to the summit of Mt Everest. Since the mean pH and PACO2 were 7.56 and 1.4kPa respectively, the authors argue that whilst the sedentary volunteers on OEII were able to achieve normal measurements, exercising mountaineers such as Pizzo were unable to compensate due to profound levels of respiratory alkalosis.
The increases seen in bicarbonate excretion and 2,3-DPG production go some way towards restoring normal levels of P50 at altitude. However these take time to occur and in many individuals this process is incomplete. In many cases the P50 will therefore be less than 3.6kPa and the Oxyhaemoglobin Dissociation Curve will shift to the left. Fortunately there is evidence to suggest that this may not be as detrimental as it might first appear. Animal studies and mathematical modelling work have both demonstrated that a small shift to the left may in fact be advantageous in hypoxia. [Bencowitz et al, 1982] [Eaton et al, 1974] [Turek et al, 1978]. In rats whose curve was shifted to the left by the administration of cyanate, they were not only found to have better tissue oxygenation in a hypoxic environment but were also found to survive longer [Eaton et al, 1974] [Turek et al, 1978]. Mathematical modelling has also shown that a shift to the left is beneficial in the presence of hypoxia [Bencowitz et al, 1982] [Turek et al, 1978]. In models that have assumed a degree of diffusion limitation, results demonstrate a consistent increase in tissue PO2. On balance, the increase in oxygen binding in the lungs caused by a small fall in P50 does not appear to interfere with the unloading of the gas in the peripheral capillaries and may enhance oxygen delivery to the tissues [Ward et al, 2001].

1.3.3 	The haemoglobin concentration [Hb]
Haemoglobin is a metalloprotein contained within erythrocytes that is responsible for the carriage of oxygen within the circulation. The production of haemoglobin molecules is strictly controlled by the release of erythropoietin. Erythropoietin is a glycoprotein hormone that is synthesised predominantly in the kidneys and is released following a fall in tissue oxygenation. On ascent to high altitude erythropoietin production rises rapidly, triggering the release of red cells and a rise in the concentration of circulating haemoglobin [Huff et al, 1951] [Refnaforje et al, 1959]. This may take several weeks or months to occur [Abbrecht and Littell, 1972]. In the short term, haemoglobin concentration is increased by a rapid redistribution of total body water, with fluid being shifted out of the circulation and deposited into the interstitial space [Pugh, 1964]. This process tends to occur within days of arriving at altitude and has, “the potential to provide mountaineers with an important boost during the first few weeks at altitude” [Windsor and Rodway, 2007]. Over the course of 10 days spent on the summit of Pike’s Peak (4300m) haemoglobin concentrations have been shown to rise by approximately 15%, with most of the increase occurring within the first two days of arrival [Douglas et al, 1913]. As red cell production increases, the haemoglobin concentration continues to rise. After one year at altitude, red cell mass and haemoglobin concentration are approximately 30% greater than that found at sea level [Hultgren, 1997].
1.3.4	The relationship between CaO2 and tissue oxygenation
Over time spent at high altitude the haematological and respiratory changes are capable of offsetting, to some degree, the fall in CaO2 (Figure 1.6). 


Figure 1.6: The partial pressure of arterial oxygen (mmHg), arterial oxygen saturation (%), haemoglobin concentration (g/l) and arterial oxygen content (mls/l) of well acclimatized mountaineers at 75m, 5300m and 6400m on Mt Everest [Grocott et al, 2009].

However this does not imply that sea level tissue oxygenation is maintained. The diffusion of oxygen across a membrane is determined by Fick’s Law of Diffusion: 
V = A x D x (P1-P2) / T
Since P1 of oxygen falls on ascent to altitude, the volume of gas being transferred from the capillaries to the tissues is reduced. This is overcome by a number of changes that occur within the tissues: 
-An increase in capillary density occurs on ascent to high altitude. Following 40 days at simulated ascent of Mt Everest, needle biopsies from 6 healthy volunteers demonstrated that this increase in capillary density was due to a reduction in the cross sectional area of Type I (25%) and II (26%) vastus lateralis muscle fibres rather than a direct increase in the number of capillaries present [Greene et al, 1989]. Indeed, more recent work in well acclimatized visitors to 4100m was unable to show any increase in the expression of genes known to control angiogenesis [Lundby et al, 2004]. However, the effect of an increase in capillary density is likely to be limited since the journey through serum, capillary walls and interstitial tissues is considerable – as much as 50µm to 100µm. Therefore a significant fall in oxygen diffusion is still to be expected and further adaptations to hypoxia will be needed if successful cellular function is to continue. 
-Transfer of oxygen through muscle tissues is facilitated by myoglobin. Myoglobin is a cytoplasmic hemoprotein that consists of a single polypeptide chain of 154 amino acids that binds reversibly with oxygen to facilitate the movement of the gas within cardiac myocytes and oxidative skeletal muscle. Unlike haemoglobin, the single oxygen binding site of myoglobin has a hyperbolic rather than a sigmoidal oxygen dissociation curve, allowing molecules to bind rapidly to oxygen at low PO2 and act as a store prior to delivering the gas into the mitochondria (Figure 1.7). 

Figure 1.7: The Myoglobin Oxygen Dissociation Curve 
The low P50 of myoglobin (0.4KPa) ensures that oxygen rapidly binds at the low PO2 values that are commonly found within the muscle.

Following hypoxic exposure, myoglobin concentrations in the muscles of a number of different animals have been shown to increase. Similar findings have also been seen in humans. Controlling for changes in muscle fibre diameter, biopsies of sartorius muscles in healthy humans born at altitude (4400m) revealed higher concentrations of myoglobin (7.03mg per g of muscle) compared to those born at sea level (6.07mg per g of muscle) [Reynafarje 1962]. Such an increase in myoglobin concentration facilitates the diffusion of oxygen towards the mitochondria and reduces the fall in PO2 within the cell cytoplasm.
-Mitochondria are the final destination for the majority of oxygen molecules inspired by the human body. Following ascent to high altitude the mitochondrial volume density (volume of mitochondria per volume of tissue) is initially preserved, however following a prolonged stay there is significant reduction. Following 19 days of exposure up to altitudes of approximately 5300m, members of Caudwell Xtreme Everest (CXE) saw no or little change in mitochondrial volume density. However in 12 healthy volunteers who spent 66 days at high altitude, significant reductions in the volumes of intermyofibrillar (14.3%) and subsarcolemmal (73.1%) mitochondria were observed [Levett et al, 2012]. These changes are commonly accompanied by an increase in pale pigmented granules known as lipofuscin. Whilst little is known about this substance, it is believed to contain the breakdown products of a number of organelles, including mitochondria. Following 8 weeks of exposure to altitudes of above 5000m, biopsies from the vastus lateralis of 7 mountaineers revealed a 235% increase in lipofuscin density [Martinelli et al, 1990]. 
Two pathways have been cited for the decline in mitochondrial volume density:
-Hypoxia inducible factor 1 (HIF-1) has been described as the, “master regulator for many of 
the body’s adaptive responses” [Murray, 2009]. Following hypoxic exposure, HIF-1 levels rise and trigger hypoxia response elements (HRE’s) in a number of different genes. Transcriptional coactivator peroxisome proliferator activated receptor coactivator-1alpha (PGC-1alpha) is the leading regulator of mitochondrial genesis and function. In hypoxic renal cancer cells levels of PGC-1alpha have been shown to fall in a HIF-dependent manner [Zhang et al, 2007]. Following 66 days at high altitude, levels of skeletal muscle PGC-1alpha in healthy mountaineers have been shown to fall by 35% [Levett et al, 2012]. HIF also controls the regulation of pro-apoptotic protein BCL2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) which is found on the mitochondrial membrane. Following hypoxic exposure levels of BNIP3 have been shown to rise in rat hearts and lead to the breakdown of mitochondrial membrane and autophagy [Murray, 2009]. These findings would go some way to suggesting that a coordinated response is triggered allowing downregulation of mitochondrial biogenesis and therefore a reduction in demand consistent with a fall in oxygen supply.
-Local factors may also play a significant part. Changes in PO2 levels within the cells can result in the production of high levels of reactive oxygen species (ROS) [Murray, 2009]. This has been extensively studied in hyperoxia, where the mitochondrial production of oxygen ions and perioxides has been linked to lung and retinal damage in newborn children. However the generation of ROS in hypoxia is far from clear. Nevertheless there is growing evidence to support the generation of ROS in hypoxia [Clanton, 2007]. This has the potential to impair mitochondrial function and inhibit muscle contraction, indirectly preserving energy stores in a low energy state.
At altitudes of more than 5000m, the reduction in mitochondrial volume density following prolonged exposure to high altitude is also accompanied by a fall in a number of mitochondrial enzyme levels. Whilst the glycolytic pathway is only moderately affected, enzymes required for oxidative metabolism are significantly reduced. After an ascent of Mt Everest, seven mountaineers were found to have reduced concentrations of enzymes involved in both the Krebs cycle (including citrate synthase and maleate dehydrogenase) and electron transport chain (cytochrome oxidase) [Howald et al, 1990]. Similarly, in the OEII hypoxic chamber study significant decreases in citrate synthase and succinate dehydrogenase, both vital to oxidative phosphorylation, were observed in volunteers exposed to a PO2 comparable with the summit of Mt Everest [Green et al, 1992]. 
Despite our ability to increase CaO2 at altitude, a dramatic fall in oxygen diffusion is seen across a series of different interfaces and limits the passage of the gas into the cells. The human body responds by reducing the number of mitochondria and in turn, the capacity of the cells to utilise oxygen. This is best illustrated by the fall in maximum oxygen consumption (VO2 max) that is seen in well acclimatized individuals at altitude. VO2 max at sea level ranges from 3 to 5 l/min, however on the summit of Mt Everest it has been estimated at approximately 1 l/min (Figure 1.8). The addition of supplemental oxygen at altitude does not restore VO2 max in well acclimatized individuals, implying that the extensive cellular changes that occur during the acclimatisation process cannot be reversed by a brief increase in PO2 [Cerretelli, 1976]. Rather than maintain sea level rates of ATP production, cells undergo considerable change and switch their focus towards survival. The implications of this choice on the heart will be discussed in the next two sections.


Figure 1.8: The mean VO2 max (l/min) measurements of well acclimatized AMREE volunteers. Measurements at 8050m and 8848m were obtained at 6300m whilst breathing hypoxic mixtures that ensured a PO2 similar to that found at the given altitude [West et al, 1983].

 
1.4	The impact of the high altitude environment upon the healthy human heart

My panting mule slackened his pace, and seemed unwilling to mount a rather steep ascent which we had now arrived at. To relieve him I dismounted, and began walking at a rapid pace. But I soon felt the influence of the rarefied air, and I experienced an oppressive sensation which I had never known before. I stood still for a few moments to recover myself, and then tried to advance. My heart throbbed audibly; my breathing was short and interrupted. A world’s weight seemed to lie upon my chest…
	[Tschudi, 1847]

	The cardiac output (Q) of healthy humans increases within minutes of ascending to high altitude. This observation was first made in resting volunteers by the eminent physiologists C. G. Douglas and J. S. Haldane during ground-breaking experiments on Pike’s Peak (4300 m) in 1911 (Figure 1.9) [Douglas et al, 1913]. On the same mountain sixty years later, researchers were also able to confirm that Q increased over a range of sub-maximal work rates [Vogel et al, 1967]. Using three different settings on a cycle ergometer, the team showed a 10–15% increase during exercise in the first 4 days at altitude. Further work has demonstrated that, irrespective of age and gender, the rapid increase in Q is proportional to the degree of hypoxic exposure [Stenberg et al, 1966]. The increase in Q is the result of changes in the autonomic nervous system [Hainsworth et al, 2007]. Within minutes of hypoxic exposure, peripheral chemoreceptors within the carotid bodies sense a fall in PO2 and stimulate afferent fibres in the brainstem. This results in a rapid rise in sympathetic activity and an increase in heart rate [Hainsworth et al, 2007]. For several years this was thought to be the only contribution made by the autonomic nervous system in hypoxia. However sympathetic activity alone cannot account for the changes seen in heart rate. In studies that have examined the effect of beta blockers at high altitude, increases in both heart rate and Q were still seen during hypoxic exposure [Koller et al, 1988]. Only by combining agents that increase parasympathetic and decrease sympathetic activity is it possible to completely suppress the cardiovascular response at altitude. This implies that the peripheral chemoreceptors may also influence the parasympathetic nervous system during hypoxic exposure and contribute to the increase in heart rate and Q.


Figure 1.9: Members of the 1911 Pike’s Peak Expedition collecting expired gas from a volunteer during exercise. J.S. Haldane is in the centre of the photograph holding a stopwatch [Douglas and Haldane, 1922].
(Image courtesy of Prof J. Milledge) 

Since any increase in Q improves DaO2 it would be reasonable to assume that the rise in Q persists under hypoxic exposure. Unfortunately, this is not the case!  Whilst the increase in heart rate remains, stroke volume begins to fall. This was first described in detail by Griffith Pugh, the leader of the 1960-61 Himalayan Scientific and Mountaineering Expedition (“Silver Hut” Expedition). Amongst four researchers who’d spent several months at 5800m, Pugh found that Q during rest and exercise returned to sea level values (Figure 1.10) [Pugh, 1964].


Figure 1.10: The cardiac output (y axis) plotted against work rate (x axis) of four well acclimatized members of the Silver Hut Expedition [Pugh, 1964]. 
Measurements were obtained at sea level (circles) and 5800m (crosses)

Given that the rise in heart rate had persisted, Pugh concluded that, “the stroke volumes were less than at sea level at the two lower work rates, the mean values being 82 and 96ml compared to 96 and 121ml respectively...”. Subsequent studies have confirmed Pugh’s findings and shown that stroke volume not only drops within days of exposure but falls with each gain in altitude. In a review of seven studies measuring Q at altitude, Wolfel and Levine identified a reduction in stroke volume of between 11 and 36% following 10 to 28 days at altitudes of up to 4350m [Wolfel and Levine, 2001]. A similar pattern is also seen at higher elevations during rest and sub-maximal exercise. Amongst those participating in the OEII hypobaric chamber study, a fall in stroke volume was seen across a wide range of simulated altitudes (0-8840m) (Figures 1.11 and 12) [Suarez et al, 1987].


Figure 1.11: The mean end diastolic volume, end systolic volume and stroke volume at rest during OEII [Suarez et/al, 1988].


Figure 1.12: The mean end diastolic volume, end systolic volume and stroke volume at 60W of exercise during OEII [Suarez et al, 1988].
Stroke volume (SV) can be determined from the equation:

SV = LVEDV – LVESV

Where:
LVEDV - Left Ventricular End Diastolic Volume
LVESV - Left Ventricular End Systolic Volume

In order for SV to fall, one of two changes must occur – either the LVEDV is reduced or the LVESV increases. Using echocardiography and invasive catheter studies, OEII researchers found that subjects exposed to barometric pressures equivalent to the summit of Mt Everest not only retained normal systolic function, but also had LVESV’s that were the same, or lower, than those found at sea level. Rather than any increase in LVESV, the fall in SV is due to a reduction in LVEDV [Suarez et al, 1988]. During OEII, mean reductions in LVEDV (21%), LVESV (40%) and SV (14%) were all observed at a barometric pressure equivalent to the summit of Mt Everest (252mmHg). LVEDV and SV are linked together by left ventricular end diastolic pressure (LVEDP) [Fukuta and Little, 2008]. The relationship between these three factors can be seen in Figures 1.13 and 1.14. 


          
Figure 1.13: The relationship between Left Ventricular End Diastolic Volume (LVEDV) and Left Ventricular End Diastolic Pressure (LVEDP). 


Figure 1.14: A modified Starling’s Curve – A plot of Left Ventricular End Diastolic Pressure (LVEDP) and Stroke Volume (SV). During OEII, results revealed that the relationship between LVEDP and SV at sea level was similar to that found at lower barometric pressures. Hence SV was appropriate for the given LVEDP.

From these figures it is possible to see that a small reduction in LVEDV has the potential to cause a much larger decline in both LVEDP and therefore, SV. At altitude, the decrease in LVEDV has been attributed to:

-A reduction in circulating volume
On ascent to altitude, plasma volume (PV) falls. Amongst four members of the Silver Hut Expedition, PV was found to be 21% lower than sea level values following 18 weeks spent above 4000m [Pugh et al, 1964]. Clearly, this has the potential to reduce LVEDV. As Figures 1.13 and 1.14 demonstrate, even a small decrease in LVEDV can cause a significant drop in LVEDP and in turn, SV. Reversing this with intravenous fluid has been attempted in both field and chamber studies. However the limited evidence available suggests that whilst increasing plasma volume does raise SV it is not enough to restore sea level values [Wolfel and Levine, 2001].

-Changes in left ventricular geometry
On exposure to a PAO2 of approximately 8kPa or less, smooth muscle cells in the pulmonary vasculature contract [Reeves and Stenmark, 2001]. This phenomenon, commonly known as the hypoxic pulmonary vasoconstrictor response (HPVR), leads to a rapid and sustained rise in mean pulmonary artery pressure (MPAP) and changes in right heart haemodynamics [Heath et al, 1973]. In a small group of healthy volunteers fitted with cardiac catheters, MPAP was found to increase from 10.3 to 21.2mmHg within 24 hours at 3800m and remained elevated throughout their stay [Kronenberg et al, 1971]. The rise in MPAP is accompanied by an increase in pulmonary vascular resistance (PVR) and in some cases, dilatation of the right ventricle [Ward et al, 2001]. Given that the heart is contained within the confines of the pericardial sac, dilatation of the right ventricle can lead to deviation of the interventricular septum and changes to left ventricular geometry [Wolfel and Levine, 2001]. In those with long standing pulmonary hypertension this can cause diastolic dysfunction and result in a marked reduction in LVEDV (Figure 1.15) [Allemann et al, 2004]. 


Figure 1.15: The presence of pulmonary hypertension can result in a decrease in left ventricular volume and a leftward shift of the interventricular septum. 





Figure 1.16: The mean E and A Max Velocities and E/A Ratios for eight male volunteers obtained at four simulated altitudes during the OEIII hypobaric chamber study [Boussuges et al, 2000]. 
For the purpose of presentation the E Max and A Max were divided by a factor of 10.

-Direct effect of hypoxia
Whilst changes in plasma volume and left ventricular geometry may explain much of the fall in SV seen in hypoxia, recent work has highlighted the potential of a further contribution. In a study of 14 healthy volunteers who undertook a 17 day trek to Mt Everest Base Camp (5300m) falls in LV diastolic volume (8%),  E/A Ratio (24%) and SV (11%) were identified following their return to sea level [Holloway et al, 2010]. By measuring peak tricuspid regurgitant velocity, researchers were able to demonstrate that PAP had returned to normal yet diastolic function was still impaired. Given this and evidence of normal plasma volume, researchers focused upon changes in cellular function to explain the persistent fall in SV. Using MRI spectroscopy, an 18% fall in cardiac phospocreatine (PCr)/ATP activity was identified on their return to sea level. Since this pattern is also seen during exercise in those with Coronary Artery Disease, researchers concluded that this change was a direct response to tissue hypoxia [Weiss et al, 1990]. The vast majority of ATP is generated in the mitochondria following aerobic glycolysis. Following exposure to low PO2, Mt Everest summiteers have been  shown to have a 30% reduction in the absolute mitochondrial volume present in their skeletal muscle [Howald et al, 1990] [Howald and Hoppeler, 2003]. Since mitochondrial volume and function are closely related, the authors argue that in the face of significant hypoxia, mitochondrial production of cardiac ATP falls and prevents the uptake of calcium ions by the sarcoplasmic reticulum. Without sufficient calcium ions diastolic relaxation is not possible and stroke volume is impaired.
	Holloway’s findings run counter to most high altitude physiologists and physicians who have previously assumed that the healthy human heart is largely unaffected by hypoxia. Evidence to support this claim comes from a wide range of electrocardiographic (ECG) and echocardiographic studies conducted over the last half century [Ward et al, 2000] [Wolfel and Levine, 2001]. Extensive studies conducted in hypobaric chambers and in the field have been unable to identify ischaemic changes on ECG, despite SaO2 measurements as low as 49% [Malconian et al, 1990]! On Mt Everest in 2007 I wore a digital ECG monitor and obtained three hours of intermittent recordings from above the South Col (7900m). At no point was I was able to identify any change in the ST interval of my 3-lead ECG. This was despite spending much of the time with SaO2 measurements of between 40% and 80% (Figure 1.17).


Figure 1.17: The SaO2 measurements obtained from an ear probe during the first three hours of a successful summit attempt on Mt Everest. Supplemental oxygen (2l/min) was worn throughout.

Similar findings were also seen during AMREE where Peter Hackett and Chris Pizzo wore continuous 3 lead ECG recorders on their summit day. Apart from a single premature atrial contraction, the morphology of their ECG recordings was otherwise unremarkable [Karliner et al, 1985]. Echocardiographic research in hypobaric chambers also supports these findings. During a series of hypobaric chamber studies markers of left ventricular function, such as ventricular ejection fraction, ratio of peak systolic pressure to end-systolic volume and mean normalized systolic volume, were all preserved at barometric pressures equivalent to the summit of Mt Everest [Boussuges et al 2000] [Reeves et al, 1987] [Suarez et al, 1987]. Similar outcomes have also been seen during activity. Exercise testing to exhaustion at 7625m and ultra-marathon events between 2350 and 4300m have failed to unearth abnormalities in left ventricular systolic function on echocardiography [Suarez et al, 1987] [Dávila-Román et al, 1997]. This ability of the heart to cope at extremes of hypoxia has been explained by two physiological adaptations:
-An increase in oxygen delivery to the myocardium
Myocardial blood flow (MBF) is regulated by myocardial oxygen demand and largely determined by three factors: heart rate, contractility and wall stress. An ascent to altitude stimulates peripheral chemoreceptor discharge and causes an increase in sympathetic nervous activity. This not only increases heart rate and contractility, but through an increase in systemic blood pressure, causes a rise in systemic vascular resistance (SVR) and afterload [Fowles and Hultgren, 1983]. Wall stress is determined by afterload (end systolic ventricular wall tension) and preload (end diastolic ventricular wall tension). Whilst an ascent to altitude is associated with an increase in afterload, the fall in circulating volume reduces preload. Therefore the overall effect of altitude upon wall stress is unclear. Nevertheless, from the increases in heart rate and contractility it is likely that myocardial oxygen consumption increases. This has grave implications in a hypoxic environment. Normally, the myocardium requires large quantities of oxygen. At rest, myocardial oxygen delivery is more than 20 times greater than skeletal muscle [Kamm and Power, 2015]. This is reflected by a resting oxygen extraction ratio of approximately 75%. As we have previously seen, the partial pressure of inspired oxygen falls and myocardial oxygen consumption increases on ascent to altitude. Since there is only limited scope to increase the oxygen extraction ratio, there is a real risk of tissue hypoxia. In response to this stress, healthy epicardial coronary arteries rapidly dilate in order to ensure an increase in myocardial blood flow [Kaufmann et/al, 2001] [Wyss et al, 2003]. Researchers from the University of Zurich have identified a 62% increase in resting myocardial blood flow on positron emission topography scanning (PET) following the inhalation of a hypoxic mixture equivalent to an altitude of 4500m ( p<0.001) [Kaufmann et al, 2001]. Importantly, this increase exceeded that expected from the rise in rate pressure product alone and therefore adequately compensated for the fall in CaO2. However as we have seen in the previous section, restoration of sea level CaO2 and DaO2 does not guarantee an increase in cellular oxygenation since PO2 is largely unaffected.

-A decrease in oxygen utilisation by the myocardium
On hypoxic exposure there is evidence to suggest that steps are taken to reduce oxygen consumption at the cellular level [Boutilier 2001] [Gnaiger et al, 2000]. Ischemic preconditioning (IP) is a physiological phenomenon in which cells are subjected to an ischemic challenge that results in protection against a subsequent lethal hypoxic insult [Semenza, 2000]. Although the exact mechanisms behind IP are unclear, it is thought that the role of hypoxia inducible factor (HIF-1a) is crucial to this process [Eckle et al, 2008]. Under normoxic conditions HIF-1a has one of the shortest half-lives of any normal protein, however in a hypoxic environment HIF-1a binds to HIF-1b and forms the more stable HIF molecule [Smith et al, 2008]. HIF’s importance cannot be understated. Not only does it influence the haematological and respiratory changes seen during periods of hypoxic exposure, it also controls the metabolic requirements of human cells [Eckle et al, 2008] [Smith et al, 2008]. Since HIF plays such a large role in IP, it may be that the protein reduces the metabolic requirements of myocardial cells during longer episodes of hypoxic exposure, therefore making them less dependent upon oxygen. This has been demonstrated by studying the myocardial energy utilisation of healthy human volunteers exposed to 14% oxygen [Chen et al, 2009]. Using positive emission tomography (PET), a substantial shift from fat to carbohydrate metabolism was observed in cardiac tissue, reflecting the use of a more oxygen efficient form of energy substrate. 




















1.5	The impact of the high altitude environment upon those with cardiovascular disease

At 28000 feet (8534m) up the Tibetan side of Everest, the wire stitches that held my chest-cage in position since a recent by-pass operation, suddenly felt as though they were tearing into and tightening my chest and lungs. Another heart attack, I realised, was imminent, and I grabbed my GTN tablets which my wife made me carry at all times on the climb. Thanks to their immediate “dilating” effect I survived the ensuing hasty midnight retreat back to Base Camp, but a Scottish climber died of a heart attack at the same altitude the following night...
										[Fiennes, 2007]

Whilst the healthy human heart tolerates hypoxia with a considerable degree of success, those with cardiovascular disease are faced with a challenge. Significant numbers of sudden cardiac deaths (SCD) occur in the mountain environment [Burtscher et al, 1993] [Farahmand et al, 2007] [McIntosh et al, 2007] [Ponchia et al, 2006] [Sherry and Clout, 1988] [Shlim and Gallie, 1992] [Weston et al, 1977] [Xiang et al, 2003]. SCD’s, commonly defined as an, “unexpected natural death from a cardiac cause within a short time period, generally <1 hour from the onset of symptoms, in a person without any prior condition that would appear fatal”, have been shown to be responsible for the deaths of up to 52% of downhill skiers and 30% of hikers in the mountain environment [Burtscher et al, 1993] [Sherry and Clout, 1988] [Zheng et al, 2001]. Whilst the risk of SCD during sea level physical activities has been thoroughly investigated, only a small number of studies have focused upon the incidence of SCD in the mountain environment [Burtscher et al, 1993] [Ponchia et al, 2006] [Sherry and Clout, 1988]. These have demonstrated that one SCD occurs for every 0.1-2.6 million hours of skiing and 0.3-1.3 million hours of mountain hiking [Burtscher et al, 1993]. Compared to the overall risk of SCD, the incidence of SCD during mountain activities is significantly greater. Amongst men aged over 34 years, the risk of SCD has been shown to increase by a factor of 4.3 during mountain hiking and 2.1 during downhill skiing [Burtscher et al, 1993].
The vast majority who die from SCD in the mountain environment have risk factors for coronary artery disease (CAD). In a case control study that examined SCD amongst skiers, 94% of victims were male and 90% were aged over 40 [Burtscher et al, 2007]. Amongst 179 hikers diagnosed with SCD in the Alps the average age was 60.6 years [Faulhaber et al, 2007]. In long distance skiers participating in the Vasaloppet races in Sweden, men aged between 51 and 70 years had the highest SCD standardised mortality rate [Farahmand et al, 2007]. In males aged over 34, factors such as a history of prior myocardial infarction, diabetes mellitus, known coronary artery disease, hypercholestrolaemia and hypertension have all been shown to be independent risk factors linked to SCD during downhill skiing and mountain hiking [Burtscher et al, 2007] [Burtscher, 2007]. 
Any imbalance between oxygen delivery and demand has the potential to trigger life threatening ventricular arrhythmias, especially in those with pre-existing areas of peri-infarction, ischaemic tissue or myocardial scarring [Thompson et al, 2003]. At altitudes of up to 7100m the process of acclimatisation ensures that sea level CaO2 is maintained [Grocott et al, 2009]. Whilst this ensures a ready supply of oxygen to the capillaries, the diffusion of oxygen into the cells is impaired by a reduction in PO2. In response to low PO2 the sympathetic nervous system is stimulated [Douglas and Haldane, 1922] [Hainsworth et al, 2007]. Since heart rate and mean arterial pressure are higher during rest and sub-maximal exercise at altitude, cardiac work is increased. In healthy individuals this results in the dilatation of epicardial coronary arteries and arterioles and an increase in myocardial blood flow [Kaufmann et al, 2001] [Wyss et al, 2003]. However in those with CAD, there is evidence to suggest that diseased vessels are unable to dilate and at modest altitudes the expected increase in coronary blood flow does not occur [Wyss et al, 2003]. This imbalance between oxygen supply and demand may be exaggerated by a number of other factors (Figure 1.18).

Figure 1.18: The physiological response to high altitude exposure and the consequences this has for myocardial oxygenation in those with cardiovascular disease.

-Impaired Microcirculation
Many of those with CAD will have extensive microvascular disease. This is particularly common in those with systemic hypertension and leads a reduction in maximal coronary blood flow since arterioles and capillaries in the endocardium are damaged by the effects of high pressure [Dimitrow et al, 2005] [Rajappan et al, 2002]. At altitude, perfusion of these vessels may be hindered by changes in the microcirculation. Using sidestream dark-field imaging, researchers at University College London have recently identified a reduction in red blood cell flow through normal small (<25μm) and medium (26-50μm) sized blood vessels following ascent to 4900m. Although the reasons behind this change are unclear, a rise in haematocrit is recognised as one of the leading explanations [Martin et al, 2009]. In those who already have a compromised microcirculation an increase in haematocrit may further hinder capillary perfusion and result in myocardial ischaemia. 
-Decrease in Cardiac Return 
Arterial beds remain dilated for some time following an abrupt cessation in exercise. This can result in reductions in venous return, cardiac output and coronary perfusion [Thompson et al, 2003]. In the mountain environment, where a fall in plasma volume is an essential part of the acclimatisation process, the reduction in venous return can be even more pronounced and may further compromise coronary perfusion. 
-Right Heart Strain
As one leading high altitude physician once memorably wrote, “the heart is well protected against chronic hypoxia but not against the consequences of brisk pulmonary vasoconstriction” [Gibbs, 2007]. The rapid increases seen in pulmonary artery pressure and right ventricular afterload following hypoxic exposure can increase wall stress and myocardial oxygen demand. As a result, oxygen supply to tissues that overlie the right atrium and ventricle may become compromised.
-Rupture or Erosion of Atherosclerotic Plaque





Study	Sample	Altitude (m)	∆ Systolic (%)	∆ Diastolic (%)	∆ Mean Arterial Pressure Change on Ascent (MAP)  (%)	Reported Statistical Difference in MAP
Alexander et al, 1967	8	3100	+7.0	+1.4	+2.2	N/S
Antezana et al, 1994	10	6542	+17.5	+23.6	+21.0	P<0.05
Hansen and Sander, 2003	8	5260	-	-	+13.0	P<0.05
Kamat and Banerji, 1972	32	3510	+12.2	+19.2	+16.7	P<0.001
Kanstrup et al, 1999	8	4559	+8.2	+13.3	+15.7	P<0.01
Klausen, 1966	5	3800	+4.7	-1.1	+1.3	-
Kumar et al, 2003	28	3500	+0.3	+8.9	+5.8	P<0.05
Malhotra et al, 1976	40	3500	+11.4	+15.2	+13.5	P<0.01
Mazzeo et al, 1991	7	4300	-	-	+27.9	P<0.05
Mazzeo et al, 1994	11	4300	-	-	+7.3	P<0.05
Modesti et al, 2006	10	4559	+6.8	+17.1	+12.4	-
Ponchia et al, 1994	8	5000	+13.9	+25.8	+21.1	N/S
Saltin et al, 1968	2	4300	+18.9	+16.2	+17.6	-
Veglio et al, 1999	9	2950	+5.4	+8.2	+7.0	P<0.05
Vogel and Harris, 1967	1616	33004500	--	--	+2.2-7.7	N/SN/S
Vogel et al, 1974	8	4300	+0.7	+1.1	+0.9	N/S
Wolfel et al, 1991	7	4300	-	-	+27.9	P<0.05
Wolfel et al, 1994	11	4300	+19.0	+18.3	+20.9	N/S

Table 1.4: The resting systemic blood pressure changes in 18 studies identified from a PubMed search conducted on the 1st December 2016. 
To be included in the table each study had to be published in English and present the mean arterial pressure of awake, previously normotensive, lowland adults at low altitude and after a minimum period of twenty four hours at high altitude. 
*Calculated from the systolic and MAP.

Importantly, it is not only the atherosclerotic plaque that may be vulnerable at altitude, but also the resulting coronary thrombus. Observational studies have identified a high incidence of portal vein thromboses and ischaemic strokes in previously healthy Indian soldiers following prolonged stays at moderate altitudes [Anand et al, 2005] [Jha et al, 2002]. These findings are consistent with the increases seen in D-Dimer and prothrombin fragment 1 + 2 concentrations in those who travel to the mountains and suggests that in certain circumstances an imbalance between coagulation and fibrinolysis may exist [Bartsch, 2006] [Le Roux et al, 1992] [Manucci et al, 2002]. 
-Coronary Vasospasm
Whilst pre-existing CAD is found in the majority of SCD victims in the mountain environment, in a small number of cases the coronary arteries are normal [Kannel and Thomas, 1982] [Sherry and Clout, 1988] [Shlim and Gallie, 1992]. Herb Hultgren, the highly respected cardiologist and high altitude physician, highlighted the case of a patient who developed severe angina following an ascent to Keystone, Colorado (2796m) [Hultgren, 1990]. Despite the presence of T wave changes in the pre cordial leads of an electrocardiogram, a subsequent coronary arteriogram was found to be normal. Hultgren ascribed the cause of these ischaemic changes to coronary vasospasm. This phenomenon, often defined as, “an abnormal contraction of an epicardial coronary artery resulting in myocardial ischaemia”, can occur in angiographically normal arteries as well as those with CAD [Yasue et al, 2008]. Whilst the mechanisms that underpin coronary vasospasm remain unclear, changes in the vascular endothelium are believed to play a significant role. Nitric oxide (NO) is thought to be largely responsible for setting the basal tone of small arteries and arterioles [Vallance and Collier, 1994].  When NO production is inhibited by L-monomethyl-arginine (L-NMMA) the coronary artery diameter in healthy human volunteers rapidly diminishes. However in those prone to coronary vasospasm, the diameter of the coronary vessel does not alter. Individuals who are prone to coronary vasospasm therefore appear to have defects in NO production. In the hypoxic environment, oxygen delivery can be elevated by increasing the diameter of blood vessels that supply the tissues [Erzurum et al, 2007]. In a study that compared lowlanders and Tibetans living permanently at 4200m, forearm blood flow was found to be more than double in Tibetans, ensuring that oxygen delivery comfortably exceeded that of the lowlanders. This improvement was largely attributed to a tenfold difference in bioactive NO constituents. In those unable to produce adequate NO at high altitude, blood vessels will be unable to dilate and myocardial perfusion will be compromised.
Writing in the early1990’s, several years before the link between vasospasm and NO had been made, Hultgren argued that the condition may be caused by a combination of respiratory alkalosis and sympathetic stimulation [Hultgren, 1990]. Following exposure to high altitude the peripheral and central chemoreceptors trigger an increase in ventilation that results in a decrease in the alveolar partial pressure of carbon dioxide (PACO2) and an increase in pH [Martin and Windsor, 2009]. Although the link between coronary spasm and respiratory alkalosis is poorly understood, a short period of controlled hyperventilation has been shown to trigger spasm in up to 65% of those vulnerable to the condition [Yasue et al, 1978]. In these cases, spasm has been linked to local changes in the ionised concentrations of electrolytes such as calcium, potassium and magnesium [Goto et al, 1990] [Hannon et al, 1971]. In addition to the impact of respiratory alkalosis, Hultgren also argued that a sympathetic stimulus could also trigger coronary vasospasm in the hypoxic environment. Plasma catecholamine concentrations increase steadily with time spent at altitude [Hainsworth et al, 2007]. Following nine weeks at 5260m, plasma adrenaline and noradrenaline concentrations increased by factors of 2 and 4 when compared with sea level values [Calbet, 2003]. In the healthy heart, catecholamines acts primarily on beta-1 receptors to causes vasodilatation. However in those vulnerable to coronary artery spasm, adrenaline and noradrenaline can cause vasoconstriction and hence induce the condition [Yasue et al, 2008].
-Leftward Shift of the Oxyhaemoglobin Dissociation Curve
Stimulation of the peripheral chemoreceptors triggers a rapid increase in the rate and depth of breathing. The respiratory alkalosis that results from hyperventilation can result in a leftward shift of the Oxyhaemoglobin Dissociation Curve (Figure 1.5). Whilst increases in bicarbonate excretion and 2,3-DPG synthesis may eventually push the curve to the right this may take several days or weeks to occur. A leftward shift of the curve improves oxygen binding within the alveoli, however a fall in P50 inhibits the release of oxygen into the tissues and may prevent the movement of oxygen into the myocardium. 














1.6	Electrocardiography in the high altitude environment

The electrical activity of the heart has fascinated researchers for more than a century. However it wasn’t until the discovery of the string galvanometer by Willem Einthoven that researchers had an effective means of studying this complex phenomenon (Figure 1.19). Using a long, silver coated quartz filament and a pair of electromagnets, a series of deflections could be detected when the electrical activity of the heart was passed through it. These deflections were subsequently magnified and projected through a thin slot onto a moving photographic plate [Rivera-Ruiz et al, 2008]. The results were impressive. In an article commemorating the 100th anniversary of its first clinical use, the string galvanometer was thought to have achieved, "such amazing technical perfection that many modern day electrocardiographs do not attain equally reliable and undistorted recordings” [Barold, 2003].  However the device was ill suited to field research. Weighing more than 250kgs, the device occupied two rooms and required a team of five to operate it. Over the course of the next two decades a series of modifications ensured that the device became smaller and lighter, leading the Cambridge Scientific Instrument Company of London to market the first portable device in 1928. Weighing just 30lbs (14kgs) this could be carried in a suitcase. Such a device would have been used by the 1936 Argentinian expedition to the Bolivian Altiplano. At a height of approximately 4000m the first ECG’s at high altitude were obtained from 78 workers employed in the tin mines of Catavi [Capedehourat, 1937]. 

Figure 1.19: The string galvanometer first described by Willem Einthoven in the early 1900’s [Barold, 2003].  

Whilst early electrocardiographs were fitted with the means of making a photographic record, later powered devices such as the Sanborn Viso-Cardiette and Cambridge Transrite Cardiograph were fitted with an electrically heated stylus that traced ECG images onto heat-sensitive plastic coated paper [Carter, 1950]. These battery powered devices were used throughout the 1950’s and 1960’s at high altitude with considerable success (Figure 1.20). 

Figure 1.20: The Transrite Cardiograph manufactured by the Cambridge Instrument Company and loaned to the 1959 British Sola Khumbu Expedition. According to researchers, “It behaved faultlessly apart from a falling off in the amplification when the batteries became overcooled.” [Jackson and Davies, 1961].

According to researchers on the 1960-61 Silver Hut Expedition the Cambridge Transrite Cardiograph “performed admirably” [Milledge, 1963]. However problems were noted,

Care had to be taken to keep the batteries warm otherwise the trace became very faint. There was no difficulty in this at the Silver Hut where the indoor temperature was usually 60-80'F (15-6-26-70C.). But difficulty was encountered at the high camps on Makalu. Another technical difficulty in the highest camp was the appearance of irregular sinusoidal waves in the cardiogram which we thought to be due possibly to the static electricity generated in the fabric of the nylon tent by the high wind in this camp. It disappeared when the wind dropped.
[Milledge, 1963]

The majority of these early recordings lasted for only a few seconds and were conducted on resting participants. A new technology was needed to study individuals during longer periods of rest and exercise. The launch of the Del Mar Avionics Holter monitor in 1962 proved to be the solution high altitude researchers were looking for. Initially, these devices weighed approximately 7kgs and recorded ECG data onto commercially available cassette tapes carried either by the mountaineer or transmitted to a low altitude site via a radio transmitter [Gawlowska et/al, 2009]. Despite widespread use the device had a number of limitations. Only a small number of leads were measured – usually V1 or V2 and V5. Electrode contact with the skin was often poor resulting in artefact from muscle tremor and respiration. But perhaps most challenging of all was the lengthy process of assessing the data and converting sound recordings into the electrocardiograms that we are familiar with today. Initially, assessment was conducted by listening to the sound recording,

Smooth humming sound meant that it was sinus rhythm, whereas choppy sounds were the markers of ventricular extrasystolic beats. For a detailed look at the fragment of ECG that “sounded bad”, it had to be stopped and played in real time.
									[Gawlowska et al, 2009]

To convert the audio recording into a visual form a demodulator, oscilloscope and clinical electrocardiograph were needed [Holter, 1961]. Nevertheless, this process was used successfully during AMREE when the first single lead continuous ECG recording was made on the summit of Mt Everest. Leads were connected,

To a miniature amplifier and a four-channel, battery-operated tape recorder (Medilog, Oxford Instruments, Oxford, U.K.), that was carried in the pocket of a special vest that the climbers wore. The instrument, in addition to recording ECG signals, could record respiration signals and event markers. This instrument was affixed the night before the summit climb, was switched on in the morning, and could record a single-lead ECG continuously for 24 hours ... This tape was then reproduced on a strip-chart recorder and was also analyzed by means of a computerized replay system provided by Oxford Instruments.
[Karliner et al, 1985]

	Further technological developments in ECG monitoring have led to renewed interest in the electrical conduction of the heart at high altitude. Digital devices such as the Welch Allyn PC-Based Resting Electrocardiograph are small, light and robust. Using the same sampling rates and levels of filtering used by standard devices, it is possible to record highly accurate and detailed 12 lead ECG’s in the remote environment. Using a USB connection these can be stored and analyzed immediately using software installed onto battery operated laptop computers. Implantable loop recorders are also now available to researchers. These provide the opportunity to study the ECG’s of individuals spending many weeks or months at high altitude (Figure 1.21) [Woods et al, 2008]. 


Figure 1.21: Researchers downloading ECG data obtained by an implantable loop recorder.





On hypoxic exposure changes in parasympathetic and sympathetic activity result in a rapid increase in heart rate (Figure 1.22) [Houston and Riley, 1947]. Heart rate is controlled by pacemaker cells contained within the sinoatrial (SA) node. Following hypoxic exposure, these receive an increase in sympathetic and a decrease in parasympathetic nervous system activity [Hainsworth et al. 2007]. 


Figure 1.22: The heart rates of four participants measured in a hypobaric chamber during a 32  day simulated ascent of Mt Everest.The Operation Everest I (OEI) study paved the way for a series of hypobaric chamber experiments that have made an immense contribution to high altitude research.

The autonomic response is controlled by the cardiovascular centre contained within the medulla oblongata and receives input from a number of different receptors:
-The nucleus of the solitary tract (NTS) in the cardiovascular centre receives input from a wide range of arterial baroreceptors. The NTS integrates and relays afferent information via several pathways to other medullary centres and triggers an autonomic response. Receptors in the aortic and carotid sinuses can be triggered by a change in circulating volume that is believed to form part of the early stages of the acclimatisation process. Following an ascent of Pike’s Peak (4300m) by 7 healthy male volunteers, mean total blood volume fell by 6.5% within 4 hours of arrival and 2.8% after 18 days spent at altitude [Wolfel et al, 1991]. Such a fall in plasma volume results in a decrease in the stretch of these receptors and induces a reflex increase in sympathetic activity to blood vessels and pacemaker cells contained within the heart.   
-Temperature and stretch receptors contained within the musculature provide afferent input into the cardiovascular centre. Resting minute ventilation increases with an ascent to altitude. During an ascent of Cho Oyu (8201m) the mean minute ventilation of six healthy male mountaineers was found to be 15.0l/min at 4900m and 16.9l/min at 5700m [Rodway et al, 2007]. Given that resting minute ventilation is normally between 4 and 6 l/min, such an increase represents widespread use of muscle fibres within the diaphragm and a range of different accessory muscles. This in turn results in an increase in stretch and temperature receptor activity and changes in autonomic function. 
-Hypoxia also stimulates peripheral chemoreceptors contained within the aortic and carotid bodies. Through a range of afferent fibres, the cardiovascular centre in the medulla oblongata modifies autonomic activity through the accelerans (sympathetic) and vagus (parasympathetic) nerves supplying the pacemaker cells. Whilst excitatory pathways from the NTS act directly upon the cardioinhibitory area and form a simple autonomic reflex arc, sympathetic activity is more complex. The NTS together with other sites in the medulla oblongata, such as the caudal and rostral ventrolateral medulla, coordinate the sympathetic response. As previously described, these receive input from a range of different receptors together with the cerebral cortex, hypothalamus and other unknown sources [Madden and Sved, 2003]. It is important to note that peripheral chemoreceptor stimulation is not linear and rises substantially, “below oxygen tensions of about 60mmHg” [Drinkhill et al, 2014].  Since an arterial PO2 of 60mmHg is typically found in lowland residents who’ve ascended to modest altitudes of between 2300 and 2400m, the role of peripheral chemoreceptors is likely to play a significant part in an ascent to high altitude. 

Although the rise in resting heart rate is small at first, with increasing hypoxia a far greater increase is observed. In a chamber study conducted on 30 healthy volunteers, mean resting heart rate rose from only 71 to 74 beats per minute at a simulated altitude of 3000m [Laciga and Koller, 1976]. However from 3000 to 6000m the heart rate rose from 74bpm to 96bpm. Unfortunately, only a small number of field studies have measured the resting heart rates of a given population at different altitudes. In the majority of these studies, small sample sizes and a limited number of sites have made it difficult to determine at what point an increase occurs and how this changes with further ascent (Table 1.5) (Figure 1.22 and 23). 

Study	Sample Size	Altitude (m)	Heart Rate (bpm)
Boussuges et al. 2000*	8	0500070008000	63799089






Table 1.5: Serial resting heart rate measurements taken from ECG studies completed under hypoxic conditions. 
Only English language studies thar presented a sea level and at least two different high altitude measurements were included. *Study conducted in a hypobaric chamber.


Figure 1.23: Serial resting heart rate measurements taken from ECG studies completed under hypoxic conditions (Table 1.5).

According to OEII researchers, the mean resting heart rate of eight healthy volunteers did not increase until a simulated altitude of 4900m was reached [Malconian et al, 1990]. Meanwhile, during an ascent of Ama Dablam (6856m), a significant increase was only observed in a group of seven well acclimatized mountaineers at 4920m [Jackson and Davies, 1960].  These results are in sharp contrast to Hoon et/al who observed a rise from 66bpm to 77bpm within five days of ascending to 3658m (n=50) and Laciga and Koller’s group who experienced an increase from 71bpm to 82bpm within five minutes of reaching a simulated altitude of 4000m (n=30) [Hoon et al, 1977] [Laciga and Koller, 1976]. At higher altitudes significant differences between studies have also been seen. The results of the 1975 Chinese Scientific Survey Expedition to Mt. Everest showed that resting heart rate increased by 81% amongst participants at 8200m compared to sea level [Shi et al, 1980]. However this was in contrast to OEII participants who experienced increases of only 48% and 55% at simulated altitudes of 7620m and 8840m respectively [Reeves et al, 1987] [Malconian et al, 1990]. The wide variation that exists between different studies means that predicting the point at which resting heart rate increases is unclear. In addition, the pattern of any further increase with subsequent gains in altitude is far from certain. 
Whilst changes in resting heart rate are seen in both men and women at high altitude, early research conducted on Pikes Peak (4300m) highlighted significant differences between the sexes. On arriving at the summit, the percentage increase in men (n=8) was found to be less than half of that seen in women (n=8) [Hannon et al, 1966]. This, several authors have subsequently argued, may be due to a need of women to generate a greater sympathetic response to hypoxia than men. Since women have a lower sea level haemoglobin concentration, women’s CaO2 is lower and a greater cardiac output is therefore needed in order to achieve sufficient DaO2 [Banchero et al, 1966] [Hannon et al, 1966] [Hultgren, 1997]. However this explanation overlooks the key role of PO2 in stimulating sympathetic activity. Assuming that men and women experience the same fall in PO2 it can be argued that peripheral chemoreceptors in the carotid bodies will behave in exactly the same way and trigger similar increases in heart rate. 
The duration of any increase in resting heart rate at high altitude is unclear. Within just a few days of arriving at altitude, a number of small studies have identified a reduction in resting heart rate and in some, a return to normal sea level values [Hainsworth et al, 2007]. Amongst eight participants based at the Capanna Margherita Hut on Monte Rosa (4559m), the mean resting heart rate increased from 58bpm to 87bpm before falling to 73bpm two days later [Kanstrup et al, 1999]. Following a longer stay on Pike’s Peak (4300m) an initial increase (7%) led eventually to an overall reduction (8%) in mean resting heart rate after 28 days [Vogel et al, 1967]. These results are supported by recent findings that show prolonged exposure to catecholamines causes a downregulation of cardiac β receptors [Hainsworth et al, 2007]. In a study of rats exposed to a simulated altitude of 5500m for 21 days, a 24% reduction in the density of β adrenoreceptors was found in both the left and right ventricles [Leon-Valarde et al, 2001]. Indirect evidence for this change has been found in healthy human volunteers. Using an isoprenaline infusion titrated to increase the heart rate by 25 beats per minute, researchers found that the dose almost doubled after 21 days at Annapurna IV Base Camp (4800m) [Richalet et al, 1988]. But despite these findings, most field studies have been unable to demonstrate a consistent fall in heart rate following long periods of time spent at high altitude. In a review of the cardiovascular system in hypoxia, Wolfel and Levine found that resting heart rate increased by up to 31% in six studies of healthy, well-acclimatized individuals living at altitude for up to 4 weeks [Wolfel and Levine, 2001]. In the largest study they examined, an 18% increase was found following ten days spent at 3658m (n=50) [Hoon et al, 1977].
Whilst many studies have obtained heart rate measurements at high altitude, many questions remain unanswered. At what altitude does the heart rate rise? After how long does the heart rate fall? And, are there significant differences between men and women? 

Rhythm
Limited information is available on rhythm disturbance during daytime activities at high altitude. However, considerable information is available from sleep studies (Figure 1.24). On arrival at altitude, sleep is often unsettled, and many newcomers complain that they ‘‘take longer to get to sleep, wake frequently, often have unpleasant dreams, and do not feel refreshed in the morning’’ [Windsor and Rodway, 2006]. This experience may stem from episodes of periodic breathing that disrupt the normal sleep pattern and trigger lengthy cycles of apnea and hyperpnea. At 4300m on Pikes Peak, researchers found in some individuals, periodic breathing to be present for up to 93% of the time spent asleep [Reite et al., 1975]. Periodic breathing at altitude causes pronounced swings in SaO2 and heart rate [West, 2002]. Fluctuations in heart rate closely resemble the pattern seen during sinus arrhythmia at sea level, with the highest heart rates being observed during hyperpnea and the slowest during the apnea phase of the breathing cycle [Weil, 2004]. At a barometric pressure equivalent to 7620 m, researchers on OEII found that during sleep the highest recorded heart rate rose from 55 to 105 bpm, whereas the lowest rate fell from 44 to 41 bpm [Malconian et al, 1990]. On AMREE, researchers found that the range of recorded heart rate varied from 49 to 105 bpm at 6300m and from 50 to 135 bpm at 8050m [West et al, 1986]. At 5030m on Annapurna, Cummings and Lysgaard found that his heart rate during sleep, ‘‘was frequently in the 30’s,’’ with R–R intervals of up to 3.3 sec compared to 1.4 sec at sea level [Cummings and Lysgaard, 1981]. The longest sinus arrest during sleep in OE II participants was 3.6 sec [Malconian et al, 1990b]. The episodes of bradycardia are often heterogeneous. Researchers on OEII found ‘‘blocked P waves without preceding PR prolongation; sinus arrest or marked bradycardia with junctional or ventricular escape beats; sinus bradycardia up to 24 beats/min without an escape rhythm; atrioventricular dissociation; and idioventricular rhythm’’ [Malconian et al, 1990b]. At altitude, the bradyarrhythmias seen during periodic breathing closely coincide with the lowest SaO2 in the breathing cycle. This may be part of a coordinated attempt by the body to maintain oxygenation to the myocardium. During breathing, vagal activity is blocked by a combination of central and peripheral stimuli. However during periods of apnea this recedes and causes the heart rate to fall. Since any decrease in heart rate reduces the work of the myocardium and improves myocardial perfusion this may be of considerable benefit during occasions when PO2 is low.


Figure 1.24: An episode of sinus bradycardia recorded during sleep at 5030m [Cummings and Lysgaard, 1981].

Historically, the study of arrhythmias during waking hours at altitude has been limited to short recordings lasting only a few seconds. Since many of these were obtained from
healthy, well-acclimatized individuals at rest, few abnormalities were seen. From these results, investigators have drawn the conclusion that arrhythmias at altitude are not significant [Harris and Hansen, 1966] [Jackson and Davies, 1960] [Karliner et al, 1985] [Malconian et al, 1990] [Milledge, 1963]. However, in recent years the use of Holter monitors and implantable loop recorders has led many to look afresh at this issue and to draw different conclusions [Alexander, 1995] [Alexander, 1999] [Das et al, 1983] [Chandrashekhar et al, 1992] [Horii et al, 1987] [Woods etal, 2008]. 
Unlike the vast majority of blood vessels, the smooth muscle cells contained within the pulmonary arterioles cause vasoconstriction upon hypoxic exposure (hypoxic pulmonary vasoconstriction - HPV) [von Euler and Liljestrand, 1946]. In localized disease states, such as pneumonia and atelectasis, this can be of benefit since it is possible to redirect blood to areas of healthy lung, improving ventilation-perfusion mismatch, and thus enhance tissue oxygenation. However, when the respiratory tract is exposed to a PO2 below 70mmHg, widespread HPV can occur within minutes and result in a significant increase in pulmonary artery pressure (PAP) [Bartsch and Gibbs, 2007]. Whilst considerable variation exists between individuals, PAP tends to increase with work load and subsequent gains in altitude (Figure 1.25) [Groves et al, 1987]. During a prolonged stay at high altitude systolic function is preserved and Q is either unchanged or reduced. This results in an increase in pulmonary vascular resistance (PVR) since:

PVR = (Mean Pulmonary Artery Pressure – Left Atrial Pressure) x 80 / Q

A rise in PVR leads to an increase in right ventricular diastolic pressure and can result in dilatation and hypertrophy of the right atrium and ventricle [Boussuges et al, 2000]. 
Observations made in patients with extensive pulmonary emboli show that right atrial distension is closely associated with an increase in atrial arrhythmias [Szucs et al, 1958]. Premature atrial ectopics are the most commonly reported supraventricular arrhythmia at altitude [Akhtar et al, 1979] [Alexander, 1995] [Alexander, 1999] [Das et al, 1983] [Harris and Hansen, 1966] [Horii et al, 1987] [Karliner et al, 1985] [Malconian et al, 1990] [Malconian et al, 1990b] [Milledge, 1963] [Nagasaka et al, 1967] [Politte et al, 1968] [West et al, 1986]. In a study of 200 Indian army recruits, 12 (6%) showed evidence of ‘‘occasional supraventricular ectopics’’ after 45 min spent in a hypobaric chamber set to a barometric pressure equivalent to an altitude of 4500m [Akhtar et al, 1979]. Although these events tend to be isolated and single, longer episodes of atrial tachycardia, atrial flutter and atrial fibrillation have also been identified [Alexander, 1995] [Alexander, 1999] [Woods et al, 2008] (Figure 1.26). In many cases, these events have resolved with descent or supplemental oxygen, suggesting that an acute process, such as a change in PVR, may have contributed to their presence. 


Figure 1.25: The mean pulmonary artery pressure of OEII participants during rest and exercise. Testing was conducted at sea level  and a range of different barometric pressures [Groves et al, 1987].


Figure 1.26: Atrial flutter (2:1 block) at a rate of 150 beats per minute and return of sinus rhythm at 4500m [Woods et al, 2008].

Ventricular arrhythmias have also been widely reported at altitude (Figure 1.27) [Alexander, 1995] [Alexander, 1999] [Bartsch and Gibbs, 2007] [Das et al, 1983] [von Euler and Liljestrand, 1946] [Karliner et al, 1985] [Malconian et al, 1990] [Milledge, 1963]. 
 

Figure 1.27: A ventricular ectopic beat (VEB) obtained during three hours of continuous ECG monitoring above 7900m on Mt Everest. In total, four VEB’s were observed.

The vast majority of these cases have been found to be ventricular ectopic beats (VEBs). Although most were single, isolated VEBs, short runs of ventricular bigeminy have also been reported [Alexander, 1995] [Cummings and Lysgaard, 1981] [Milledge, 1963] [Malconian et al, 1990]. VEBs tend to occur with increasing frequency as individuals ascend to altitude. 
At the age of 65, the cardiologist J. K. Alexander wore a Holter monitor during an
ascent of Kilimanjaro (5895 m) and wrote [Alexander, 1995],

During the climb from 4610 to 5895 m, the recording demonstrated frequent premature ventricular complexes, predominantly of left ventricular origin, with multiple runs of
ventricular bigeminy, which increased in frequency and duration until the mountain peak was reached. Ventricular ectopy was reduced markedly as I began the descent, and virtually disappeared within 3 hours. 
[Alexander, 1995]

Ten years later the author returned to the same mountain [Alexander, 1999]. On this occasion he experienced an average of 62 VEBs/hour during ascent and 12 VEBs/hour while descending between the altitudes of 4700 and 5100 m. The majority of VEBs originated in the left ventricle, with 56/62 (90%) being recorded on the ascent and 10/12 (83%) on descending Kilimanjaro. Despite a battery of normal sea-level investigations, Alexander also experienced 10 episodes of ventricular tachycardia (VT) between 4710 and 5100 m. The longest run of VT lasted 14 complexes and coincided with the climber feeling ‘‘rather dyspneic’’ (Figure 1.28)! 


Figure 1.28: A fourteen complex run of left ventricular tachycardia at 250 beats per minute recorded at approximately 5100m [Alexander, 1999]







Figure 1.29: An arrhythmia recorded in a healthy lowland resident following ascent to 4700m. According to the authors, “this is probably an artefact but find it difficult to completely exclude a 5 beat run if polymorphic ventricular tachycardia” [Woods et al, 2008]





Following an ascent to high altitude, changes in ECG morphology are often seen. These tend to present quickly and tend to resolve following return to sea level [Karliner et al, 1985]. Changes in ECG morphology at high altitude can be divided into two categories:

1 - Right heart strain 
Signs of right heart strain are often found in the ECG’s of those who ascend to high altitude. These are widely believed to be effect of changes in pulmonary haemodynamics caused by the hypoxic pulmonary vascular response (HPVR):
Right axis deviation (RAD)




Figure 1.30: The mean cardiac axis of long term residents at sea level (0m), Denver (1600m), Leadville (3100m) and Morococha (4300m) [Pryor, 1970].

However, exceptions do exist. Sherpas and other ethnic groups living on the Tibetan plateau, having benefited from thousands of years of genetic evolution, no longer demonstrate such a pronounced increase in PAP as sea-level residents who ascend to altitude [Groves et al, 1993). After 15 ascents of Mt. Everest (8848 m), the ECG of a 48-yr-old Sherpa lacked any signs of right ventricular overload [Garrido et al, 2003]. Whilst ECG studies undertaken in Lhasa (3658 m) revealed that Han Chinese immigrants were far more likely to have signs of right ventricular hypertrophy (RVH) on ECG (29%) than Tibetan natives (17%) [Halperin et al, 1998]. 




Figure 1.31: The cardiac axis of 10 participants at sea level (left) and following one year of residence at approximately 4300m. A shift towards right axis deviation was seen amongst the majority of the participants. This was one of the earliest electrocardiographic studies conducted on lowland residents ascending to high altitude [Penaloza and Echevaria, 1957].

Over the 40 days of OEII, the frontal plane QRS axis of 8 volunteers slowly shifted rightward from a mean of 55 degrees at sea level to 107 degrees at a barometric pressure equivalent to 8848m (p<0.05) [Malconian et al, 1990]. During AMREE, the mean QRS axis in the frontal plane was shown to shift rightward in 10/12 (83%) members following an ascent to Camp 2 (6300 m) (Karliner et al, 1985). Any increase in RAD appears to persist with prolonged exposure. Among 202 Indian soldiers, 95 (53.9%) demonstrated a rightward shift of axis of more than 10° in the frontal plane following 23 months spent above 3600m (Groves et al, 1993). On returning to sea level, RAD was still present in 32 (20.7%) soldiers after 1 month, suggesting that remodelling of the right ventricle may have taken place. After 6 months the axis had returned to normal.

Right Bundle Branch Block (RBBB)

Although the width of the QRS complex is unaffected by altitude exposure, the R and S components often undergo significant changes [Albrecht and Albrecht, 1969] [Das et al, 1983] [Kapoor, 1984] [Karliner et al, 1985] [Rotta and Lopez, 1959] [Saurenmann and Koller, 1984]. In a large-scale hypobaric chamber study, an RSR pattern in V1 was noted in 28/200 (14%) healthy volunteers following 45 min of hypoxic exposure [Saurenmann and Koller, 1984]. Meanwhile, in the mountain environment, 20% to 40% of Indian soldiers and
26% of American mountaineers developed an RSR pattern within days of arriving at altitude (Figure 1.32) [Das et al, 1983] [Karliner et al, 1985]. 

Figure 1.32: RSR pattern visible in V1 and 2 following rapid ascent to high altitude [Das et al, 1983]. 

Similar changes also occur in long-term high altitude residents. In 23 healthy Bolivians found to have evidence of RVH, 5 (22%) had evidence of RBBB in their precordial ECG leads [Rotta and Lopez, 1959]. In a number of cases the presence of RBBB resolves during high altitude residence. Das et/al noted amongst his participants, “all, except one case, showed disappearance of this finding by 10th day at high altitude” [Das et al, 1983].
	Although evidence of a RSR pattern in V1 can be seen on several published ECG’s obtained at high altitude, it is unclear whether these can be defined as RBBB. For instance, in Figure 1.32 the heart rhythm clearly originates above the ventricles, the terminal R wave is present and the QRS is more than 120ms, however the slurring of the S waves in I and V6 is absent [Hampton, 2013] [Surawicz and Knilans, 2008] [Wagner, 2013]. This may suggest an earlier tendency to overdiagnose RBBB at high altitude.

Changes in P Wave Amplitude

An increase in P wave amplitude in leads II, III, and aVF is frequently observed on ascent to altitude (Figure 1.33) [Albrecht and Albrecht, 1969] [Alexander, 1995] [Alexander, 1999] [Das et al, 1983] [Laciga and Koller, 1976] [Karliner et al., 1985] [Malconian et al, 1990] [Saurenmann and Koller, 1984] [Shi et al, 1980]. 


Figure 1.33: Lead II of a mountaineer climbing Mt Everest – (a) 50m (b) 5000m (c) 8680m* (d) 3700m (e) 2 months after descent (f) 3 months after descent. The P wave amplitude was considerably greater at the summit than elsewhere [Shi et al, 1980]. 
*The authors used a height of 8680m to denote the summit of Mt Everest.  









Figure 1.34: Widespread T wave changes observed in a member of AMREE at 6300m [Karliner et al, 1985]
 On acute exposure to 15,000 ft, 85% of healthy volunteers were shown to have experienced a 50% or more decrease in T wave amplitude in V1 and V2 compared to only 18% in V5 and V6 [Akhtar et al, 1979]. In some cases T wave changes have normalised following a prolonged period of high altitude exposure [Das et al, 1983] [Jackson and Davies, 1960]. The reasons for this are unclear. However, transient alterations in plasma electrolyte and catecholamine concentrations have been cited as possible explanations [Das et al, 1983] [Jackson and Davies, 1960] [Sauermann and Koller, 1984].
Extensive T wave inversion can also be seen in those with high altitude pulmonary edema (HAPE) [Fiorenzano et al, 1997] [Milledge, 1963]. HAPE is a form of noncardiogenic pulmonary edema that affects up to 15% of those who ascend to altitude [Luks and Swenson, 2007]. Although the pathophysiological process that underlies this condition is unclear, it is thought that a high PAP is transmitted to the pulmonary capillaries, which results in damage to the alveolar capillary membrane and the accumulation of a fluid transudate in the airways [Das et al, 1983]. Italian researchers reported the case of a 40-yr-old male who developed HAPE during a 3-day stay at a mountain refuge situated at 3100m above sea level [Fiorenzano et al, 1997]. On admission, the SaO2 was measured at 70% and 12-lead ECG revealed T wave inversion in II, III, and all the precordial leads. In another case, a mountaineer developed signs of HAPE on attempting to climb Makalu (8462 m), the world’s fifth highest mountain [Milledge, 1963]. Prior to this, he had undergone an ECG at 19,000 ft (4572 m) that revealed T wave inversion in V1 and V2; however, following hospital admission in Kathmandu, changes in V3 and V4 were also identified. In both cases their ECG’s rapidly returned to normal following descent and further investigations were unable to identify any evidence of myocardial ischemia. Although oxygen availability falls precipitously following an ascent to altitude, T wave changes do not appear to be related to ischemic injury [Jackson and Davies, 1960] [Karliner et al, 1985] [Reeves et al, 1987] [Malconian et al, 1990]. In the autumn of 1981, two members of the AMREE group climbed to the summit of Mt. Everest. Despite the handicap of an arterial PO2 of 28mmHg (3.7 kPa), continuous Holter monitoring was unable to identify any changes in the QRS, ST, or T wave components of either climbers during their summit attempt [Karliner et al, 1985] [West et al, 1983]. These reassuring results led the well respected high altitude physician Herb Hultgren to conclude, ‘‘Heavy exercise can be performed at extreme altitudes without evidence of myocardial ischaemia’’ [Hultgren, 1997]. 
Within ten minutes of breathing 10% oxygen at sea level, MPAP in healthy human volunteers has been shown to increase by 13 to 23mmHg [Motley et al, 1947]. This increase has been shown to persist. After 1 year spent at 4540m, the MPAP of acclimatized lowlanders at rest have been shown to have increased by 50% - from 12mmHg to 18mmHg [Sime et al, 1974]. Whilst the introduction of supplemental oxygen restores sea level pulmonary haemodynamics in those who have recently ascended to high altitude, smaller changes are observed following a more prolonged stay. After more than 30 days of hypoxic exposure, OEII participants saw only small reductions in resting MPAP following the breathing of 100% oxygen. At a PB of 32kPa, the administration of 100% oxygen reduced MPAP from 33mmHg to 24mmHg, - still 9mmHg higher than that found at sea level measurement [Groves et al, 1987]. This is thought to be largely due to the development of smooth muscle bands in pulmonary arterioles. These bands are largely unaffected by supplemental oxygen and lead to persistent narrowing of the vessel lumen and a prolonged increase in MPAP [Heath and Williams, 1995]. Changes also take place within the right atrium and ventricle. Animal experiments reveal right ventricular hypertrophy within weeks of exposure to hypoxic conditions equivalent to 4500m and higher [Marki et al, 1982]. Post mortem results in humans have confirmed this, with the ratio of left to right ventricular weights changing from 1:8 at sea level to 1:3 at altitudes of between 3700 and 4260m [Arias-Stella and Recavarren, 1962].
Whilst the majority of ECG studies at altitude have taken a small number of single“snapshots” at modest altitudes, little is known about how the ECG changes with a prolonged stay at high altitude. Given the dilatation and subsequent hypertrophy of the right heart, a dynamic process may be at work and further changes occur with time. Similarly, much is known about the development of right heart strain at altitude, however little is known about what happens following descent. Given the extensive remodelling that occurs it is possible that changes may persist for days or weeks following descent.


2 - QT Interval Prolongation

The time between the onset of the Q wave and the end of the T wave is commonly referred to as the QT interval [Figures 1.35 and 1.36]. Prolongation of the QT interval is due to a delay in ventricular repolarisation caused by changes in the flow of ions across the myocardial cell membrane [Morita et al, 2008]. In some cases, this can lead to activation of inward depolarising currents known as early afterdepolarisations (EAD’s). If EAD’s reach threshold voltage these can trigger ventricular extrasystoles. Cells vary in their susceptibility to EAD’s and the subsequent development of ventricular extrasystoles. This is a source of concern since, “heterogeneity in the development of prolongation of the action potential and early afterdepolarisations result in a myocardium that is vulnerable to re-entrant excitation, the probable proximate cause of torsades de points (polymorphic ventricular tachycardia – PVT)” (Figure 1.37) [Roden, 2004]. The link between prolongation of the QT interval and the development of life threatening tachyarrhythmias is now well known. Over recent decades considerable work has been undertaken that has not only identified an extensive genetic basis for QT prolongation but also a number of medical and environmental triggers of the condition.







Figure 1.35: The QT interval is measured from the deviation of the Q wave to the isoelectric line to the point of the T wave that rejoins the isoelectric line. The QT is measured in Lead II. Since QT varies with heart rate, a correction formula is applied (QTc). The most commonly used is Bazett’s Formula. QTc is considered normal if it is less than 440 in men and 460 in women [Abrams et al, 2010].

Figure 1.36: The passage of electrical current through the heart is governed by the cardiac action potential (AP).The cardiac action potential is triggered by the opening of sodium channels and a rapid influx of sodium ions (INa) (Phase 0). This is followed by a brief period of repolarisation caused by transient outward flow of potassium ions (IKto) and influx of calcium ions (ICa-L and ICa-T) (Phase 1). The subsequent plateau in the cardiac AP results from a balance achieved between the inward ICa-L and ICa-T currents and the outward potassium rectifier current (IKr) (Phase 2). This distinguishes cardiac action potentials from the much shorter action potentials found in skeletal muscle and nerves. Phase 3 results from a further fall in calcium influx (ICa-L and ICa-T) and a significant increase in potassium efflux (IKs and IK1) that eventually leads to the restoration of resting potential (Phase 4).
Adapted from Morita et al, 2008.











To determine the electrocardiographic changes that occur in lowland residents during high altitude exposure. 

HYPOTHESES
The following hypotheses were determined prior to the CXE, TE and AHS studies: 

Mean resting heart rate changes following hypoxic exposure.
Mean resting heart rate changes with an increase in hypoxic exposure.
Mean resting heart rate differs between men and women undergoing hypoxic exposure. 
Mean resting heart rate changes with prolonged hypoxic exposure.
The incidence of atrial and ventricular ectopics does changes with hypoxic exposure.
The incidence of atrial and ventricular ectopics changes with prolonged hypoxic exposure.
Electrocardiographic signs of right heart strain are present during hypoxic exposure.
Electrocardiographic signs of right heart strain are present following the return of normoxic exposure. 
The corrected QT interval (QTc) changes following hypoxic exposure.
The corrected QT interval (QTc) changes following prolonged hypoxic exposure.
The corrected QT interval (QTc) changes with an increase in hypoxic exposure.


















CHAPTER 2 – ELECTROCARDIOGRAPHIC CHANGES DURING A PROLONGED STAY ON MT EVEREST

2.1	Introduction
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In the spring of 2007 a group of scientists from the University College London’s Centre for Altitude, Space and Extreme Environment Medicine (CASE) undertook a medical research expedition to the world’s highest mountain - Mt Everest (8850m). The expedition was named, “Caudwell Xtreme Everest (CXE)” and its aim was to study, “comprehensively, a large cohort of healthy humans exposed to progressive, sustained environmental hypobaric hypoxia” [Levett et al, 2010]. 
Sixteen male members of CXE, aged between 19 and 47, were consented for the study. The participants had previously ascended uneventfully to an altitude of more than 4500m. A comprehensive health assessment was undertaken by experienced medical staff. No evidence of significant cardiovascular or respiratory disease was identified. Participants were prevented from taking any medication that aided acclimatisation or ameliorate high altitude illness. To minimize any effect of hypoxic adaptation, all participants refrained from any form of hypoxic training and did not travel above 3000m during the three months prior to departure.
A baseline ECG was performed at the CASE human physiology laboratory in London prior to departure (75m). All participants flew to Kathmandu (1300m) and then on to Lukla (2800m) in the Sagarmatha National Park [Figures 2.1 and 2.2]. 
One participant was lost to follow up in Kathmandu.

Figure 2.1: Map of Nepal.
Nepal is bordered to the south by India and China to the north. Lukla lies approximately 140km east of Kathmandu.


Figure 2.2: Map of Sagarmartha National Park.
The distance from Lukla to Mt Everest Base Camp is approximately 60kms.












Figure 2.3: The ascent profile of CXE participants to Mt Everest Base Camp.  










Location	Altitude (m)	Barometric Pressure (KPa)	Partial Pressure of Inspired Oxygen (KPa)
London	75	100.5	19.7
Kathmandu	1300	86.7	16.8
Mt Everest Base Camp (EBC1-3)	5300	53.8	9.9

Table 2.1: The altitude, barometric pressure and partial pressure of oxygen of the sites that ECG studies were obtained during CXE. 




Digital 12 lead ECG’s were obtained from a Welch Allyn PC-Based Resting Electrocardiograph and interpreted using Cardioperfect Workstation software (Welch Allyn, Skaneateles Falls, NY). The electrocardiograph measured 147mm (length) x 108mm (width) x 32.5mm (height) and weighed approximately 200g. ECG data was transmitted via banana electrode adapters and a 10 lead patient cable to the electrocardiograph. A USB connection linked the electrocardiograph to a laptop computer. Data collection, interpretation and storage were performed on a battery-powered Dell Inspiron laptop computer with a Pentium III processor, 512MB of RAM memory and a Windows 2000 operating system.
Cardioperfect Workstation software did not permit the transfer of ECG’s directly into text files. Therefore ECG’s were stored and printed in PDF format. These were subsequently scanned in JPEG format and transferred into text files.
A standard recording scale was used. The scale of the vertical axis was 10mm for every 1mV and the recording speed was 25mm/second. A sampling rate of 600 samples per second was used to digitise the analogue electrical signal generated by the electrocardiograph. A rate of 250 samples per second or greater has been shown to accurately present components of the ECG in a digital format [Pizzutti and Nolfe, 1985]. Filtering was applied by the electrocardiograph in order to reduce artefact. Low (0.05Hz) and high (150Hz) frequency cut offs were applied. A 35Hz filter was applied to minimise artefact from muscle tremor. These were consistent with guidelines endorsed by the International Society for Computerized Electrocardiography [Kligfield, et al, 2007]. To further minimise artefact from respiration and movement each participant lay supine on a comfortable mattress for a minimum of 5 minutes prior to ECG measurement. Single use disposable electrodes were used for each ECG. To maintain consistency, the same tester placed the electrodes for each ECG recording. The standard placements for a 12 lead ECG were used [Hampton, 2008]:
Limb leads:
V1 – Fourth intercostal space, right sternal border
V2 – Fourth intercostals space, left sterna border
V3 – Midway between V2 and V4
V4 – Fifth intercostals space, left midclavicular line
V5 – Level with V4 left anterior axillary line
V6 – Level with V4 mid axillary line

Chest Leads:
Right Upper – Distal right clavicle
Left Upper – Distal left clavicle
Right Lower – Right medial malleolus




Right heart strain was assessed by the following measurements:

QRS Axis (degrees)
Sum of P wave amplitudes in II, III and aVF (mV)
Amplitude of T wave in V1 (mV)

The quadrant system was used to determine cardiac axis. Normal cardiac axis (-30 to 90 degrees) was defined as positive QRS complexes in leads I and aVF. Right axis deviation (90 to 180 degrees) was defined as a negative QRS complex in I and a positive QRS complex in aVF [Hampton, 2013] [Surawicz and Knilans, 2008] [Wagner, 2013].
The QRS axis was calculated to the nearest 15 degrees using the hexaxial reference system (Figure 2.4) [Davies, 2007]. This is performed by identifying the smallest or most equiphasic QRS complex in a limb lead. Using the hexaxial reference system, the lead at right angles is then recorded. If it is positively deflected on the ECG the axis is given by the positive pole (labelled I, II, II, aVF and aVL). If this lead is negatively deflected on the ECG the axis is given by the negative pole. 


Figure 2.4: The hexaxial reference system (Morris et al, 2003].

The axis is then refined by returning to the original lead.  If the deflection of the initial lead is more negative, 15 degrees is added, whilst if the deflection is more positive, 15 degrees is subtracted [Davies, 2007].  




Mean P wave (Manual 1)	1.16














Mean T wave (Manual 1)	-0.02






Table 2.3: A comparison of the two manual T wave amplitude measurements taken from the CXE results (mm).


































Figure 2.5: The relationship between manual QT measurement (x axis) and the digital measurement (y axis). A line of unity has been inserted.


Figure 2.6: The relationship between the manual R-R interval (x axis) and the digital R-R calculation (y axis). A line of unity has been inserted.












Table 2.6: A comparison of the digital and manual QTc measurements taken on CXE (ms).

Since the digital QTc interval was found to lie within 10ms of the manual value it was therefore assumed that the, “computer knows how to compute the average RR interval, use the heart rate correction formula, and generate an accurate QTc” [Johnson and Ackerman, 2009]. 

Analysis of the QT Interval (QTc) 

Since manual and digital values were in close agreement, QT and RR intervals were obtained from digital data. These were then substituted into correction formulae that had been previously used in either hypobaric chamber or high altitude field studies. The following correction formulae were used:
Bazett			QTc = QT / RR1/2
Fridericia		QTc = QT / RR1/3
Hodges		QTc = QT + 0.154(1-RR)
Framingham 		QTc = QT + 0.154(heart rate-60)

Arterial Oxygen Saturation (SpO2)









Using GraphPad Prism 7.01, normality was assessed using a Shapiro-Wilk test. A P value of 0.05 or greater was assumed to reflect a normally distributed sample. Normally distributed datasets were analyzed using one way ANOVA and Tukey’s multiple comparison test. The mean, standard deviation, standard error of the mean and 95% confidence intervals were presented in numerical form. The mean and 95% confidence interval were presented in graphical form. Statistical significance was accepted at a P value of 0.05 or less. For data sets that were not normally distributed, a Kruskall-Wallis and Dunn’s Multiple Comparison Test were used. The median and interquartile range (IQR) were presented in numerical and graphical form. Statistical significance was accepted at a P value of 0.05 or less. 

















U 95% CI	68.4 	75.8	80.5	79.7	72.6





Table 2.7: The heart rate of participants during the CXE study (beats per minute).
^ denotes a normally distributed sample and * denotes a significant difference with London (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 2.7: The heart rate of participants during the CXE study (beats per minute). 








 No significant change in cardiac axis was observed during CXE (Table 2.8 and Figure 2.8).
 The sum of P wave amplitudes in II, III and aVF increased at EBC (P<0.05) (Table 2.9 and Figure 2.9). No significant difference was observed between London and Kathmandu.












Table 2.8: The QRS axis of participants in the CXE study (degrees).




Figure 2.8: The QRS axis of participants in the CXE study (degrees).









Table 2.9: The sum of P wave amplitudes in II, III and aVF of participants in the CXE study (mm) (10mm=1mV).
All samples were normally distributed. * denotes a significant difference with London, ‡ with EBC1 and † Kathmandu.


Figure 2.9: The sum of P wave amplitudes in II, III and aVF of participants in the CXE study (mm) (10mm=1mV).













Table 2.10: The T wave amplitude (V1) of participants during the CXE study (mm) (10mm=1mV).
All samples were normally distributed. * denotes a significant difference with London (P<0.05).

Figure 2.10: The T wave amplitude (V1) of participants during the CXE study (mm) (10mm=1mV).











Figures 2.11 to 2.15: The ECG’s of a CXE participant. The ECG’s of a CXE participant. The 1st and 5th ECG’s were recorded at low altitude. The 2nd, 3rd and 4th ECG’s were obtained at Mt Everest BC. T wave inversion can be seen in V1 at high altitude and persist following return to Kathmandu.













Figures 2.16 to 2.20: The ECG’s of a CXE participant. The 1st and 5th ECG’s were recorded at low altitude. An RSR pattern can be seen in Figure 2.18. The heart rhythm clearly originates above the ventricles, the terminal R wave is present and the QRS is more than 120ms. However slurring of the S waves in I and V6 are absent. Therefore, the criteria for a diagnosis of Right Bundle Branch Block (RBBB) is not met [Hampton, 2013] [Surawicz and Knilans, 2008] [Wagner, 2013].








T wave inversion in V1	4	9	8	13	5

Table 2.11: The incidence of right axis deviation and T wave inversion (V1) in CXE participants.

QTc (Bazett’s and Fridericia’s) increased on arrival at EBC (P<0.05) (Tables 2.12 and 13 and Figures 2.21 and 22). No subsequent change was observed following stay at high altitude. No significant difference was observed between London and Kathmandu.












Table 2.12: The QTc (Bazett’s) of participants during the CXE study.
All samples were normally distributed. * denotes a significant difference with London (P<0.05). ‡ denotes a significant difference with Kathmandu.

Figure 2.21: The QTc (Bazett’s) of participants during the CXE study.











Table 2.13: The QTc (Fridericia’s) of participants during the CXE study.
^ denotes a normally distributed sample, * denotes a significant difference with London (P<0.05) and ‡ denotes a significant difference with Kathmandu identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 2.22: The QTc (Fridericia’s) of participants during the CXE study.









Table 2.14: The QTc (Hodges) of participants during the CXE study.
All samples were normally distributed. No significant differences were observed.

Figure 2.23: The QTc (Hodges’) of participants during the CXE study.









Table 2.15: The QTc (Framingham) of participants during the CXE study.
All samples were normally distributed. No significant differences were observed.

Figure 2.24: The QTc (Framingham) of participants during the CXE study.
The bars represent mean and 95% confidence intervals.














Table 2.16: Body weight amongst CXE participants in London and Kathmandu. 
Both samples were normally distributed. An unpaired t-test demonstrated a significant difference between the two samples (P<0.05).






Figure 2.26: Correlation between the changes in QTc (ms) (Bazett’s) (x axis) and body weight (kg) (y axis) amongst CXE participants in EBC3. The r2=0.01 (NS).













Table 2.17: Arterial oxygen saturation (SpO2) amongst CXE participants (%).






Figure 2.28 to 2.30: Correlation between the changes in QTc (Bazett’s) (x axis) and arterial oxygen saturation (SpO2) (y axis) amongst CXE participants in EBC1, 2 and 3. SpO2 in London was assumed to be 100%. The r2 values were found to be 0.01 (NS), <0.01 (NS) and -0.04 (NS) respectively. 

Figure 2.31: Correlation between the QTc (Bazett’s) (x axis) and arterial oxygen saturation (SpO2) (y axis) amongst CXE participants in EBC1, 2 and 3. The r2 value was <0.01 (NS).
2.4	Conclusions



























Ethics Approval and Consent





In the autumn of 2007 a group of medical students and doctors from University College London undertook a medical research expedition to the world’s highest mountain - Mt Everest (8850m). The expedition was named, “Team Everest” and its aim was to study the effect of an ascent to high altitude upon a group of healthy lowland residents.
Thirty seven members of TE (17 men and 20 women), aged between 19 and 28, were consented for the study. A comprehensive health assessment was undertaken by experienced medical staff. No evidence of significant cardiovascular or respiratory disease was identified. Participants were prevented from taking any medication that aided acclimatisation or ameliorate high altitude illness. To minimize any effect of hypoxic adaptation, all participants refrained from any form of hypoxic training and did not travel above 3000m during the three months prior to departure.

















Table 3.1: The altitude, barometric pressure and partial pressure of oxygen of the three locations that ECG studies were obtained during TE. Barometric pressure and partial pressure of oxygen values for London, Namche Bazaar and Pheriche were obtained from CXE results, whilst values for Gorak Shep were calculated using West’s quadratic equation [West, 1996]. Altitudes were taken from map values and calculated to the nearest 50m.

To ensure adequate acclimatisation and prevent high altitude illness, the ascent from Lukla to Mt Everest Base Camp was undertaken over 7 days. The ascent profile complied with Wilderness Medical Society guidelines that recommended, “above an altitude of 3000m, individuals should not increase the sleeping elevation by more than 500m per day and should include a rest day (ie no ascent to higher sleeping elevation) every 3 to 4 days” [Luks et/al, 2009]. To maintain an identical pattern of hypoxic exposure, participants remained within 300m vertical metres of the accommodation during rest days at Namche Bazaar (3500m) and Pheriche (4250m). 
ECG recordings were obtained within 24 hours of arriving in Namche Bazaar (3500m), Pheriche (4250m) and Gorak Shep (5200m). 

ECG Recording and Analysis

	As described in Chapter 2


Arterial Oxygen Saturation (SpO2)




Using GraphPad Prism 7.01, normality was assessed using a Shapiro-Wilk test. A P value of 0.05 or greater was assumed to reflect a normally distributed sample. Normally distributed datasets were analyzed using one way ANOVA and Tukey’s multiple comparison test. The mean, standard deviation, standard error of the mean and 95% confidence intervals were presented in numerical form. The mean and 95% confidence interval were presented in graphical form. Statistical significance was accepted at a P value of 0.05 or less. For data sets that were not normally distributed, a Kruskall-Wallis and Dunn’s Multiple Comparison Test were used. The median and interquartile range (IQR) were presented in numerical and graphical form. Statistical significance was accepted at a P value of 0.05 or less. 
A student’s t test was used to compare heart rate, arterial oxygen saturation and QTc between sexes. Statistical significance was accepted at a P value of 0.05 or less. 


























Table 3.2: The heart rate of participants during the TE study (beats per minute).
All samples were normally distributed. *denotes a significant difference with London (P<0.05)

Figure 3.2: The heart rate of participants during the TE study (beats per minute).








Table 3.3: The heart rate of male participants during the TE study (beats per minute).
All samples were normally distributed. *denotes a significant difference with London (P<0.05)

Figure 3.3: The heart rate of male participants during the TE study (beats per minute).














Table 3.4: The heart rate of female participants during the TE study (beats per minute).
All samples were normally distributed. *denotes a significant difference with London (P<0.05)

Figure 3.4: The heart rate of female participants during the TE study (beats per minute).
The bars represent mean and 95% confidence intervals.












Table 3.5: The arterial oxygen saturation (SpO2) of all participants during the TE study (%).
^ denotes a normally distributed sample, * denotes a significant difference with London (P<0.05), ‡ denotes a significant difference with Namche (P<0.05) and † denotes a significant difference with Pheriche (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.

Figure 3.5: The arterial oxygen saturation (SpO2) of participants during the TE study (%).

















Table 3.6: The arterial oxygen saturation (SpO2) of male participants during the TE study (%).
^ denotes a normally distributed sample, * denotes a significant difference with London (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 3.6: The arterial oxygen saturation (SpO2) of male participants during the TE study (%).


















Table 3.7: The arterial oxygen saturation (SpO2) of female participants during the TE study (%).
^ denotes a normally distributed sample, * denotes a significant difference with London (P<0.05) and ‡ denotes a significant difference with Namche (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 3.7: The arterial oxygen saturation (SpO2) of female participants during the TE study (%).
The bars represent the median and inter-quartile range.








Figures 3.8 to 3.10: Correlation between the changes in heart rate (x axis) and arterial oxygen saturation (y axis) amongst TE participants in Namche, Pheriche and Gorak. The r2 values were found to be -0.42 (P<0.05), -0.16 (NS) and -0.47 (P<0.05) respectively. 






















Table 3.8: The QTc (Bazett’s) of participants during the TE study.
All samples were normally distributed. * denotes significant difference to London (P<0.05), ‡ denotes significant difference to Namche (P<0.05).

Figure 3.12: The QTc (Bazett’s) of participants during the TE study.












Table 3.9: The QTc (Bazett’s) of male participants during the TE study.
^ denotes a normally distributed sample and * denotes a significant difference with London (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 3.13: The QTc (Bazett’s) of male participants during the TE study.









Table 3.10: The QTc (Bazett’s) of female participants during the TE study.
All samples were normally distributed. * denotes significant difference to London (P<0.05).

Figure 3.14: The QTc (Bazett’s) of female participants during the TE study.









Figure 3.18: Correlation between the QTc (Bazett’s) (x axis) and arterial oxygen saturation (SpO2) (y axis) amongst TE participants. The r2 value is -0.52 (P<0.05).


















Table 3.11: The QTc (Fridericia’s) of participants during the TE study.
^ denotes a normally distributed sample and * denotes a significant difference with London (P<0.05) identified by Kruskal-Wallis and Dunn’s Multiple Comparisons Tests.


Figure 3.19: The QTc (Fridericia’s) of participants during the TE study.

















Table 3.12: The QTc (Fridericia’s) of male participants during the TE study.
All samples were normally distributed. * denotes significant difference to London (P<0.05).

Figure 3.20: The QTc (Fridericia’s) of male participants during the TE study.








Table 3.13: The QTc (Fridericia’s) of female participants during the TE study.
All samples were normally distributed. * denotes significant difference to London (P<0.05).

Figure 3.21: The QTc (Fridericia’s) of female participants during the TE study.
The bars represent mean and 95% confidence intervals.









Table 3.14: The QTc (Hodges’) of participants during the TE study.
All samples were normally distributed.

Figure 3.22: The QTc (Hodges’) of participants during the TE study.









Table 3.15: The QTc (Framingham’s) of participants during the TE study.
All samples were normally distributed.

Figure 3.23: The QTc (Framingham’s) of participants during the TE study.










Heart rate increased in men and women following ascent to high altitude (P<0.05). Whilst increases were seen with each gain in height, these were not found to be significantly different. No significant differences were noted between men and women at each of the locations studied. 
There was no evidence of rhythm disturbance during TE.












CHAPTER 4 – THE EFFECT OF ACUTE HYPOXIA UPON VENTRICULAR REPOLARISATION.

4.1	Introduction
	The duration between the onset of the Q wave and the end of the T wave is commonly referred to as the QT interval. Prolongation of the QT interval is due to a delay in ventricular repolarisation caused by changes in the flow of ions across the myocardial cell membrane [Morita et/al, 2008]. In some cases, this can lead to activation of inward depolarising currents and the triggering of ventricular extrasystoles resulting in the development of torsades de points (polymorphic ventricular tachycardia – PVT) [Roden, 2004]. 
The effect of hypoxic exposure upon the QT interval has been previously studied. Following the administration of 11% oxygen for 15 minutes researchers found a 19% fall in SaO2 and an increase in QTc from 404 ms to 418 ms (P<0.05) [Roche et al, 2003]. A similar rise was also seen in eight healthy volunteers who were exposed to a level of hypoxia that resulted in a SaO2 of 90%. Following 15 to 30 minutes of exposure, the mean QTc had increased by a mean of 15.6 ms (P<0.05) [Bremner et al, 1992]. However conflicting results have also been reported. In patients with underlying chronic lung disease a change in QTc has not been observed. Following 15 minutes of exposure to 15% oxygen the QTc in 101 patients remained unchanged and a correlation between SaO2 and QTc was not identified [Skipworth et al, 2011].
The aim of this study is to examine the effect of a range of different hypoxic conditions upon the QTc of healthy volunteers and therefore develop a more extensive understanding of the relationship between ventricular repolarisation and tissue oxygenation.
4.2	Methods

Ethics Approval and Consent





-Acute Hypoxia Study (AHS)

































Table 4.2: The study design of the AHS. X, Y and Z represent 12, 15 and 18% oxygen concentrations that were delivered randomly to the participants

The hypoxic mixture was delivered continuously through a close fitting facemask that was attached to a Portable Hypoxicator (GO2Altitude, London, UK). The system was fitted with two oxygen sensors. The first was housed within the hypoxicator and automatically controlled the hypoxic mixture that was delivered. The second sensor was fitted into the first 10cm of tubing and was attached to a battery powered LCD display (Maxtec Handi, Salt Lake City, UT, USA). Immediately adjacent to the facemask was a 2 litre reservoir bag and a one way expiratory valve. These two devices ensured that a continuous supply of hypoxic gas was always available and exhaled gas was immediately vented to the atmosphere. No difference was observed in the partial pressure of oxygen between the two sensors.
ECG Recording and Analysis





Using GraphPad Prism 7.01, normality was assessed using a Shapiro-Wilk test. A P value of 0.05 or greater was assumed to reflect a normally distributed sample. Normally distributed datasets were analyzed using one way ANOVA and Tukey’s multiple comparison test. The mean, standard deviation, standard error of the mean and 95% confidence intervals were presented in numerical form. The mean and 95% confidence interval were presented in graphical form. Statistical significance was accepted at a P value of 0.05 or less. For data sets that were not normally distributed, a Kruskall-Wallis and Dunn’s Multiple Comparison Test were used. The median and interquartile range (IQR) were presented in numerical and graphical form. Statistical significance was accepted at a P value of 0.05 or less. 

















Table 4.3: The arterial oxygen saturation (SaO2) of participants during AHS (%).






Figure 4.1: The arterial oxygen saturation (SaO2) of participants during AHS (%).

















Table 4.4: The heart rate of participants during AHS (beats per minute).
All samples were normally distributed.

Figure 4.2: The heart rate of participants during AHS (beats per minute).
The bars represent mean and 95% confidence intervals.
Rhythm














Table 4.5: The QTc (Bazett’s) of participants during AHS.
All samples were normally distributed. * denotes a significant difference with 21% oxygen.

Figure 4.3: The QTc (Bazett’s) of participants during AHS.
The bars represent mean and 95% confidence intervals

	The correlation between QTc (Bazett’s) and SaO2 showed a r2 value of -0.29 (P<0.05).


Figure 4.4: Correlation between the QTc (Bazett’s) (x axis) and arterial oxygen saturation (SaO2) (y axis) during AHS. The r2 value is -0.29 (P<0.05).















Table 4.6: The QTc (Fridericia’s) of participants during AHS.
All samples were normally distributed. 

Figure 4.5: The QTc (Fridericia’s) of participants during AHS.
The bars represent mean and 95% confidence intervals.









Table 4.7: The QTc (Hodges’) of participants during AHS.


Figure 4.6: The QTc (Hodges’) of participants during AHS.









Table 4.8: The QTc (Framingham’s) of participants during AHS.

Figure 4.7: The QTc (Framingham’s) of participants during AHS.
The bars represent mean and 95% confidence intervals.

The effect of different levels of hypoxia upon the QTc (Bazett’s) can be seen during AHS (Figure 4.8). During the 3 periods of hypoxic exposure the QTc rose rapidly and remained elevated throughout before rapidly returning to baseline values. 


Figure 4.8: The QTc (Bazett’s) during AHS. The percentage of inspired oxygen is marked on the x axis. Blank values represent 21% oxygen.




























CHAPTER 5 – DISCUSSION





The median heart rate of CXE members increased following ascent to Mt Everest Base Camp (EBC) (5300m) (P<0.05) (Table 2.7 and Figure 2.7). There were no significant changes in median heart rate during the stay at EBC. No significant difference in median heart rate was observed between London and Kathmandu.
There was no evidence of arrhythmic activity during CXE.
No significant change in cardiac axis was observed during CXE (Table 2.8 and Figure 2.8). The sum of P wave amplitudes in II, III and aVF increased at EBC (P<0.05) (Table 2.9 and Figure 2.9). No significant difference was observed between London and Kathmandu. The T wave amplitude in V1 decreased at EBC (P<0.05) (Table 2.10 and Figure 2.10) (Figures 2.11 to 2.15). No significant difference was observed between London and Kathmandu. 
Right axis deviation and T wave inversion in V1 increased following ascent to high altitude. However in many participants these changes did not persist and only appeared intermittently during the stay at high altitude (Table 2.11).
QTc (Bazett’s and Fridericia’s) increased on arrival at EBC (P<0.05) (Tables 2.12 and 13 and Figures 2.21 and 22). No subsequent change was observed following stay at high altitude. No significant difference was observed between London and Kathmandu. No change in QTc (Hodges’ and Framingham) was observed during CXE (Tables 2.14 and 2.15 and Figures 2.23 and 24).
Mean body weight fell by 8kg during CXE (P<0.05) (Table 2.16 and Figure 2.25). However a correlation between changes in body weight and QTc (Bazett’s formula) was not identified (Figure 2.26).











Rate - On ascending to Mt Everest Base Camp the median heart rate of CXE members increased by 9 beats per minute (14%). This increase persisted throughout the stay at high altitude. Previous studies have tended to concentrate upon resting heart rate measurements at lower altitudes over shorter periods of time [Baggish et al, 2014]. For example, Wolfel et/al demonstrated that mean heart rate increased by 11% on reaching Pike’s Peak (4300m) and persisted throughout 21 days spent on the summit [Wolfel et al, 1991]. The mechanism behind this sustained increase in heart rate is likely to be complex. Prolonged hypoxic exposure leads to downregulation of cardiac beta adrenoreceptors in both animal and human subjects. In a novel study conducted by researchers on Mt Blanc, the concentration of isoprenaline (a non-selective beta adrenergic agonist) needed to increase resting heart rate by 25 beats per minute rose with time spent above 4000m [Richalet et al, 1988]. Clearly this finding would favour a move towards a fall in heart rate following prolonged high altitude exposure. Indeed, at low altitudes this has been seen. At 1860m, the mean heart rate of 15 healthy male volunteers fell from 85 to 75 beats per minute following 150 days of exposure [Sizlan et al, 2008]. However this has not been demonstrated at higher altitudes. In their comprehensive review of the cardiovascular system at altitude, Wolfel and Levine identified six studies conducted between altitudes of 3658 and 4350m that all observed a prolonged rise in resting heart rate for stays of up to 28 days [Wolfel and Levine, 2001]. Two possible explanations for a persistent increase in heart rate at high altitude are described below:
An increase in sympathetic nervous system activity overcomes the effects of beta adrenoreceptor downregulation. 
A prolonged stay in hypoxic conditions is commonly accompanied by “high altitude deterioration”. This phenomenon was first outlined by Michael Ward, the doctor on the first successful ascent of Mt Everest in 1953, who described it as, “a gradual diminution in man’s capacity to do work at great heights” [Ward, 1954]. Whilst little scientific study has been done to identify the underlying causes of this condition, prolonged hypoxic exposure is known to predispose individuals to weight loss, dehydration, infection, low mood and sleep disturbance. When this is combined with the effects on the human body of other environmental factors such as extremes in temperature, UV light and humidity, a significant increase in sympathetic nervous system activity seems likely to occur. This increase is likely to be accentuated by a series of poorly understood changes that occur in the sympathetic neural pathway following prolonged hypoxic exposure [Hansen and Sander, 2003]. After a 4 week stay at 5260m, sympathetic activity measured by peroneal microneurography rose from 16 to 48 bursts per minute (P<0.05). Following efforts to restore sea level physiology with intravenous fluid and supplemental oxygen, sympathetic activity fell by only 10 bursts per minute, leading the authors to conclude, “hypoxic exposure may engage long-term potentiation of synaptic transmission in brain centres involved in the control of central sympathetic outflow”. Subsequently, commentators have speculated that Hansen and Sander’s results reveal changes in the thresholds for baroreceptor and chemoreceptor activity following prolonged hypoxic exposure that cause an increase in activity at any given level of hypovolaemia and hypoxia [Baggish et al, 2014]. As a result, any decline in adrenoreceptor density may be offset by an increase in sympathetic activity. 
A decrease in parasympathetic nervous system activity. 
Initially, the increase in heart rate on ascent to altitude is believed to be due to a combination of increased sympathetic and decreased parasympathetic nervous system activity. As downregulation of beta adrenoreceptors occurs with prolonged exposure, some commentators have argued that the rise in resting heart rate is maintained by a decrease in parasympathetic activity [Seals et al, 2001]. By using atropine to block muscarinic receptors, researchers have been able to identify changes in cardiac vagal tone during sustained periods of hypoxia. A smaller increase in heart rate following administration would imply a reduction in cardiac vagal tone. This was identified in a group of healthy male volunteers residing at 4350m for seven days [Grover et al, 1986]. Support for this finding can be found in heart rate variability studies [Hainsworth et al, 2007]. R–R interval power measurements can distinguish between the contributions of the sympathetic and parasympathetic nervous systems. Whilst high frequency measurements solely reflect sympathetic activity, low frequency measurements are associated with both autonomic components. The balance between the two measurements shifts during acclimatisation.  This not only represents an increase in sympathetic activity but also a decline in parasympathetic function [Kanai et al, 2001].
	CXE participants experienced a significant rise in resting heart rate following ascent to 5300m. This persisted throughout their high altitude stay and only returned to normal following descent to Kathmandu. Whilst studies at lower altitude have revealed a reduction in resting heart rate during a prolonged stay, changes in sympathetic and parasympathetic activity may be responsible for this persistent rise at 5300m.     


















Aigner et al, 1980	Five healthy mountaineers, aged 32 to 42 years of age, ascending from 4800m to 7800m with continuous ECG recording.	“Revealed heart rates in the range of 120 to 150 beats per minute and both atrial and ventricular premature complexes”*.
Alexander, 1995	Unacclimatized, healthy 65 year old male wearing Holter monitoring for 24 hours during summit day on Kilimanjaro (5895m).	“One episode of atrial tachycardia occurred.”
Das et al, 1983	Standard ECG recordings were undertaken for 10 days in two groups of 20 unacclimatized participants at 3200m and 3771m. 	“Intermittent Wolff-Parkinson-White syndrome was noted in one subject on day 5, 7 and 10 of high altitude stay at 3200m.”
Karliner et al, 1985	12-lead ECG’s were obtained in 19 healthy participants at sea level, 5400m and 6300m.Continuous single lead ECG recording was then obtained on 8 participants up to the summit of Mt Everest (8850m).   	Continuous ECG recording on two participants during summit day revealed, “only one atrial premature contraction during the recording sequence of the successful summit attempts”.
Nagasaka et al, 1967	Continuous ECG recording was obtained on three healthy participants during as ascent of Aconcagua (6962m)	“Another characteristic feature in the EKG was the appearance of extrasystoles ... in one subject. They [could] be classified into supraventricular extrasystoles. Similar extrasystoles were observed even during sleep.”
Woods et al, 2008	9 healthy male volunteers were fitted with implantable loop recorders and monitored throughout an expedition to a height of 6325m.	“In one subject an episode of asymptomatic atrial flutter with 2:1 conduction was observed for 8.5 minutes immediately after a period of severe exertion at 4500 m.”

Table 5.1: A summary of previously reported atrial arrhythmias at high altitude.
*Published in German and summarised in [Alexander, 1995].

Similar changes have also been found during acute episodes of hypobaric exposure [Akhtar et al 1979]. Amongst 200 healthy lowland residents exposed to a PO2 comparable to that found at 4572m, 12 experienced atrial ectopics during ECG recording [Akhtar et al, 1979]. The absence of atrial ectopics during CXE may have been due to:
-Baseline atrial ectopic activity was likely to be very low in the CXE population
According to a recent study of 1742 participants who had undergone 24-hour Holter electrocardiography, the number of recorded atrial ectopic beats was greatest in those with risk factors for cardiovascular disease [Conen et al, 2012]. The mean incidence of atrial ectopics was found to range from 0.8 (age 50 to 55) to 2.6 (age 70 or older) per hour. Sedentary lifestyle and the presence of diabetes mellitus, hypertension and hypercholestrolaemia were found to be associated with an increase in atrial ectopic activity. [Conen et al, 2012]. Since CXE participants were young, active and healthy, the incidence of atrial ectopics was likely to be even lower than the 0.8 per hour found in this study.  An ECG recording ten seconds of data was therefore unlikely to reflect accurately changes in atrial ectopic activity in London or Kathmandu. Nevertheless, if atrial activity was significant at high altitude ECG measurement may have identified the presence of ectopics. Previous high altitude studies have suggested a rise in atrial ectopic activity at high altitude [Table 5.1], however the quantification of this increase prior to CXE was not possible. Only with the publication of Woods et al, shortly after the completion of our study, has it become clear that any increase in atrial arrhythmic activity is modest in young, healthy and well acclimatized individuals. Longer periods of data collection are therefore needed to determine any pattern that might exist. 
-The CXE population was not exposed to a significant stimulus to trigger an increase in atrial ectopic activity
CXE participants may not have been exposed to a significant degree and duration of PVR to trigger atrial ectopic activity or a supraventricular tachycardia. At a simulated altitude of 6100m, the resting mean pulmonary artery pressure of OEII’s seven healthy volunteers was shown to rise from 15 to 24mmHg [Sutton et al, 1987]. However, the mean right atrial pressure was found to fall from 2.6 to 0.5mmHg. This would suggest that contractility of the right heart was preserved and high altitude exposure, at least at rest, may not have produced the right heart strain needed to distort the right atrium and precipitate rhythm disturbance. In addition, any significant rise in PVR would need to be present for a long period of time to trigger a supraventricular arrhythmia. In a 6-year retrospective of 231 patients with pulmonary hypertension the incidence of SVT was 11.7% and the annual risk was 2.8% per patient [Tongers et al, 2007]. The average interval from the diagnosis of pulmonary hypertension to the identification of an arrhythmia was 3.5 years. This would suggest that supraventricular arrhythmias, “are a manifestation of long standing pulmonary hypertension” [Rajdev et al, 2012]. Three months of exposure to a modest increase in PVR is therefore unlikely to trigger significant changes in cardiac rhythm amongst young, healthy and well acclimatized lowland residents residing at high altitude.
Despite the publication of a number of studies confirming the presence of atrial ectopics at high altitude, these were not found amongst the ECG’s of CXE members at 5300m. The absence of atrial ectopics may be explained by the health of participants and the absence of factors that may trigger their appearance at high altitude. 
Morphology - The changes seen in cardiac axis, P wave and T wave morphology during CXE are consistent with the findings of previous high altitude field studies (Table 5.2). At the same height as CXE, AMREE researchers identified a mean rightward shift of axis (10-15 degrees) compared to CXE (20 degrees) [Karliner et al 1987]. Similar results were also obtained during the OEII hypobaric chamber study, which showed a rightward shift of 13 degrees at a simulated altitude of 4900m and 23 degrees at 6100m [Malconian et al, 1990]. These results are also consistent with a number of studies that report a high incidence of right axis deviation in healthy lowland residents who ascend to high altitude (Table 5.2). 

Author	Altitude(m)	Participants	Right Axis Deviation(degrees)	Increase in P Wave Amplitude(mV)	Decrease in T Wave Amplitude(mV)
Albrecht and Albrecht, 1969	<6200	72	“Only at 6200m could a distinct uniform R decrease and S increase be observed ... indicating a right axis shift”	“The amplitude of the P wave increased continually ... during ascent above 2700m”	“At 6200m all groups showed a significant flattening”
Das et al, 1983	32003771	2020	10.79.1	0.048mV0.018mV(in lead II)	50-60% had inversion in V1-3
Harris and Hansen, 1966	4301	16	13.6*	Not Reported	“Inversion of the T wave was often observed in tracings”
Jackson and Davies, 1960	<5837	12	20-50	“No significant changes”	83% had a decrease in amplitude at “high altitude”
Kapoor, 1984	4200	175	57.1% had more than 10 degrees of right axis deviation†	Not Reported	18.2% had inversion in V2 and 9.1% in V4
Karliner et al, 1985	<6300	19	11/18 developed right axis deviation (approximately 10-15°)	P Wave in II increased in 10/18	T wave flattening in  7/18 and inversion in 4/18 (V1)
Milledge, 1963	<7437	6	“the trend is for the shift to increase with altitude”	0	All had inversion in V1-3 at 5791m
Penaloza and Echevarria, 1957	4540	10	9/10 showed right axis deviation‡	0	20% had inversion in precordial leads

Table 5.2: A summary of electrocardiographic results obtained from field studies conducted at high altitude.
*After 4 weeks of residence at approximately 4300m. †After 11 months of residence at 4200m. ‡After 12 months of residence at 4540m

The mean sum of P waves in II, III and aVF increased from 3.1mm to 4.2mm during CXE (10mm=1mV). This is consistent with that found during OEII where a rise from 2.1mm to 3.4mm at 4900m and 4.1mm at 6100m was observed [Malconian et al, 1990]. A reduction in T wave amplitude is also commonly seen in those venturing to high altitude (Table 5.2) (Figure 5.1 and 5.2). 


Figures 5.1 and 5.2: ECG’s obtained from a CXE participant prior to departure (above) and on arrival at Mt Everest Base Camp (below). The presence of right axis deviation and T wave inversion in V1, 2 and 3 can be seen in the high altitude ECG. 

Following ECG recordings on Mt Everest, AMREE researchers found flattened T waves in 7/18 and inversion in 4/18 [Karliner et/al, 1987]. During CXE, 13/16 participants were found to have T wave inversion in V1 following a period of 50 to 60 days spent at high altitude. Mean T wave amplitude in V1 fell from 1.3mm to -1.3mm during CXE. This was comparable to a fall from 0.44mm to 0.4mm (4900m) and -0.4mm (6100m) during OEII (10mm=1mV) [Malconian et al, 1990]. 






Figures 5.3 to 5.7: The ECG’s of a CXE participant. The 1st and 5th ECG’s were recorded at low altitude. The 2nd, 3rd and 4th ECG’s were obtained at Mt Everest BC. In this participant, T wave amplitude in V1 does not fall with duration of stay. The lowest amplitude can be found at the second high altitude tracing. 

Similar findings have also been seen in previously published work. [Das et al, 1983] [Harris and Hansen, 1966] [Kapoor, 1984]. Following 10 days spent at altitudes of between 3200m and 3771m, early evidence of right axis deviation and T wave inversion in V1 to 3 had largely resolved [Das et al, 1983]. Over 4 weeks spent at 4301m the axis of 16 healthy lowland residents had increased from 77 degrees to 87 degrees, however the incidence of T wave inversion in V1 had fallen [Harris and Hansen, 1966]. In one of the most extensive ECG field studies conducted at altitude, Kapoor found that amongst 200 Indian soldiers, those with right axis deviation of more than 10 degrees from baseline increased during a period of 23 months spent above 3600m [Kapoor, 1984]. Nevertheless, the incidence of T wave inversion in V2 fell from 18.5% to 13.5% over the same study period. 
Considerable variation was also noted on descent. Whilst no differences in axis, P and T wave morphology were identified between CXE participants studied in London and Kathmandu, T wave inversion in V1 was still present in 5/15 and right axis deviation in 4/15 following descent [Figures 5.8 to 5.11]. 






Figures 5.10 and 5.11: 12 lead ECG’s of a CXE participant taken at high altitude and following return to Kathmandu. T wave inversion in V1 can only be seen in the high altitude trace. 

Previous studies have demonstrated that resolution of ECG changes may take several months to occur [Das et/al, 1983] [Harris and Hansen, 1966] [Kapoor, 1984]. Harris and Hansen showed that axis on descent remained 11 degrees above baseline following 4 weeks at 4301m [Harris and Hansen, 1966]. Kapoor noted that 21% still had right axis deviation of more than 10 degrees one month after descending from 3600m and at the same time, 4% still had T wave insertion in V2 [Kapoor, 1984]. These results would suggest that in some of those descending to low altitude, resolution may take longer than that seen during CXE.
The highly variable pattern of ECG changes highlighted by CXE and a number of other published studies may be explained by three factors:
-Electrocardiography is not an accurate way to identify right heart strain.
According to guidelines issued by the American Heart Association, 
Considerable degrees of RVH are often required to change the balance of right and left ventricular vectors, because the vector of left ventricular activation dominates the balance in the normal heart and even more so in the setting of LVH. Thus, the ability of the ECG to detect RVH may be expected to be low.
[Hancock et al, 2009]
Clearly, this lack of sensitivity may present a significant problem to researchers conducting ECG studies at high altitude. This may be compounded by the small populations of participants commonly available for testing and in many cases, the practical difficulties of controlling duration and degree of hypoxic exposure.
-Right heart strain varies significantly at high altitude.
Pulmonary hypertension is defined as a mean pulmonary artery pressure of 25mmHg or more at rest or 30mmHg or greater during exercise [Barst et al, 2004]. This was not exceeded during OEII. Despite a rapid ascent to a simulated altitude of more than 8800m, systolic pulmonary artery pressure remained below 35mmHg [Malconian et al, 1991]. Estimating PASP from right atrium and ventricular gradient, researchers on OEIII revealed an increase of only 4mmHg amongst eight healthy lowland residents following a slow ascent from sea level to a simulated altitude of 5000m [Boussuges et al, 2000]. Using portable Doppler echocardiography at 4250m, Dubowitz and Peacock were able to identify a PASP of 25mmHg amongst 36 healthy trekkers en-route to Mt Everest Base Camp [Dubowitz and Peacock, 2007]. Low altitude measurements were not available. Whilst larger increases in PASP have been seen during rest at altitude, these tend to occur following rapid ascent in those who are prone to high altitude pulmonary edema (HAPE) [Allemann et al, 2000]. After a two day ascent to 4559m, the mean PASP was found to be 57mmHg in 14 mountaineers susceptible to HAPE and 37mmHg in 14 healthy controls. In those susceptible to HAPE, mean PASP varied between 30 and 83mmHg.  Since all 16 CXE participants ascended slowly to Mt Everest Base Camp and remained healthy for many weeks, the majority were unlikely to have developed an exaggerated PASP response and significant right heart strain at rest. However, this may not have been the case during exercise [Banchero et al, 1966] [Sime et al, 1974]. During exercise, the mean pulmonary artery pressure rose during moderate exercise from 33mmHg at sea level to 54mmHg at a barometric pressure of 282mmHg [Grover et al, 1987]. Unfortunately, it was not possible to control the level of exercise undertaken by participants during CXE. The fluctuations in right axis deviation and T wave inversion may therefore reflect the impact of recent exercise prior to measurement rather than a slowly evolving process.  
-ECG evidence of right heart strain may be due to changes in breathing pattern. 
Hyperventilation is associated with a reduction in QRS amplitude and displacement of the diaphragm causing, “clockwise rotation of the heart along its longitudinal axis” [Harrigan and Jones, 2002]. Unfortunately the ventilatory response to hypoxia varies widely between individuals. Age, physical fitness, duration of high altitude exposure and alcohol consumption may all influence the hypoxic ventilatory response (HVR) [Ward et al, 2001]. Therefore, ECG changes may reflect ventilatory patterns controlled by HVR and not the direct effect of hypoxia upon pulmonary haemodynamics.
An ascent to 5300m is associated with ECG changes consistent with right heart strain. However the presence of right axis deviation and T wave inversion in V1 often fluctuated amongst CXE participants. This may be explained by the inability of electrocardiography to accurately identify right heart changes, variation in right heart strain at high altitude and the impact of different breathing patterns upon the ECG.




Author	Sample	Time at High Altitude	Altitude	Correction Factor	Percentage QTc change
Albrecht and Albrecht, 1969	72	Not recorded	2700-6200m	Not recorded	Not recorded
Alexander 1995	1	Not recorded	4700-5895m	Not recorded	Not recorded
Das et al, 1983	40	10 days	3200-3771m	Not recorded	Not recorded
Horii et al, 1987	24	Not recorded	4400-7800m	Bazett’s	7% increase (day) and 11% increase (night)
Jackson and Davies, 1960	4-7	Not recorded	3710-5745m	Not recorded	Not recorded
Karliner et al 1987	19	Not recorded	5400-8050m	Not recorded	Not recorded
Nagasaka et al	6	Not recorded	4200-6200m	Not recorded	Not recorded
Penaloza and Echevarria, 1957	10	12 months	4540m	Bazett’s	Not recorded
Politte et al, 1968	3	4 days	3048-3505m	Bazett’s	6% increase
Sanders and Mart, 1968	2	Not recorded	3353-4345m	Not recorded	Not recorded
Shi et al, 1980	9	Not recorded	7600-8848m	Not recorded	Not recorded

Table 5.3: A summary of field studies that have investigated changes in QT interval at high altitude (Part 1).
Author	Comments
Albrecht and Albrecht, 1969	“Neither at 2700m nor at 4300m did the QT interval of the leads show any change. At 6200m it was relatively prolonged in relation to the increased heart rate”
Alexander, 1999	“Unchanged QT interval”
Das et al, 1983	“No significant changes were observed”
Horii et al, 1987	QTc increase seen in day and night measurements
Jackson and Davies, 1960	“No noteworthy alterations occurred...”
Karliner et al, 1987	QTc decreased in 15/19 participants“Accompanying the increase in heart rate at rest was a decline in the QTc interval”  
Nagasaka et al, 1967	“Prolongation of QT time was observed even during sleep at high altitude”
Penaloza and Echevarria, 1957	In one participant, “the difference between the QT interval measured and the ideal QT interval slightly exceeded the maximal normal value determined by Bazett’s formula”
Politte et al, 1968	Mean increase of 26ms in QTc amongst 3 participants
Sanders and Mart, 1968	“Significant prolongation of the QT interval was seen on many tracings obtained at high altitude”
Shi et al, 1980	“The reaction of QTr was quite extraordinary. It was also increased with the increasing altitudes ...” *

Table 5.4: A summary of field studies that have investigated changes in QT interval at high altitude (Part 2).
*Cardiac repolarisation is referred to as “QTr”

Whilst a small number of studies have found that QTc is unaffected or decreased during high altitude exposure, the majority have described an increase (Tables 5.3 and 5.4). This is supported by the changes seen in the QTc of healthy infants born at altitude [Fuenmayor et al, 2002]. In those born in Venezuela at 3500m, the QTc was 25ms longer than that found at 1600m (P<0.01). Sea level hypoxic studies also favour an increase in the duration of the QT interval. Following the administration of 11% oxygen (PO2 equivalent to 4800m) researchers found a 19% fall in SaO2 and an increase in QTc from 404 ms to 418 ms (3%) (P<0.05) [Roche et al, 2003]. A similar rise was also seen in eight healthy volunteers who were exposed to a level of hypoxia that resulted in a SaO2 of 90%. Following 15 to 30 minutes of exposure, the mean QTc had increased by 15.6 ms (P<0.05) [Bremner et al, 1992]. 
Whilst the results of controlled laboratory studies would imply that hypoxia has a direct impact upon ventricular repolarisation, no direct correlation between SpO2 and QTc (Bazett’s) was found during CXE (Figures 2.28 to 2.31). This might imply that hypoxia is not directly responsible for the delay in ventricular repolarisation and instead hypoxia triggers a range of physiological responses that vary between individuals and result in different degrees of QTc prolongation:

 -Ventricular hypertrophy
Hypoxic pulmonary vasoconstriction (HPV) is a common finding in healthy human adults exposed to hypoxic exposure. During OEII, MPAP increased from 15 to 34mmHg following a hypoxic exposure comparable to the summit of Mt Everest [Groves et al, 1987]. In animal studies, the resulting pulmonary hypertension is associated with the rapid development of pulmonary arteriole smooth muscle bands and right ventricular hypertrophy [Marki et al, 1982]. Post mortem results in humans have confirmed this, with the ratio of left to right ventricular weights changing from 1:8 at sea level to 1:3 at altitudes of between 3700 and 4260m [Arias-Stella and Recavarren, 1962]. Pulmonary hypertension is closely associated with prolonged ventricular repolarisation. Patients with severe pulmonary hypertension (MPAP=74.9mmHg) have been shown to have a longer QTc (17.5ms) than that of healthy individuals (MPAP=19.9mmHg) [Hong-Liang et/al, 2009]. Amongst 36 pulmonary hypertension patients who responded to medical treatment, reductions in MPAP (14.9mmHg), right ventricular systolic pressure (27.9mmHg) and QTc (7ms) were all observed [Snipelisky et al, 2013]. However it should be noted that hypoxic pulmonary vasoconstriction (HPV) varies markedly between individuals at high altitude. An illustration of this can be seen in the study of 36 healthy trekkers and mountaineers who underwent Doppler echocardiography at Pheriche (4250m) [Dubowitz and Peacock, 2007]. Whilst the mean pulmonary artery systolic pressure (PASP) was 25mmHg, the measurements ranged from 18 to 36mmHg. Similar degrees of variability are also seen with increasing hypoxia. During OEII, the MPAP ranged from 20 to 32mmHg in levels of hypoxia comparable to altitudes of 7620 and 8840m [Groves et al, 1987]. Although individuals may be exposed to the same degree of hypoxia, differences in HPV may account for variation in QTc prolongation.
Variation in systemic blood pressure has also been noted amongst lowland residents ascending to high altitude. As Luks wrote, “Some studies report increased pressures and others report either no change or even a decrease in blood pressure following acute hypoxic exposure” [Luks, 2009]. Nevertheless, in left ventricular hypertrophy (LVH) the QTc has been shown to correlate positively with left ventricular mass index and left ventricular internal diastolic dimensions [Kulan et al, 1998].Following treatment with enalapril (40mg/day), the left ventricular mass index and QTc of 34 patients with LVH was found to fall significantly, suggests that the hypertrophy has a direct impact upon QTc [Gonzalez-Juanatey et al, 1998]. Whilst the underlying mechanisms are unknown, it has been speculated that the combination of myocyte hypertrophy and increased collagenous interstitial matrix, commonly seen in ventricular hypertrophy, prolongs the duration of the action potential [Mayet et al, 1996]. Individuals that respond to hypoxia with a much greater increase in systemic blood pressure may therefore experience a greater delay in ventricular repolarisation than those that do not. 
-Changes in calcium ion availability and transport
 Following exposure to hypoxia, peripheral chemoreceptors in the carotid body trigger an increase in the rate and depth of breathing. This quickly leads to the retention of bicarbonate ions and the development of a respiratory alkalosis. Over the course of several days or weeks at altitude, the volume of bicarbonate excreted by the kidneys increases and pH falls. However in many instances pH does not return to normal. This is seen most clearly at the very highest altitudes. Four arterial blood gas measurements taken close to the summit of Mt Everest revealed pH measurements of between 7.45 and 7.60 [Grocott et al, 2009]. QTc prolongation has been described in patients with respiratory alkalosis [Ronco et al, 2008]. Whilst the reasons behind this are unclear, one leading explanation focuses upon the effect of alkalosis upon the concentration of ionized calcium [Nijjer et al, 2010]. An increase in plasma pH enhances the binding of calcium ions to protein molecules and reduces the availability of the more physiologically active ionized component. This has been demonstrated following an ascent from 2303m to 4424m by 20 healthy lowland soldiers. Following 4 days at altitude, the mean ionized calcium fell from 1.32mmol/l to 1.20mmol/l (P<0.01) [Khan, et al, 1996]. To address this, channels within the cardiac myocyte remain open for longer, prolonging the plateau phase of the cardiac action potential and ensuring more time for calcium to move into the cells [Nijjer et al, 2010]. The effect of a reduction in ionized calcium may also be compounded by changes in a range of physiological mechanisms that transport ions through cardiac myocytes [Gaur et al, 2009]. The Na/Ca exchanger plays an important role in maintaining calcium homeostasis. Prior to depolarisation, the exchanger transports three sodium ions into the cardiac myocyte for every one calcium ion out. In hypoxia this process is impaired. Calcium ions instead accumulate in the cell and prolong the AP.  Similar hypoxic responses have been observed in a range of calcium pumps throughout the cardiac myocyte [Macdonald and Hool, 2008]. The importance of minor alterations in calcium ions availability cannot be underestimated. As Macdonald and Hool state, “small changes in calcium ion flux can have a profound effect upon cell excitability and function” [Macdonald and Hool, 2008]. This, either alone or in combination with other factors, may delay ventricular repolarisation in the hypoxic environment. 
The availability and transport of ionized calcium through cardiac myocytes is likely to differ between individuals at high altitude. As studies on Mt Everest have shown, pH values amongst well acclimatized lowland residents vary between 7.45 and 7.6. [Grocott et al, 2009] [West et al, 1983]. Despite the same degree of hypoxic exposure the concentration of ionized calcium is therefore likely to vary. This is demonstrated in the Khan et al study where the mean and standard deviation of ionized calcium concentration at 4424m were found to be 1.20 and 0.05mmol/l respectively [Khan et al, 1996]. Variations in the genetic make-up of ion channels can also affect the transport of calcium ions through cardiac myocytes. Under hypoxic conditions these differences can create further variations in ventricular repolarisation between individuals exposed to the same hypoxic stimulus [Macdonald and Hool, 2008].
-Weight loss
An ascent to high altitude is often associated with weight loss and a reduction in muscle mass [Murray and Montgomery, 2014]. In OEII participants lost 7.4kg (9%) of their body weight over the course of 40 days whilst being gradually exposed to a PO2 similar to that found on the summit of Mt Everest [Houston et al, 1987]. Total muscle volume calculated from CT scans of the thigh and upper arms revealed decreases of 13% and 15% respectively [MacDougall et al, 1991]. Whilst a number of processes are believed to contribute, it is the reduction in energy intake that appears to be the most significant factor [Westerterp-Plantenga et al, 1999]. During CXE the mean body mass of participants fell by 8kg (10%). However in one individual the loss was as much as 21kg! In a recent meta-analysis, 22 studies of obese patients undergoing weight reduction surgery the QTc was shown to fall by 26ms [Omran et al, 2016]. However in those with a normal or low body mass index weight loss is associated with a delay in ventricular repolarisation [Camm et al, 2004]. In a study of 41 consecutive patients with anorexia nervosa the QTc was 30ms longer than an age and sex matched control group [Cooke et al, 1994]. Following restoration of target weight the QTc was comparable with that of the control group (435 vs 432ms). Whilst the pathways responsible for this are unclear, the authors argued that since there was no evidence of cardiovascular abnormalities at post mortem, autonomic dysfunction was likely to be responsible. Rapid weight loss in healthy mountaineers may therefore contribute to a delay in ventricular depolarisation that is not directly related to the duration or degree of hypoxic exposure. However this is unlikely to be a significant factor in CXE. Firstly, post hoc analysis did not identify any correlation between weight loss and QTc prolongation and secondly, there was no difference QTc measurements between London and Kathmandu. Put simply, whilst the QTc had returned to normal on returning to Kathmandu the mean body weight of the CXE participants was more than 7kg lower than that found in London.  This would suggest that amongst CXE participants other factors may have played a more significant role (Figures 2.14 and 2.15).
The absence of a correlation between SaO2 and QTc during CXE implies that rather than a direct effect, hypoxia may instead trigger a range of physiological responses that vary between individuals and result in different degrees of delayed ventricular repolarisation.

5.1.3	Clinical Implications and Future Studies

-Heart Rate















Table 5.5: The resting results of 12 healthy male volunteers tested on arrival at Pikes Peak (4300m) and after a 21 day stay [Wolfel et al, 1991].

Initially, the fall in stroke volume was offset by an increase in heart rate which resulted in a cardiac output similar to that found at sea level. Whilst this did not restore baseline DaO2, the increase in heart rate was a clear step in that direction. A similar picture can be seen in TE members. On arrival in Namche Bazaar (3500m), SaO2 fell from 98 to 84% and heart rate increased from 62 to 74 beats per minute. Whilst the fall in SaO2 leads to a decline in CaO2, the rise in heart rate is an attempt to maintain cardiac output and prevent a precipitous fall in DaO2. Since heart rate plays such an important part in DaO2, it is reasonable to hypothesise that pharmacological manipulation of the heart rate may enhance tissue oxygenation and therefore improve physical performance at high altitude. Previous research to address this hypothesis stems largely from work examining the fall in maximum heart rate that is commonly seen during extreme exercise during hypoxic exposure. During Operation Everest II, the mean maximum heart rate was shown to fall from 160 beats per minute at sea level to 118 beats per minute at a barometric pressure equivalent to the summit of Mt Everest (8850m) [Sutton et al, 1987]. Using muscarinic antagonists such as atropine and glycopyrralate it has been possible to demonstrate the increasing role of the parasympathetic nervous system at the extremes of exertion. This was first described more than forty years ago by US military researchers working on Pike’s Peak (4600m) [Hartley et al, 1974].  Whilst atropine had no effect upon maximal heart rate at sea level, the researchers found that the same dose of the drug was responsible for an 11 beats/minute increase amongst 5 healthy male volunteers at altitude. Subsequent studies have sought to determine whether similar drugs could not only increase maximal heart rate in humans but also Q, DaO2 and work rate at the very highest work intensities [Boushel et al, 2001] [Bogaard et al, 2002]. Early encouragement to support this hypothesis was found in the results of a novel study on rats acclimatized to a barometric pressure of 50KPa [Gonzalez et al, 1998]. Using atrial pacing, researchers were able to increase maximal heart rate by 20% in hypoxia which resulted in significant increases in maximal Q (10%), DaO2 (9%) and oxygen consumption (VO2 max) (8%). However contradictory results were subsequently reported in healthy human volunteers. Following a two week acclimatisation process at the White Mountain Research Station in Bishop, California (3800m), the mean maximal heart rate of six healthy volunteers increased from 170 to 184 beats per minute following the administration of glycopyrralate (800mcg) (P<0.05) [Bogaard et al, 2002]. However maximal Q, DaO2 and work rate were unchanged. Similar results were obtained from a small Danish group following a 9 week stay at Mt Everest Base Camp (5260m) [Boushel et al, 2001]. Despite a significant rise in heart rate across a range of different work intensities, glycopyrrolate had no effect upon Q or any subsequent marker of oxygen utilisation or performance. 
Increasing heart rate seems to have little effect upon physical performance in healthy, well acclimatized human volunteers at altitude. Evidence to explain this finding can be found in the extensive theoretical work of Peter Wagner. Using mathematical modelling, Wagner found that with increasing hypoxic exposure any increase in Q or DaO2 had little impact upon VO2 max [Wagner, 1996]. As we have seen earlier, the volume of oxygen (VO2) that diffuses through a membrane is dictated by Fick’s Law of Diffusion. Therefore VO2 diminishes as the pressure difference between the two sides fall. At sea level, the mixed venous PO2 (5.3KPa) entering the pulmonary capillary rapidly increases and achieves a PO2 close to that contained within the alveolus (13.3KPa). Such a transformation occurs in 0.3 seconds – just over one third of the time spent in the capillary (0.75 seconds) [West and Wagner, 1980]. On the summit of Mt Everest, the pattern is very different. The mixed venous PO2 (2.8KPa) rises very slowly and after 0.75 seconds within the capillary it only reaches 3.7KPa – that is 0.7KPa less than that found within the alveolus. Any attempt to increase Q at high altitude will lead to a reduction in the time spent by the blood in the pulmonary capillary and have the potential to cause an even lower PO2. As Wolfel and Levine succinctly conclude,

A higher Q might trade off a higher conductance oxygen delivery for a reduced diffusion oxygen transfer such that actual net oxygen flux could actually be decreased.
[Wolfel and Levine, 2001]

In the past it had been assumed that heart rate and stroke volume were set independently in hypoxia. Q was simply the product of these two factors. However this may not be the case. In hypoxia, Q is unaffected by pharmacological manipulation of the heart rate. Recent authors have therefore argued that instead of heart rate or stroke volume, it is Q that is set in direct response to PO2 [Boushel et al, 2001]. The pathway through which this process occurs is unclear. However recent evidence supports the existence of a coordinated “oxygen chemosensitive network” within the brainstem that not only senses hypoxia but also coordinates a cardiovascular response to ensure that the movement of oxygen from the alveoli to the capillaries is optimised [Neubauer, 2004]. Such a network might allow the human body to find a Q that maximises “net oxygen flux” by ensuring oxygen uptake from the lungs and delivery to the tissues is at an optimum. 
Unravelling the process that determines Q in hypoxia is clearly beyond the scope of this dissertation. However there are important implications for critically ill patients that are worthy of consideration. Maintaining Q within narrow limits is vital in critically ill patients. A low Q will lead to inadequate oxygenation of the tissues [Rivers et al, 2001]. Conversely, a high Q may also have adverse effects. During the 1990’s a growing number of critical illness physicians sought to manipulate Q and DaO2 in patients undergoing major surgery in order to improve tissue oxygenation. However evidence to dispute this approach rapidly emerged. In 1997, Hayes et/al published a landmark paper in the New England Journal of Medicine that showed an increase in hospital mortality in patients who had received dobutamine (5-200mcg/kg/min) in order to increase cardiac index (>4.5l/min/m2) and DaO2 (600ml/min/m2) to median maximal values found in survivors who had undergone high-risk surgery [Hayes et al, 1997]. Importantly, no difference was found in oxygen consumption between those who were treated with dobutamine and a well matched control group. This led the authors to conclude that it was often, “impossible to increase oxygen consumption” and, “aggressive efforts to boost oxygen consumption may have been detrimental” [Hayes et al, 1997]. 
More recently, pharmacological blockade of beta-1 adrenoreceptors has become increasingly used in those where the effects of sympathetic stimulation might prove harmful. Indeed, until only recently, the American Heart Association (AHA) encouraged the widespread use of beta-blockers in high-risk patients undergoing major surgery. Unfortunately, the results of extensive trials have revealed that such an approach results in an increase in mortality [Bangalore et al, 2008]. This has led the AHA to narrow its recommendations. Carefully titrated doses of beta-blockers should now only be used in patients with significant risk factors for cardiovascular disease provided extensive monitoring of heart rate and blood pressure is available [Wijeysundera et al, 2014]. Despite such a setback, interest in the use of beta blockers continues. This has stemmed from evidence highlighting the detrimental effect of sympathetic drive upon the brain, heart and lungs of critically ill patients [Van der Jagt and Miranda, 2012]. In patients with Acute Lung Injury (ALI), high pulmonary vascular flow has been shown to cause extensive damage to the alveolar-capillary membrane [Ehrhart et al, 1999]. Reduction of blood flow using beta-1 adrenoreceptor antagonists has been shown in animal models to limit lung injury [Van der Jagt and Miranda, 2012]. However, such agents can also reduce heart rate and stroke volume, resulting in a significant fall in Q, DaO2 and oxygen utilisation. Any beta-blocker that is to be used in critical care research will need to heed the warnings of earlier work and have minimal impact upon Q.
Pharmacological manipulation of heart rate can improve DaO2 in those venturing to high altitude. However it has little impact upon tissue oxygenation and physical performance. As we have previously seen, DaO2 only ensures that sufficient oxygen reaches the capillaries and it is the PO2 that act as the driver that pushes oxygen into the cells. Q therefore needs to be set at a rate that ensures there is sufficient time for this to occur. This has important implications for the critically ill. Whilst manipulation of the autonomic nervous system may offer some benefits, changes in Q can have dire consequences for tissue oxygenation.
-Rhythm
Minor changes in ectopic activity are unlikely to pose significant risks to those with normal hearts. However in certain individuals there is the potential for significant cardiovascular compromise to occur. Atrial ectopic activity has been associated with the initiation and maintenance of atrial fibrillation (AF) [Waktare et al, 2001]. AF is the commonest cardiac arrhythmia. In the UK, the condition affects 2% of those aged over 45 and increases to 8% in those 75 or older [Davis et al, 2012]. The presence of AF is associated with an increase in thromboembolic disease. In those aged 75 or older, the annual risk of ischaemic stroke in those with AF is 8.1% [Masoudi and Goldschlager, 1997]. Although the incidence of AF is not known at high altitude it has been reported on a number of occasions [Bartsch and Gibbs, 2007] [Higgins et al, 2010]. During my work as a medical advisor to a commercial expedition company I have identified at least five individuals who have developed AF during an ascent to high altitude. The presence of atrial ectopics has been correlated with an increased incidence of AF in population based cohort studies [Conen et al, 2012]. Similarly, the ablation of atrial ectopics is associated with a lower risk of recurrence in those with AF undergoing catheter ablation [Inoue et al, 2012]. To establish a clear link between high altitude exposure, an increase in atrial ectopic activity and the development of AF it is necessary to address three questions:
-Is AF commoner at high altitude than at sea level?
A common approach for researchers who wish to study the incidence of a medical condition at high altitude is to first publish a case series. Most famously, this was done by Charles Houston who was the first to describe 12 cases of, “severe altitude illness ... in which the neurological signs and symptoms dominated the picture” [Houston and Dickinson, 1975]. In subsequent years, this life threatening condition became known as High Altitude Cerebral Edema (HACE) and has been shown to affect 1% of all trekkers ascending to between 4243m and 5500m in Nepal [Hackett and Rennie, 1975]. Left untreated it is fatal. In recent years the information for case series has been obtained through online questionnaires and follow-up telephone interviews conducted with individuals who respond to on-line advertisements. This has been made possible by the dramatic rise in the use of specialist websites, blogs and chat rooms dedicated to mountain based activities. Although a case series offers little information on incidence, precipitating factors or consequences, it does identify the presence, sometimes in significant numbers, of those with the condition and provides researchers with the impetus to generate hypotheses and undertake more extensive studies [Nissen and Wynn, 2014]. Due to the relatively small incidence of this condition, large populations at sea level and high altitude would need to be studied. Each would have resided at their respective altitude for a prolonged period of time and be matched for AF risk factors such as age, sex, smoking history, diabetes mellitus and cardiorespiratory disease. Such an approach has been used extensively in South America where high altitude populations, commonly based in long established mining communities, have been compared with sea level residents [Reeves and Grover, 2005]. This has resulted in extensive work on the changes seen to the right heart at high altitude, the detrimental effects this has on some individuals and the impact of therapeutic interventions. A large observational trial that compared the incidence of AF at sea level with that found at high altitude would not only identify any difference but also those likely to be at greatest risk.
-Is atrial ectopic activity commoner at high altitude than at sea level?
Identifying what triggers AF in an individual is often unclear. The first episodes of atrial fibrillation are believed to originate in one or more muscle sleeves contained within the pulmonary veins. Here, a combination of cellular and structural abnormalities alters the action potential of cardiac myocytes, whilst tissue changes elsewhere result in abnormalities in electrical conduction throughout the atria. The role of an atrial ectopic beat in this process is not fully understood. Nevertheless, an increase in atrial ectopic activity is widely believed to increase the risk of an individual developing AF. To determine whether atrial ectopic activity increases at high altitude, it would be necessary to complete lengthy periods of continuous ECG recording on populations at sea level and high altitude. Importantly, several days of data collection would be needed at different high altitude locations in order to assess the change of ectopic activity during the acclimatisation process. Alternatively, a given population, such as that seen in CXE, may be studied at sea level and following ascent to high altitude. Whilst this crossover design allows the population to act as its own control, it can be difficult to recruit large numbers and dropout rates may be high. Nevertheless this has been used successfully by small teams of highly motivated researchers and participants when studying the effect of high altitude upon a range of chronic cardiac conditions [Higgins et al, 2010].
Despite the small populations often studied during crossover studies at high altitude, large amounts of data can be obtained. For instance, researchers using implantable loop recorders have been able to record several weeks of continuous ECG data in nine healthy male volunteers during an expedition to the Nepali Himalaya [Woods et al, 2008]. During which, “all subjects demonstrated sinus tachycardia and marked sinus arrhythmia; one subject demonstrated atrial flutter; one subject had non-conducted p waves, and a further subject had marked ST segment depression.” Therefore, small populations may provide valuable information on atrial ectopic activity provided sufficient data is recorded.
-Does an increase in atrial ectopic activity cause AF at high altitude?
In order to demonstrate that an increase in the incidence of AF at high altitude is due to a rise in atrial ectopic activity, it is necessary to show causation. A number of different approaches may be needed. The most feasible may be to focus upon those who are susceptible to AF. More than half of those in AF have underlying structural heart disease [Waktare et al, 2001]. Therefore populations with stable coronary artery disease or congestive cardiac failure could be studied. Alternatively, those with paroxysmal AF may prove to be a suitable population. Irrespective of the underlying disease, participants will need continuous ECG monitoring at sea level and following ascent to altitude in order to identify a clear connection between atrial ectopic beats and the onset of AF. 
Despite extensive study, a clear link between an increase in atrial ectopic beats at high altitude and the development of AF may prove difficult to make. An alternative approach may be to reduce the frequency of atrial ectopic beats. A similar approach has been used in the study of High Altitude Pulmonary Edema (HAPE). HAPE occurs in 0.2 to 15% of those who ascend to altitudes between 2500 and 5000m [Luks and Swenson, 2007]. Like HACE, this condition is often fatal if left untreated. HAPE sufferers have evidence of raised pulmonary artery pressure (PAP) [Maggiorini, 2010]. Novel studies conducted on HAPE victims have shown that by dampening the PAP increase during a subsequent ascent, the likelihood of developing the condition is greatly decreased [Bartsch et al, 1991] [Maggiorini et/al, 2006]. Nifedipine 20mg slow release taken every 8 hours during an ascent to 4559m has been shown to reduce the incidence of HAPE from 63% to 10% [Bartsch et al, 1991]. In a similar way, it may be possible to reduce the incidence of AF by reducing the frequency of atrial ectopic beats. This could be done directly with anti-arrhythmic drugs or alternatively, by addressing the underlying causes of the increase in atrial ectopic activity. One approach may be to use agents that are used in the management of pulmonary hypertension. Phosphodiesterase inhibitors such as tadalafil are able to reduce pulmonary vascular resistance at high altitude and therefore have the potential to prevent distension and hypertrophy of the atria [Maggiorini et al, 2006]. Alternatively, the use of oral nitrates may improve coronary perfusion and therefore reduce areas of myocardial ischaemia that may be responsible for initiating ectopic activity.
-Morphology
Prior to OEII, high altitude changes in ECG right heart morphology were attributed to a number of different causes. Electrolyte disturbance, an increase in haematocrit, hyperventilation, myocardial ischaemia, vagal withdrawal and an excess in circulating catecholamines had all been cited as potential influences [Das et al, 1983] [Harris and Hansen, 1966] [Kapoor, 1984] [Saurenmann and Koller, 1984]. However the results of OEII provided a compelling argument linking the rise in mean pulmonary artery pressure (MPAP) with changes in the ECG [Malconian et al, 1990]. Since cardiac output and left atrial pressure rapidly return to sea level values following ascent to high altitude, the rise in MPAP pressure results in an increase in pulmonary vascular resistance (PVR). This, the OEII authors argued, has the potential to cause dilatation of the chambers of the right heart and the development of right ventricular hypertrophy. By measuring MPAP with a Swann Ganz flow catheter, the authors were able to show a rise in PVR alongside changes in axis, P and T wave morphology with each subsequently increasing in hypoxia. However this may not be the complete story. As we have seen earlier, the MPAP of healthy lowland residents who ascend to high altitude often remains within normal sea level limits [Dubowitz and Peacock, 2007]. Therefore any dilatation or hypertrophy of the right heart may be limited. A recent MRI study of 14 healthy lowland residents who ascended to EBC (5300m) revealed a 12% reduction in left ventricular mass following descent to sea level [Holloway et al, 2011]. This is consistent with wider changes in muscle physiology that occur following hypoxic exposure. As the availability for oxygen decreases, the diameter of some muscle fibres diminishes [Howald and Hoppelar, 2003]. Whilst the reasons for this are unclear, at moderate altitudes this is believed to increase both capillary and mitochondrial densities and therefore improve diffusion of oxygen into the tissues [Ward et al, 2001]. The ECG changes seen in axis, P and T wave amplitudes may therefore reflect a reduction in left ventricular mass (left ventricular vector) as well as changes that occur in the right heart (right ventricular vector). These changes have major implications for two groups ascending to high altitude:
-Patients with Pulmonary Hypertension
Pulmonary Hypertension (PH) is defined as a sustained elevation of mean pulmonary artery pressure to more than 25mmHg at rest or 30mmHg during exercise [Farber and Loscalzo, 2004]. The most common causes of PH in Europe and the USA are left heart disease and chronic hypoxic lung disease [Peacock, 2013]. Normally, the pulmonary vasculature is a highly compliant circuit that allows the right ventricle to pump the same stroke volume as the left ventricle with just 25% of the effort. This advantage is lost in those with PH. An increase in PVR can lead to right ventricular hypertrophy. Unfortunately, this can result in impaired muscle contraction, dilatation of the right ventricle and, “clinical evidence of decompensated right ventricular failure ... characterized by rising filling pressures, diastolic dysfunction and diminishing cardiac output” [Voelkel et al, 2006]. As we have previously seen, high altitude exposure results in hypoxic pulmonary vasoconstriction and an increase in PVR [Barer et al, 1971]. Whilst the effects of high altitude exposure on PH patients have not been formally studied, it is widely believed that such a stimulus could further increase MPAP and precipitate right ventricular dysfunction [Luks, 2009]. However at present recommendations are, “arbitrary and limited by the lack of clear data in the literature on these issues” [Luks, 2009]. Since large numbers of individuals are residing at high altitude it is not enough to simply encourage those with PH to descend. Instead, those with PH need to know how high they can ascend, what levels of physical exercise they can undertake and what effective measures are available to prevent right heart dysfunction. As a starting point, patients with PH can be studied in a hypoxic chamber where the inspired PO2 can be set to correspond with a range of different altitudes. Using ECG and echocardiography it would then be possible to monitor physiological performance at rest and during graded exercise. Further work could then seek to identify whether drugs, such as phosphodiesterase inhibitors, were capable of controlling the rise in PH and prevent right heart dysfunction. This approach has been used extensively in the testing of sildenafil on healthy individuals exercising in hypoxia [Ghofrani et al, 2004] [Hsu et al, 2006] [Richalet et al, 2005]. Using a range of hypoxic gas mixtures, studies have shown improvements in a number of cardiac and respiratory markers following drug administration. This has led to improvements in physical performance across a wide range of exercise intensities. However it is important to note that these improvements are not universal.  Whilst sildenafil has been shown to reduce the time taken by hypoxic volunteers to pedal 6km, post hoc analysis has revealed two groups - those who responded to the drug (39% reduction) and those that did not (1% reduction) [Hsu et al, 2006] Similar differences may also exist in those with PH. PH can be triggered by a range of different disease processes [Simonneau et al, 2009]. These may respond differently to hypoxia and any medication that is administered to counter its effects.
Whilst it may be possible to study common causes of PH at high altitude, such as left heart disease and chronic hypoxic lung disease, the assessment of rarer conditions is likely to prove impractical. In these cases it may still be necessary to rely upon “best practise”. Wherever possible this need to be agreed by a large consensus of high altitude researchers and clinicians and regularly reviewed in a clear and transparent way.
-Patients with Diastolic Heart Failure
The 11% reduction in left ventricular mass found in trekkers returning from EBC was also accompanied by changes in diastolic function [Holloway et al, 2011]. According to the authors, these alterations may be the consequences of changes in protein synthesis and mitochondrial function that attempt, “to match tissue oxygen demand to the diminished oxygen supply, thereby limiting production of harmful reactive oxygen species and protecting the remaining mitochondria” [Holloway et al, 2011]. Similar changes in diastolic function have also been observed in other healthy lowland residents who are exposed to short periods of hypoxic exposure [Boussuges et al, 2000] [Ghofrani et al, 2004]. Using transmural E/A measurements from Doppler studies, it has been possible to show a consistent fall in mitral peak E velocity, reflecting impairment in left ventricular relaxation and a reduction in early diastolic filling. These findings may have serious implications for those with pre-existing diastolic impairment. Diastolic heart failure (DHF), “occurs when the ventricular chamber is unable to accept an adequate volume of blood during diastole, at normal diastolic pressures and at volumes sufficient to maintain an appropriate stroke volume” [Zile and Brutsaert, 2002]. Whilst systolic function is preserved in DHF, echocardiography reveals, “evidence of abnormal left ventricular relaxation, filling, diastolic distensibility or diastolic stiffness” [European Study Group, 1998]. This has a marked impact on morbidity and mortality [Zile and Brutsaert, 2002]. Approximately one half of those aged over 70 with DHF are admitted to hospital with an episode of heart failure each year. Five year mortality rates range from 15% (<50 years) to 50% (>70 years). The impact of high altitude exposure upon those with pre-existing DHF has not been studied. However in keeping with the research proposed for PH, studies in hypoxic chambers may be able to identify changes in physiological performance during rest and graded exercise in those with DHF. However unlike PH research, there is limited evidence to support the use of specific drugs in the treatment of DHF [Yancy et al, 2013]. Nevertheless an exacerbation of DHF at high altitude may have different triggers to that seen at sea level. As we have seen earlier, an increase in MPAP can cause a left ward shift of the interventricular septum, interference with left ventricular filling and a fall in mitral peak E velocity [Boussuges et al, 2000] [Ghofrani et al, 2004]. The testing of pulmonary vasodilators such as sildenafil may therefore offer a way of preventing exacerbations of DHF at high altitude. Research conducted during CXE points towards a further mechanism [Holloway et al, 2011]. In a study of 14 healthy lowland residents who undertook a 17 day trek to Mt Everest Base Camp, reductions in peak left ventricular filling rate (17%) and E/A Ratio (24%) were observed following descent to sea level. Using MRI scanning, the researchers were also able to identify an 18% reduction in the ratio of phosphocreatine (a high energy phosphate reserve) to ATP (PCr/ATP). A fall in phospocreatinine may be explained by the change seen in mitochondrial density at high altitude. Although the myocardium has not been directly studied at high altitude, the mitochondrial density in skeletal muscle is known to fall by 30% in mountaineers returning from an ascent of Mt Everest [Howald and Hoppeler, 2003]. A fall in myocardial mitochondrial density would reduce ATP production, delay the uncoupling of actin-myosin cross bridges and impair diastolic function. Treatment aimed at reducing PVR would therefore prove to be ineffective. Instead, prevention of further diastolic dysfunction would focus upon following sea level recommendations that involve maintaining sinus rhythm, preventing tachycardia and aggressively managing systemic hypertension [Yancy et al, 2013]. This may be achieved by increasing the dosage of drugs already in use or adding an appropriate dose of a beta blocker. 
Hypoxic chamber studies provide a useful starting point in identifying interventions that may help those with PH and DHF at high altitude. However, longer periods of study are required in order to determine the impact these have upon morbidity and mortality of patients. As we know from earlier, large populations are permanently resident at high altitude.  Once those with PH and DHF are identified and the details of their condition are known, it may then be possible to randomise two groups to receive either a drug or placebo and determine whether a significant benefit is elicited.
Polymorphic Ventricular Tachycardia (PVT) is rare in individuals with a QTc of less than 500 milliseconds [Montanez et al, 2004]. Therefore in isolation, the increases seen at high altitude are unlikely to have any significant effect upon those in good health. However it has become increasingly recognised that QTc prolongation and the development of PVT is complex and depends upon a number of different factors falling into place. The following section will focus upon the effect of hypoxia upon those with congenital forms of Long QT Syndrome and how complications could be avoided.

Sudden death in an otherwise healthy young person is an emotionally devastating event and unfortunately an all-too-common presentation of genetic arrhythmia syndromes.
[Roden, 2008]




















1	30-35	KCNQ1	IKs	“Syncope or sudden death is triggered by emotional or physical stress; diving and swimming are LQTS1-specific triggers” [Roden, 2008]“... most frequently occur during exercise (62%), but only rarely during sleep and rest (3%)” [Patel and Antzelevitch, 2008].
2	25-30	KCNH2	IKr	“Syncope or sudden death can occur with stress or rest, and the triggering of events by sudden loud noises, such as that produced by an alarm clock, is virtually diagnostic of this form” [Roden, 2008].“Cardiac events occur equally during exercise (13%) or during sleep/rest 15%”  [Patel and Antzelevitch, 2008]
3	5-10	SCN5A	fast INa	“In LQTS3 cardiac events principally occur during sleep and rest (39%) and less frequently during exercise (13%)” [Patel and Antzelevitch, 2008]

Table 5.6: The incidence, genetic mutation, affected ion channel and triggers of LQTS 1, 2 and 3 [Splawski et al, 2000].









Table 5.7: The effect of an epinephrine bolus (0.1mcg/kg) and infusion (0.1mcg/kg/min) upon healthy controls and patients with congenital LQTS [Noda et al, 2002].

After 3 to 5 minutes of an epinephrine infusion (0.1mcg/kg/min) the QTc of controls and LQTS3 patients returned to baseline values. Whilst sustained rises were observed in the other patients, this was greatest in those with LQTS1. These findings reflect the way in which we manage patients with congenital LQTS. Whilst beta blockers can shorten QTc, prevent tachyarrhymias and reduce the incidence of sudden cardiac death in LQTS1, they are considered less effective in LQTS2 and 3. Instead, the early use of an implantable cardioverter-defibrillator (ICD) is considered to be better in many of these patients [Abrams et al, 2010]. Given the activation of the sympathetic nervous system in hypoxia there is potential for significant QTc prolongation in patients with LQTS1 and to a lesser extent, LQTS2. 
How should patients with Congenital LQTS be managed in a hypoxic environment? The first step would be to determine what impact hypoxia has upon the QTc of those with LQTS 1 and 2. Using a hypoxic chamber it would be possible to study the effect of different degrees of hypoxia during rest and a range of exercise intensities. In addition, the impact of drugs, such as beta blockers, could also be studied in order to see if the effects of hypoxia can be negated. Given evidence of a significant increase in QTc in patients with LQTS 1 and 2, it would then be possible to propose an intervention. A number of different approaches might be possible. The most straightforward would be to simply recommend a “ceiling” of 2500m and advise all those with congenital LQTS 1 and 2 to remain below it. Alternatively, a more personalised approach could be adopted. This would provide individuals with a better understanding of their risk of SCD and the means by which they can prevent it. Using a hypoxic chamber, individuals with LQTS 1 and 2 could be exposed to levels of hypoxia and physical exertion that they might expect during their stay at high altitude. Pharmacological interventions could also be tested. This could result in an increase in pre-existing medication or the introduction of a new agent in the days prior to ascent. This approach may be particularly useful in LQTS 1 and 2 patients planning a long haul flight. The barometric pressure inside a commercial aircraft is not restored to sea level whilst airborne. At a cruising altitude of 11000 to 12200m, the barometric pressure is comparable to a height of between 1800 and 2400m [World Health Organisation, 2015]. This has been shown to result in arterial oxygen saturations of between 80 and 90% in healthy individuals [Schacke et al, 2007]. Whilst this is well tolerated by the majority of passengers and crew it may have significant effects upon those with congenital LQTS. Prior testing in a hypoxic chamber may therefore identify an increase in QTc. This could lead to an increase in prophylactic medication or alternatively, the use of supplemental oxygen, titrated using a portable pulse oximeter, could be used to restore sea level SpO2 measurements. 





Heart rate increased in men and women following ascent to high altitude (P<0.05). Whilst increases were seen with each gain in height, these were not found to be significantly different (Tables 3.2, 3 and 4) (Figures 3.2, 3 and 4). No significant differences were noted between men and women at each of the locations studied.
Arterial oxygen saturation (SpO2) in men and women decreased on ascent to high altitude (P<0.05). When male and female participants were combined, significant decreases were found with each gain in height (P<0.05) (Tables 3.5, 6 and 7) (Figures 3.5, 6 and 7). No significant differences were noted between men and women at each of the locations studied. A correlation between the changes in heart rate and arterial oxygen saturation was also investigated. The r2 values at Namche, Pheriche and Gorak were found to be -0.42 (P<0.05), -0.16 (NS) and -0.47 (P<0.05) respectively (Figures 3.8, 9 and 10). When all SpO2 and heart rate values were analyzed the r2 value was -0.22 (P<0.05) (Figure 3.11).
The mean QTc (Bazett’s) amongst men and women increased on ascent to high altitude (P<0.05). When both men and women were combined, a further increase was found on ascent to Gorak (P<0.05) (Tables 3.8, 9 and 10) (Figures 3.12, 13 and 14). A significant difference was noted between men and women in London (P<0.05) however this was not seen at each of the high altitude locations studied. A correlation was found between the changes in QTc (Bazett’s) (x axis) and arterial oxygen saturation (SpO2) (y axis) amongst TE participants in Namche, Pheriche and Gorak. The r2 values were -0.75, -0.73 and -0.71 respectively (all P<0.05) (Figures 3.15, 16 and 17). Similarly, a correlation was identified when all SpO2 and QTc (Bazett’s) values were analyzed. The r2 value was -0.52 (P<0.05) (Figure 3.18).
The mean QTc (Fridericia’s) amongst men and women increased on ascent to high altitude (P<0.05) (Tables 3.11, 12 and 13 and Figures 3.19, 20 and 21). A significant difference was noted between men and women in London (P<0.05) however this was not seen at each of the high altitude locations studied.




This is the most comprehensive field study of mean resting heart rate undertaken at high altitude. Unlike the majority of previous studies where only single measurements were obtained from small populations ascending to between 5000 and 6000m, TE was able to obtain measurements from 37 healthy lowland residents at three separate altitudes. These results are comparable with the landmark hypobaric chamber study conducted by Laciga and Koller [Laciga and Koller, 1976]. In their work, the authors identified little change in heart rate until a simulated altitude of 4000m was reached (Figure 5.12). At this point, mean heart rate was 11 beats per minute (15%) higher than that found at sea level. Further increases of between 7 and 13% were subsequently observed at 1000m intervals up to a simulated altitude of 7000m. Whilst statistical significance is not observed between the TE heart rate measurements at different high altitude sites, a similar pattern to Laciga and Koller’s can be identified (Figure 5.12). At 3500m, mean resting heart rate was 12 beats per minute (19%) higher than that found at sea level. Increases of between 3 and 5% were subsequently found between each high altitude measurement.
There are many reasons for resting heart rate to increase following ascent to altitude. Changes in ambient temperature, the administration of drugs, episodes of dehydration, illness or injury may all cause a rise. However, extensive animal and human studies in controlled conditions have demonstrated a clear causal relationship between the degree of hypoxia at altitude and an increase in resting heart rate [Hainsworth et al, 2007]. Further evidence to support this link can be drawn from the negative correlation found between the changes in heart rate and arterial oxygen saturation during TE. The r2 values at Namche, Pheriche and Gorak were found to be -0.42 (P<0.05), -0.16 (NS) and -0.47 (P<0.05) respectively (Figures 3.8-10). When all SpO2 and heart rate values were analyzed the r2 value was -0.22 (P<0.05) (Figure 3.11). Whilst this pattern has not been previously described in field studies at high altitude, some supporting evidence can be found in hypobaric chamber studies. Laciga and Koller demonstrated a similar pattern during TE when the lines representing resting heart rate and SpO2 were shown to closely mirror each other and intersect at an inspired PO2 equivalent to an altitude of between 3000 and 5000m (Figure 5.12). Such a pattern can also be seen at lower PO2 values. OE II researchers showed that the increase in resting heart rate and decrease in SpO2 continued down to a barometric pressure equivalent to that found on the summit of Mt Everest (8850m) [Sutton et al, 1987].


Figure 5.12: The resting heart rate (squares) and estimated arterial oxygen saturation* (diamonds) [y axis] of 30 volunteers exposed to a range of simulated altitudes [x axis] [Laciga and Koller, 1976].
*Calculated from alveolar PO2 measurements by assuming that the arterial PO2 was 7.6mmHg lower than the alveolar PO2 and a standard sea level oxyhaemoglobin dissociation curve was present.

No significant difference in mean resting heart rate was observed between men and women during TE. On ascending to Gorak Shep, mean heart rate rose from 59.9 to 78.5 beats per minute in men and from 64.5 to 82.0 beats per minute in women, representing a difference of 18.6 beats per minute in men (31%) and 17.5 beats per minute in women (27%). This was reasonable to expect since the fall in SpO2 was similar between the sexes at all three field location. On ascending to Gorak Shep, SpO2 fell by 23.5% in men and 21.7% in women. Given comparable SpO2 values at 5350m, men and women would experience a similar degree of sympathetic stimulation and therefore comparable increases in resting heart rate should occur. To some extent this is borne out by existing data.  Whilst Hannon et/al found an enormous difference in the initial increase in percentage heart rate between men and women, over time this rapidly narrowed [Hannon et al, 1966]. After 30 days on the summit of Pike’s Peak (4300m) the mean resting heart rate of both sexes had increased by approximately 15%. Given this finding and the small number of women in their sample, the initial result may have been due to other factors that stimulated the sympathetic nervous system rather than a difference in their response to hypoxia.
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Alexander, 1995	Unacclimatized, healthy 65 year old male wearing Holter monitoring for 24 hours during a successful summit day on Kilimanjaro (5895m).	“The most notable finding in these recordings was the development of very frequent premature ventricular complexes, and multiple runs of ventricular bigeminy during the climb from approximately 4,800m to 5,895 m at the peak. There was a dramatic lessening of left ventricular ectopy on leaving the peak, followed by virtually complete disappearance 3 hours into the descent.”
Alexander, 1999	Unacclimatized, healthy 75 year old male wearing Holter monitoring for 24 hours during an unsuccessful summit day on Kilimanjaro (5895m).  The participant abandoned his attempt at 5100m after experiencing severe breathlessness.	“Ectopy of left ventricular origin increased progressively with higher altitude exposure during the climb, at rest, and during sleep, reaching an average of 56 complexes per hour during ascent, and falling to 10 complexes per hour during descent at the highest altitude. Although short runs of left ventricular tachycardia occurred during climbing, resting, and sleeping, the incidence increased somewhat during the climb at higher altitude, with the 14-complex run occurring near 5,100m. The incidence of ectopy rose with increasing altitude during climbing, reaching a maximum of 61 complexes per hour near 4,900 m, and fell sharply 30 minutes after descent from 5,100 to approximately 5,000 m, to 4 complexes per hour. Blood oxygen saturation levels fell from 92% at 1,800 m to 71% at approximately 5,000 m during the climb.”
Chandrashekhar et al, 1992	Holter recordings were obtained from four unacclimatized participants rapidky ascending to altitudes of between 3800m and 6000m	“Asymptomatic transient run of bigeminy (monomorphic ventricular ectopics with left bundle branch block morphology) lasting three minutes whilst the subject was asleep.”A participant taking atenolol 50mg for mild hypertension developed,“frequent ventricular complexes at 6000m including one run of ill sustained ventricular tachycardia (4 beats, 140 beats/min, left bundle branch block morphology).
Das et al, 1983	Standard ECG recordings were undertaken for 10 days in two groups of 20 unacclimatized participants at 3200m and 3771m. 	“VPC (less than 5/min) in one subject at both the altitudes.”
Karliner et al, 1985	12-lead ECG’s were obtained in 19 healthy participants at sea level, 5400m and 6300m.Continuous single lead ECG recording was then obtained on 8 participants up to the summit of Mt Everest (8850m).   	“One subject had premature ventricular contractions on the 12-lead ECG at rest at base camp”
Milledge et al, 1963	Standard 12 lead ECG’s were obtained on 15 well acclimatized participants at rest and on cessation of exercise up to an altitude of 7437m. 	“Exercise did, however, produce single focus ventricular extrasystoles in one subject on one occasion.”
Politte et al, 1968	Single lead continuous ECG monitoring on seven healthy participants during rest and skiing at altitudes between 3048m to 3505m.	“Premature ventricular contractions occurred in four of the seven participants. RB had runs of quadrigeminy, JL had one episode of multiple PVC’s with some PAC’s. The other two (WM and WL) had only occasional unifocal PVC’s.”
Woods et al, 2008	9 healthy male volunteers were fitted with implantable loop recorders and monitored throughout an expedition to a height of 6325m.	“There was the possibility ofasymptomatic polymorphic ventricular ectopy (5-beat duration) in a second subject during exercise at 4,700m (SaO2 86%) but this may well have been an artefact.”

Table 5.8: A summary of previously reported ventricular arrhythmias at high altitude.

Similar findings have also been identified in hypobaric chamber studies. During OEII, 
One subject had isolated unifocal ventricular premature beats during submaximal exercise at 7,620 m. The contour of the premature beats suggested a left ventricular origin. Another subject had several multifocal left ventricular premature beats and a short run of bigeminal rhythm at the same amplitude. Another subject had occasional multifocal ventricular premature beats and a run of bigeminy at the same altitude and multifocal ventricular premature beats at 8,848 m.” 					[Malconian et al, 1990] 
As we have seen previously, there are a number of factors that may explain the absence of ectopic beats in high altitude studies. Firstly, premature ventricular contractions (PVC’s) amongst TE participants are likely to be rare. Whilst 40-75% of healthy individuals will have one or more PVC’s during 24-48 hours of ambulatory Holter monitoring, only 1% will have PVC’s on a standard ECG [Perez-Silva A and Merino JL, 2011].  Second, the TE population was not exposed to a sufficient stimulus. PVC’s are commonly associated with sympathetic activity and importantly, beta-blockers form an important part in the treatment of symptomatic patients [Ng, 2006]. The ascent to altitude was gradual. Levels of exercise were restricted to just a few hours of walking each day. As a result, all remained relaxed, healthy and well acclimatized. Participants were discouraged from smoking tobacco and drinking alcohol or caffeine. Prior to testing, all were warm, rested and well hydrated. Therefore it is possible that the stimulus was insufficient to promote a sufficient sympathetic response to trigger PVC’s.
Morphology
In keeping with the majority of previously published research, an increase in mean QTc was observed amongst TE participants ascending to high altitude. Importantly, the TE study also presents data that demonstrate further increases in QTc with successive gains in altitude. Of those studies that had previously recorded QTc measurements at high altitude only a very small number made recordings at different heights. Shi et/al identified a similar pattern to TE. Using the acronym QTr to describe cardiac repolarisation, the authors concluded, “The reaction of QTr was quite extraordinary. It was also increased with the increasing altitudes ...” [Shi et al, 1980]. Albrecht and Albrecht made a similar observation on South America’s tallest mountain, “Neither at 2700m nor at 4300m did the QT interval of the leads show any change. At 6200m it was relatively prolonged in relation to the increased heart rate” [Albrecht and Albrecht, 1969]. In direct contrast to these studies are the findings of the AMREE and OEII researchers [Karliner et al, 1985] [Malconian et al, 1990]. During AMREE, each gain in altitude was accompanied by an increase in resting heart rate and, “a decline in the QTc interval” [Karliner et al, 1985]. Throughout OEII, Malconian et/al concluded, “No significant changes occurred in the QRS duration, PR interval, QT interval, T waves or ST segments on the resting electrocardiograms. No arrhythmias were noted and conduction defects did not occur” [Malconian et al, 1990]. These conclusions may be explained in part by the use of different correction formulae. Whilst Bazett’s was claimed to be used by AMREE researchers, the fall in QTc (106ms) suggests that an alternative was used. Indeed, the enormity of the fall suggests that no correction formula was used at all. Meanwhile the correction formula used by Malconian et al was not stated. As we can see from the results of CXE, TE and AHS, the use of different formula can result in a number of different outcomes.




Figure 5.13: The effect of hypoxia upon QTc interval amongst 11 healthy individuals exposed to 11% oxygen for 15 minutes [Roche et al, 2003].























Current	Effect of Acute Hypoxia	Impact on Duration of AP
INa	Two forms of INa exist – fast INa and persistent INa. Fast INa is responsible for 98% of the sodium current that occurs in Phase 0. However in hypoxic conditions, a 20 fold increase occurs in persistent INa activity causing a delay in Phase 0, a decrease in maximum amplitude of the AP and an increased risk of early after-depolarisations [Noble and Noble, 2006] [Saint, 2006].	Increase
IKto	The direct effect of acute hypoxia on IKto is unknown. However, reducing agents such as dithiothreitol (DTT) increase activity whilst oxidising agents such as 5,5’-dithio-bis[2-nitrobenzoic acid] (DTNB) decrease activity of Ito. [Hool, 2004] [Rozanski and Xu, 2002].	Decrease
ICa-L and ICa-T	Hypoxia causes a decrease in intracellular hydrogen peroxide (H2O2) and as a result, a fall in ICa-L and ICa-T activity. However in the presence of beta-adrenergic stimulation this is reversed and leads to an increase in calcium influx and a prolongation of the cardiac action potential. 	Increase*
IKr	Not affected by hypoxia. Reducing and oxidising agents have no effect.	None
IKs	Activity is inhibited by hypoxia. This is exaggerated in the presence of beta-adrenergic stimulation and results in prolongation of the cardiac action potential.	Increase
IK1	Activity is increased by hypoxia.	Decrease

Table 5.9: The behaviour of ion current during acute hypoxia.
Adapted from Macdonald and Hool, 2008.

*only in the presence of beta-adrenergic stimulation

The question therefore remains - what is causing a delay in ventricular repolarisation at high altitude? As outlined in CXE, ventricular hypertrophy, changes in calcium availability and weight loss may all play a role in QTc prolongation during long term residence at high altitude. Indeed, differences in these responses to hypoxia may explain the lack of correlation between changes in SaO2 and QTc seen during CXE.  However in healthy, well acclimatized lowland residents who have recently arrived at modest altitudes, these explanations seem unlikely. The answer to the question may lie instead in the response of the sympathetic nervous system to hypoxic exposure.
An increase in sympathetic nervous system activity is a common feature in individuals exposed to hypoxic conditions [Richalet et al, 1988]. Indirect measurements of catecholamine activity reveal rapid increases in tissue adrenaline and noradrenaline in the hours following exposure [Mazzeo et al, 1991] [Mazzeo et al, 1998]. The duration of the cardiac AP has been shown to increase in the presence of beta-adrenergic activity [Magnano et al, 2003] [Magnano et al, 2006] [Noda et al, 2003]. This is believed to result from the augmentation of a number of calcium dependent exchangers, pumps and co-transporters [MacDonald and Hool, 2008] [Noda et al, 2003]. Infusions of sympathomimetics have been shown to delay ventricular repolarisation [Noda et al, 2003] [Shimizu and Antzelevitch, 1998 and 2000]. Following administration of epinephrine to patients with congenital LQTS (0.1µg/kg bolus followed by 0.1µg/kg/min infusion) the QTc (Bazett’s) was found to increase by 11 to 32% (P<0.05) [Noda et al, 2003]. Whilst this increase was sustained in patients with some forms of LQTS, the QTc in normal healthy volunteers returned to baseline values within 3 to 5 minutes of starting the infusion. However those with LQTS 1 experienced a persistent increase in QTc following epinephrine exposure. This, the authors argued, may have been due to the KCNQ1 gene mutation in LQTS 1 that leads to impaired function of the IKs channel, resulting in a delay in potassium efflux and prolonged ventricular repolarisation. Since the function of the IKs channel is also impaired in hypoxia, QTc prolongation during TE may be the result of a combination of reduced IKs activity and persistent beta-adrenergic stimulation. 









5.2.3	Clinical Implications and Future Studies
-Rate
Success at high altitude relies upon an individual’s ability to adapt to hypoxia. Those who don’t respond tend to develop Acute Mountain Sickness (AMS) and other high altitude illnesses [Hackett and Rennie, 1976]. Whilst AMS is benign and self limiting, it is intensely unpleasant and leads many to abandon any ambitions to ascend further. AMS is rare below 2500m. However rates of between 9 and 34% have been cited at altitudes of up to 3650m [Maggiorini et al, 1990]. AMS tends to be even commoner following a rapid ascent to high altitude. An incidence of 75% has been cited amongst those making a 5 day ascent of Kilimanjaro (5895m) [Karinen et al, 2008]. In recent years there has been a growing effort to find a tool that can accurately predict whether an individual will develop AMS or not. Much of this research has focused upon the use of pulse oximetry [Windsor, 2012]. Since AMS is caused by a period of sustained hypoxia, it follows that a low SpO2 measurement may identify those who subsequently go on to develop this condition. Unfortunately the studies published in this field have been largely inconclusive [Windsor and Rodway, 2014]. Whilst the majority of those who have subsequently developed AMS have been identified by a low SpO2 (high sensitivity), large numbers have been found to have a low SpO2 but have not developed the condition (low specificity). Why this should be the case is unclear. However practical problems with the pulse oximeter have led to inaccurate measurements:

 Take for instance, a trekker sat at Barafu Camp (4600m) on Kilimanjaro. He’s been told by his guide that a SpO2 measurement of less than X% puts him at risk of developing Acute Mountain Sickness (AMS) and therefore means that he’ll be prevented from making  a summit bid. At first he struggles to get any measurement because he’s shivering and his finger tips are too cold. Eventually when he’s warm enough, he notices that the measurements are changing on a second by second basis. Unknown to him, the interplay between arterial PO2 and the sigmoidal shape of the haemoglobin-oxygen dissociation curve means that small differences in ventilation quickly affect SpO2. Indeed, he finds that by hyperventilating for a few seconds his SpO2 hits 90% or more. At the same time he also notices that by making small changes in his hand position the SpO2 measurement alters. The high level of ambient UV light around him is causing interference...
[Windsor and Rodway, 2014]

Since TE has identified an inverse correlation between SpO2 and heart rate, an alternative approach would be to use a change in heart rate as a predictor of AMS. This would have a number of practical advantages to the trekker or mountaineer ascending to high altitude. Firstly, the underlying principle is simple to understand. Secondly, the test is easy to perform. Sophisticated equipment or extensive training is not necessary. Whilst finally, the test is clean, painless and repeatable.  This would allow individuals to obtain a series of measurements and therefore improve the reliability of the test. The link between a heart rate increase and prediction of AMS could be tested in a similar way to those studies conducted with pulse oximetry. A large group of healthy, lowland residents would have their heart rate measured at sea level and following arrival at high altitude. Following further time at altitude, the group would then be divided into those who developed AMS and those who did not. The increase in heart rate would then be compared between each group and the hypothesis accepted if those who developed AMS had a higher increase in heart rate. In order for the test to be clinically useful it would need to have high levels of sensitivity and specificity. Therefore the test would not only need to predict those who developed AMS but also ensure that those individuals who remained healthy were not labelled with the condition. This work could then be undertaken at a number of popular high altitude destinations in order to determine the different heart rate rises that would occur with a range of ascent profiles.

-Rhythm
Ventricular ectopic beats (VEB) at rest are a common electrocardiographic finding. In healthy adults, they appear in 1% of 12 lead ECG’s and 40-75% of 24-48 hour ambulatory ECG monitoring [Ng, 2006]. In healthy hearts their presence is thought to be benign [Kennedy et al, 1985]. Indeed, the CAST study demonstrated that attempts to suppress VEB’s using class Ic drugs increased mortality [CAST Investigators, 1989]. As one author subsequently wrote, “this study further highlights the proarrhythmic effect of these drugs in patients with heart disease and disputes the notion of using drugs simply for the sake of suppressing VEBs” [Ng, 2006].  Therefore any attempt to reduce VEB’s in individuals at sea level or high altitude should be done cautiously. One group who may benefit from a reduction in VEB’s are those individuals predisposed to Idiopathic Ventricular Fibrillation (IVF). IVF is defined as, “ventricular fibrillation in the absence of any identifiable known cardiac and extra-cardiac abnormality responsible for the arrhythmic event” [Tilz et al, 2007]. Unfortunately the condition is common and tends to reoccur.  IVF accounts for between 5 and 10% of out-of-hospital survivors of cardiac arrest and reoccurs in more than 30% within three years [Chugh et al, 2007]. In some individuals IVF can be triggered by VEB’s. In cases of Right Ventricular Outflow Tract (RVOT) tachycardia, exercise and emotional stress can increase the incidence of VEB’s and ventricular tachyarrhythmias. Whilst sudden cardiac death is rare in these individuals, RVOT can sometimes mimic arrhythmogenic right ventricular dysplasia (ARVD). ARVD is a form of right ventricular cardiomyopathy where, “progressive, patchy fibro-fatty infiltration of the right ventricle and subsequent ventricular dilatation provides an ideal arrhythmogenic substrate” [Fontaine et al, 1999]. Ventricular tachyarrhythmias are more common and the prognosis of ARVD is much less favourable [Ng, 2006]. Admittedly, the low incidence of RVOT tachycardia and ARVD means that meaningful study at high altitude is unlikely to be possible. However the identification of high altitude as a potential trigger for life threatening arrhythmias in these conditions means that clinicians and patients can take steps to avoid ascent to altitude or take measures to improve their safety.

-Morphology

















Table 5.10: Cardiovascular conditions associated with QT prolongation. Adapted from Camm et al, 2004
Anorexia Nervosa
Chronic Obstructive Pulmonary Disease
Diabetes Mellitus





















Table 5.12: The ten drugs most commonly associated with the development of PVT between 1983 and 1999. Information was obtained from adverse drug reaction (ADR) forms submitted to the World Health Organisation’s Drug Monitoring Centre [Darpo, 2001].

In recent years evidence has emerged to suggest that the distinction between the two forms of LQTS is blurring. This is largely due to extensive genetic mapping that has identified the presence of genetic mutations in a number of patients who have developed acquired LQTS [Al-Khatib et/al, 2003]. Amongst 92 patients who experienced an episode of drug induced LQTS, between 5 and 10% were subsequently found to have mutations in the three commonest genes encoding cardiac ion channels [Yang et al, 2002]. Despite such a wide range of factors, generating QT prolongation and life threatening episodes of polymorphic ventricular tachycardia (PVT) is not a straightforward task. Cardiac tissue has, “multiple, redundant mechanisms” that ensure normal repolarisation will occur wherever possible [Roden, 2006]. Therefore PVT can only result from the, “culmination of multiple risk factors existing in combination with some degree of genetic predisposition” [Sauer and Newton-Cheh, 2012]. This has been extensively described by Dan Roden, Professor of Experimental Therapeutics at Vanderbilt University, who first used the phrase, “reduced repolarisation reserve” in order to describe the extensive changes needed to develop PVT. According to Roden, PVT is the result of “multiple hits” and requires genetic mutations, predisposing medical conditions and environmental factors to all coincide. It may be that hypoxia, either at sea level or high altitude, may prove to be one of these “hits”. Whilst it would be impractical to test the effect of hypoxia upon all known causes of LQTS, patients with common conditions could be studied. Positive results would have important implications for those experiencing hypoxia following ascent to altitude.
A growing number of visitors to high altitude have pre-existing risk factors for acquired LQTS (Tables 5.10 and 5.11). Of those hikers and skiers ascending to more than 2000m in the Austrian Alps, approximately 12% have reported the existence of at least one cardiovascular disease [Faulhaber et al, 2007]. Whilst the incidence of visitors with other chronic illnesses has not been reported, the combination of easier access to the mountains, improvements in treatment and importantly, the growing desire to lead a full and active life, has meant that the high altitude environment is now experienced by those with a much wider range of medical conditions.  Despite this enthusiasm, there is the potential for a worsening in the pre-existing condition and QTc prolongation at high altitude:

-Weight Loss
Factors such as low weight, low body mass index and rapid weight loss have all been shown to be associated with QTc prolongation [Svenne and Larsson, 1999]. Weight loss in the mountain environment is common and results from a combination of reduced intake, increased energy expenditure and in some cases, changes in absorption [Brooks and Butterfield, 2001]. Typically weight loss is greatest above 5000m. During AMREE, 13 members lost on average 1.9kg during a 23 day trek to Mt Everest Base Camp (5300m).
However, this increased by a further 4kg (range 0-8kg) over the course of 26 days spent higher on the mountain [Boyer and Blume, 1984]. In some cases weight loss can be dramatic.
During CXE, one summiteer reported weight loss of 21kgs! Clearly this degree of weight loss is comparable to those with significant eating disorders and may be associated with QTc prolongation. 

-Drugs
A wide range of drugs can interfere with the action potential of the cardiac myocyte. 
In recent years this has led to the well publicised withdrawal of drugs such as terfenadine, droperidol and cisapride (Table 5.12) [Gupta et al, 2007]. Meanwhile other drugs, including several antipsychotics, antidepressants and antiarrhythmics, have the potential to cause QTc prolongation. Their impact in hypoxia is unknown. Drugs used for acute illnesses may also predispose individuals to acquired LQTS. Bacterial infections are common at high altitude [Rodway and Windsor, 2006]. Quinlones, macrolides and tetracyclines are frequently used.
Those who develop Acute Mountain Sickness (AMS) may be administered antiemetics such as domperidone, whilst sufferers of High Altitude Pulmonary Edema (HAPE) often opt to use nifedipine to either treat or prevent the condition on future ascents to altitude [Luks et al, 2010]. Long acting beta-2 agonists such as salmeterol are also used in the prevention of HAPE. Whilst the effect of this class of drugs upon the QTc interval is unclear, there is some evidence to suggest that in a hypoxic environment prolongation may occur [Bremner et al, 1992].

-Electrolyte Disturbances
Prolongation of the QTc interval has been linked to low concentrations of serum electrolytes such as calcium, magnesium and potassium [Camm et al, 2004]. Changes in the intake and output of these electrolytes can vary significantly in the mountain environment [Hannon et al, 1971]. Episodes of gastroenteritis are common and can cause prolonged episodes of vomiting, diarrhoea and anorexia that can lead to significant losses of fluid and electrolytes. This can be compounded by the limited availability of food and drink. Episodes of Acute Mountain Sickness (AMS) and High Altitude Cerebral Edema (HACE) can cause lethargy, nausea and vomiting, whilst bouts of tonsillitis and pharyngitis may make swallowing difficult. The effect of these conditions upon electrolyte balance may be compounded by concomitant use of diuretics. Despite a paucity of evidence and the concerns of a number of high altitude specialists, diuretics are still commonly used to treat life threatening conditions such as HAPE and HACE [Luks, 2008].

-Hypothermia
A fall in core temperature below 35 degrees C can quickly result in bradycardia, heart block and prolongation of the PR, QRS and QT intervals [Mattu et al, 2002]. A recent case series of four patients who underwent therapeutic hypothermia to 35 degrees C following cardiac arrest were all found to have developed QTc prolongation (>460ms) that only returned to normal following rewarming [Khan et al, 2010].
In isolation these factors are unlikely to have a significant effect upon the QTc interval. However, in combination with a genetic susceptibility and pre-existing medical conditions cases of acquired LQTS may occur. In order to prevent this it is therefore necessary to address a number of issues. Prior to departure, all chronic medical conditions need to be optimised and plans should be made to deal with acute deterioration. 
Acute medical conditions should be treated promptly with medications known to cause minimal changes in QTc. Wherever possible, long term medications known to precipitate LQTS should be identified and alternatives sought. Weight loss, electrolyte disturbance and hypothermia should be identified quickly and avoided wherever possible. Symptoms such as dizziness, syncope, palpitations and seizures in the mountain environment should raise the possibility of LQTS and trigger an appropriate response from physicians. In the event of a suspected episode of PVT at high altitude a number of steps could therefore be taken (Table 5.13). 

Lie patient in supine position
Keep patient warm and comfortable
Administer supplemental oxygen (2-4 l/min)
Encourage patient to eat and drink
Omit drugs that may prolong the QTc
Optimise chronic medical conditions (eg diabetes mellitus, hypertension, hypothyroidism, pain)
Treat precipitating medical conditions (eg AMS, HAPE, HACE, gastroenteritis, pharyngitis, tonsillitis)
Provide reassurance and support
Arrange urgent evacuation

Table 5.13: Proposed treatment of suspected PVT in the high altitude environment.






















5.3	Acute Hypoxia Study (AHS)

5.3.1	Results
The heart rate increased rapidly whilst breathing hypoxic gas mixtures and returns to normal following return of normoxia.
 There was no evidence of rhythm disturbance during short periods of breathing hypoxia gas mixtures. 





The results of CXE and TE support the assertion that a significant and persistent increase in resting heart rate occurs during hypoxic exposure. However the results from AHS do not support this. During different levels of hypoxic exposure and SpO2 measurements, the mean resting heart rate remained largely unchanged.  This finding has been observed in other hypoxic chamber studies where smaller heart rate increases have been shown when compared with field studies using comparable levels of hypoxia. Whilst field studies located at 3100-4350m have demonstrated an increase of between 9 and 31%, results from one of the largest hypobaric chamber studies revealed a 9 to 22% increase at comparable PO2 values [Laciga and Koller, 1976]. Whilst the added physiological challenges of operating at high altitude may go some way to explaining this difference, timing is likely to play an important factor. AHS measurements were obtained within minutes of hypoxic exposure whilst CXE and TE recordings were made after several hours or days at high altitude. The effect of “Hypoxic Ventilatory Decline” (HVD) may form part of the explanation [Smith et al, 2001]. 
HVD describes the reduction in minute ventilation that occurs in healthy humans within minutes of hypoxic exposure [Powell et al, 1998]. Whilst the mechanisms underlying HVD are controversial, it is not thought to be due to changes in PaCO2 or hydrogen ion concentration. Instead, it is believed to be caused by several independent central and peripheral mechanisms that together reduce tidal volume (VT) and minute ventilation (VE) for several hours after hypoxic exposure [Neubauer et al, 1990]. How does this affect resting heart rate? Hypoxia stimulates peripheral chemoreceptors in the carotid body to relay impulses through glossopharyngeal (IX) and vagus (X) nerve fibres [Drinkhill et al, 2014]. Ordinarily, this would cause a bradycardia.  However sympathetic impulses from the respiratory muscles override this and produce the characteristic increase in heart rate seen during hypoxic exposure. During HVD ventilation sharply declines and sympathetic impulses are therefore reduced.  This has the potential to limit the increase in heart rate and in some instances, cause the heart rate to fall. Given that the resting heart rate measurements during AHS were obtained within minutes of hypoxic exposure, the absence of an increase in heart rate may be explained by HVD.
-Morphology
The results of AHS are consistent with several studies that demonstrate prolonged ventricular repolarisation in healthy human adults following exposure to acute hypoxia. The greatest increase in mean QTc (Bazett’s) occurred whilst breathing 12% oxygen. This increase (22.8ms - 5.9%) is consistent with that reported by Roche et al (14.0ms – 3.5%) who studied a similar number of participants breathing 11% oxygen [Roche et al, 2003]. Since the mean SaO2 of AHS participants was found to be 91.7%, these results can be compared to the work of Bremner et/al who identified a 15.6ms increase in mean QTc amongst 8 healthy male participants breathing a hypoxic mixture titrated to a SaO2 of 90% [Bremner et al, 1992]. At 15% and 18% oxygen, increases in mean QTc (Bazett’s) were also observed. However statistically significant differences were not identifed. This is consistent with evidence gathered from “fitness to fly” tests [Skipworth et al, 2010]. Amongst 101 patients with chronic respiratory disease, mean QTc (Bazett’s) only increased by 1.8ms (NS) following the breathing of 15% oxygen. As TE has previously demonstrated, the increase in QTc, calculated using Bazett’s and Fredericia’s formulae, appears to follow a “dose effect” with the greatest increase in QTc being triggered by the most profound levels of hypoxic exposure. This is supported in AHS by a negative correlation between QTc (Bazett’s) and SaO2 (r2=-0.29 P<0.05). 
The effect of hypoxic exposure upon ventricular repolarisation is rapid. In AHS, an increase in QTc, measured by Bazett’s and Fridericia’s formulae, is observed within fifteen minutes of exposure. This is supported by the results of Roche et al and Bremner et al which identified increases over similar periods of time. However the increase in QTc may occur much more rapidly. From Figure 4.8 it can be seen that QTc had already begun to increase within five minutes of hypoxic exposure. QTc appears to resolve at a similar rate. Roche et/al and Bremner et/al found that QTc had resolved during measurements made within 15 to 30 minutes of breathing room air. Earlier measurements were not taken. During AHS a return to baseline values was observed within five minutes and no statistically significant differences were observed after 15 minutes of breathing room air.
Alterations in ion movement can lead to changes in the duration of the AP. Indeed laboratory studies have identified changes in all five phases during hypoxic exposure (Table 5.9). However researchers have concluded that the overall effect of hypoxia is to reduce, rather than prolong, the duration of the AP [Macdonald and Hool, 2008]. Therefore a more nuanced explanation is needed to explain the AHS results. Given the short period of hypoxic exposure and rapid increase in QTc, the factors presented during CXE would not explain the changes seen here. In such a small period of time, ventricular hypertrophy, weight loss and changes in calcium ion availability and transport would not have occurred. Instead, the explanation given for the TE results would make a better fit.  Following a brief period of hypoxic exposure the increase in QTc may be explained by a persistent increase in beta-adrenergic stimulation. The role of beta-adrenergic stimulation in short periods of hypoxia is supported by the results of Roche et/al and Bremner et/al. Using spectral analysis Roche et/al demonstrated enhanced sympathetic and reduced parasympathetic activity during brief episodes of hypoxic exposure. Importantly, these changes coincided with an increase in QTc and resolved rapidly when normoxia was restored [Roche et/al, 2003]. The addition of further beta-adrenergic stimulation has been shown to augment QTc during hypoxic exposure. Under hypoxic conditions the use of inhaled fenoterol 800mcg increased the mean QTc of eight healthy male participants by 27.9ms [Bremner et al, 1992]. However, it is important to note that the effect of beta-adrenergic stimulation upon the QTc interval may be transient [Noda et al, 2002]. In a study of patients with Congenital LQTS, those with LQTS 1 had a persistently elevated QTc following the administration of an adrenaline infusion (0.1mcg/kg/min). However healthy controls and patients with LQTS 2 and 3 experienced a rapid return to baseline values. This would imply that specific differences in LQTS1, such as mutations of the IKs channel, may lead to a persistent rise in QTc following beta-adrenergic stimulation. Since IKs activity is reduced in hypoxia, the effect of beta-adrenergic stimulation may persist and explain the changes seen during CXE, TE and AHS.
The results of this thesis point towards a mechanism that triggers a rapid and persistent rise in QTc following hypoxic exposure. Neither hypoxia nor beta-adrenergic stimulation can do this in isolation. However in combination this may be possible. Future studies using beta-blockade will be able to elucidate the role of beta-adrenergic stimulation in QTc prolongation during hypoxic exposure. 

5.3.3	Clinical Implications and Future Studies
The presence of QTc prolongation during brief episodes of hypoxia exposure has important implications for those with Obstructive Sleep Apnea (OSA) [Gami et al, 2005]. OSA is an increasingly common condition that is characterised by frequent, sometimes prolonged, episodes of hypoxia during sleep. Whilst the use of a screening questionnaire and polysomnography can lead to rapid diagnosis and appropriate treatment, the condition is often left undiagnosed. Patients with OSA have been shown to have a greater frequency of ventricular arrhythmias during sleep than the normal population [Rossi et al, 2013]. Consequently, the incidence of sudden cardiac death between the hours of midnight and 6am is more than 2.5 times greater in OSA patients compared to the general population [Gami et al, 2005]. This has been attributed, in part, to a delay in ventricular repolarisation. In the first study to utilise continuous ECG and polysomnography recordings in OSA, researchers were able to identify considerable variation in QTc throughout the respiratory cycle [Gillis et al, 1991]. The QTc was found to be 423ms during hyperventilation and 482ms at the onset of apnea. This has been subsequently confirmed in a recent study of 41 patients with OSA, where the QTc was found to increase by 21.4ms following the cessation of continuous positive airway pressure (CPAP) treatment [Rossi et al, 2012]. In this study, a correlation between the QTc and urinary noradrenaline concentration was also identified, leading the authors to conclude that, “increased sympathetic nervous system activity may be one of the underlying mechanisms between OSA and the increased dispersion of cardiac repolarisation”.  
CPAP has been shown to be a highly effective means of relieving OSA symptoms and reducing risk factors for cardiovascular disease [Donovan et al, 2015]. However compliance is often limited [Wolkove et al, 2008]. Future studies will need to identify new solutions, both pharmacological and physical, that are well tolerated and offer benefits comparable to CPAP therapy. Testing of these interventions should include extensive cardiovascular monitoring in order to assess the impact these have upon a wide range of endpoints.
The impact of hypoxia upon the QTc interval may also play a significant part in “Dead in Bed Syndrome”. This condition is most commonly seen in young adults with diabetes mellitus and accounts for between 5 and 10% of deaths in this population [Koltin and Daneman, 2008]. Typically, the victim is found, “lying in an undisturbed bed, with no obvious antecedents or abnormal post mortem findings” [Tattersall and Gill, 1991]. The rarity and sporadic nature of these presentations has meant that our understanding of the condition is limited. At present it is unclear whether these individuals have some form of congenital LQTS. However it is widely believed that nocturnal hypoglycaemia has the potential to trigger QTc prolongation and the development of life threatening arrhythmias [Heller, 2002]. Hypoglycaemia may be just one of many “hits” that are needed to trigger “reduced repolarisation reserve” in these patients. Brief episodes of hypoxia triggered during OSA may therefore play a part. 


























-Mean resting heart rate changes following hypoxic exposure.
CXE: The median resting heart rate increased following ascent to Mt Everest Base Camp (EBC) (5300m) (P<0.05). 
TE: The mean resting heart rate of male and female participants increased following ascent to high altitude (P<0.05).
AHS: No significant difference in mean resting heart rate was observed following hypoxic exposure (12 to 18% oxygen).
 
-Mean resting heart rate changes with an increase in hypoxic exposure.
TE: No significant difference in mean resting heart rate was observed following an ascent from Namche Bazaar (3500m) to Gorak Shep (5200m).
AHS: No significant difference in mean resting heart rate was observed following an increase in hypoxic exposure from 18% oxygen to 12% oxygen.

-Mean resting heart rate differs between men and women undergoing hypoxic exposure.
TE: No significant difference in mean resting heart rate was observed between men and women at high altitude.

-Mean resting heart rate changes with prolonged hypoxic exposure.
CXE: No significant difference in mean resting heart rate was observed following a prolonged stay at Mt Everest Base Camp (5300m)

-The incidence of atrial and ventricular ectopics changes with hypoxic exposure.
CXE: No significant difference was observed in the incidence of atrial or ventricular ectopics following ascent to Mt Everest Base Camp (5300m).
TE: No significant difference was observed in the incidence of atrial or ventricular ectopics following ascent to high altitude.
AHS: No significant difference was observed in the incidence of atrial or ventricular ectopics following hypoxic exposure (12 to 18% oxygen).

-The incidence of atrial and ventricular ectopics changes with prolonged hypoxic exposure.
CXE: No significant difference was observed in the incidence of atrial or ventricular ectopics following a prolonged stay at high altitude.

-Electrocardiographic signs of right heart strain are present during hypoxic exposure.
CXE: No significant difference in cardiac axis was observed following ascent to Mt Everest Base Camp (5300m). The sum of P wave amplitudes in II, III and aVF increased at EBC (P<0.05). The T wave amplitude in V1 decreased at EBC (P<0.05). The incidence of right axis deviation and T wave inversion in V1 increased following ascent to high altitude.

-Electrocardiographic signs of right heart strain are present following the return of normoxic exposure. 
CXE: No significant difference in cardiac axis, the sum of P wave amplitudes in II, III and aVF and the T wave amplitude in V1 was observed between London and Kathmandu. Evidence of right axis deviation and T wave inversion in V1 was still present in some CXE participants following descent.

-The corrected QT interval (QTc) changes following hypoxic exposure.
CXE: QTc (Bazett’s and Fridericia’s) increased on arrival at EBC (P<0.05) No significant difference in QTc (Hodges’ and Framingham) was observed.
TE: QTc (Bazett’s and Fridericia’s) increased on ascent to high altitude. No significant difference in QTc (Hodges’ and Framingham) was observed.
AHS: QTc (Bazett’s and Fridericia’s) increased in hypoxia (P<0.05). No significant difference in QTc (Hodges’ and Framingham) was observed.

-The corrected QT interval (QTc) changes following prolonged hypoxic exposure.
CXE: No significant difference was observed in the QTc following a prolonged stay at Mt Everest Base Camp (5300m) 

-The corrected QT interval (QTc) changes with an increase in hypoxic exposure.
TE: QTc (Bazett’s) increased following ascent from Namche Bazaar (3500m) to Gorak Shep (5200m) (P<0.05).
AHS: No significant difference was observed in the QTc following an increase in hypoxic exposure. 

-The corrected QT interval (QTc) is normal following the return of normoxic exposure.
CXE: No significant difference in QTc was observed between London and Kathmandu.
TE: No significant difference in QTc was observed between London and Kathmandu














All dwellers at high altitude are persons of impaired physical and mental powers
[Barcroft, 1925]
High altitude places are amongst the most inhospitable on earth
[Hainsworth et al, 2007]

Historically, field studies were undertaken by small groups of friends or colleagues during brief holidays to high altitude. Baseline and follow up testing were often overlooked. Small budgets for equipment and testing facilities meant that studies were often incomplete and sometimes lacked reliability. Levels of physical health and fitness varied between individuals making the response to high altitude difficult to gauge. More recently, large prospective studies have attempted to address these and other issues, however practical constraints have often led to results being obtained from a series of small groups passing testing facilities at regular intervals. This has sometimes led to variations in ascent profile, environmental conditions and levels of intercurrent illness. Considerable efforts were made to overcome these factors during CXE and TE however a number of limitations still existed:
-Previous electrocardiographic research at high altitude focused their attention upon small groups at a single high altitude location. CXE and TE recruited some of the largest groups previously studied - 16 in CXE and 37 in TE – and tested them over a wide range of altitudes – 75m to 5300m. Whilst the sample sizes and number of testing sites were considerable in terms of high altitude field studies, they were modest in the wider field of scientific experimentation. But as with any research at high altitude, there were practical constraints. Not only were there a small number of participants willing to travel to the Himalayas and be tested, there was also only a handful of sites where studies could be performed en-route to Mt Everest Base Camp. The location also ensured that only a few seconds of data were recorded at any given height.  These may have led to a number of Type II errors. For example, a larger sample may have identified differences in heart rate between men and women. A longer period of testing may have identified significant changes in atrial and ventricular ectopic activity, whilst a greater altitude difference may have revealed noticeable differences in QTc. 
Published data was of limited help in guiding power calculations. Prior field studies showing statistically significant differences were often not available. For instance, the work by Laciga and Koller proved to be the only guide for examining changes in heart rate at altitude [Laciga and Koller, 1975]. Here, the authors were able to identify a difference in mean heart rate in 30 participants following incremental ascents of 1000m. However it was not clear from the manuscript whether this was statistically significant. Similarly, the largest study that reported an increase in ‘‘occasional supraventricular ectopics’’ did not report a statistically significant difference [Akhtar et al, 1979]. Given all these factors, a priori power analysis was not undertaken. Instead, for CXE and TE a large group of volunteers were recruited and as wide a range of altitudes were chosen for testing. The sample size chosen for AHS was consistent with previous research focused upon QTc changes in acute hypoxia. Bremner et al used a sample of eight, whilst Roche et al used a sample of 11. Whilst both obtained statistically significant results, the AHS tested participants over a much wider range of hypoxic mixtures. Whilst 12% oxygen (similar to the 11% used by Roche et al) revealed statistically significant results, these were not seen whilst breathing 15 and 18% oxygen. A larger sample size may have identified small but significant results.   
-Participants in TE and CXE all ascended together. Each shared a common ascent profile that resulted in the same pattern of hypoxic exposure.  The ascent profile complied with guidelines issued by the Wilderness Medical Society (WMS) [Luks et al, 2010]. According to WMS, the risk of developing high altitude illnesses can be minimised if the following guideline is followed, “above an altitude of 3000 m, individuals should not increase their sleeping elevation by more than 500 m per day and should include a rest day (ie, no ascent to a higher sleeping elevation) every 3 to 4 days”. This approach was adopted successfully by both groups and no one descended to low altitude or required medical assistance en-route. All CXE and TE participants completed their studies. However, since the presence of AMS or other medical conditions were not recorded it is unclear whether the changes in rate, rhythm or morphology were influenced by illness rather than hypoxia alone.
-All CXE and TE members undertook a health screening assessment prior to departure. This was conducted by a doctor experienced in high altitude medicine. All participants were found to be in good health. No significant medical problems were identified.  Normal baseline electrocardiography was obtained in London (75m) prior to departure. Follow up was performed on CXE members following descent to Kathmandu (1300m). As a result of this approach, the results obtained from CXE and TE can only apply to young, fit and healthy lowland residents who ascend slowly to high altitude. The effect of different ascent profiles is impossible to predict. Those unacclimatized individuals ascending quicker may show significant differences in their rate, rhythm and morphology compared to those who’ve spent considerably longer at altitude. Many months or years at altitude may lead to the development of a range of compensatory physiological mechanisms. Indeed those who’ve lived for many generations at high altitude may benefit from evolutionary processes that promote a very different ECG response. Only by studying these groups will it be possible to identify potential variations. In addition, it is impossible to draw conclusions about how those with pre-existing medical conditions respond to high altitude exposure. The impact on rate, rhythm and morphology is likely to differ in those with cardiovascular or respiratory disease. Those already predisposed to QT prolongation may or may not respond to hypoxia in a more exaggerated way. Similarly, those taking anti-arrhythmic medications may be conferred some protection. However, only by testing these individuals and the drugs they take, can any conclusions be safely made. Similarly, the effect of common high altitude conditions (AMS, HAPE and HACE) upon electrocardiography was not addressed. Nor was the effect of common drugs such as acetazolamide, dexamethasone or nifedipine used to prevent these conditions. This is particularly important as recent research has revealed widespread use of prescription and non-prescription drugs during ascents to high altitude [Luks et al, 2016].
-All participants were unacclimatized prior to departure. No one had ascended above 3000m in the previous 3 months, nor used any hypoxic devices at low altitude in order to aid acclimatisation. Participants were encouraged to avoid taking any substance that could improve performance at altitude. Supplemental oxygen was not used during CXE until after the final ECG measurements were obtained. The ascent profile was carefully regulated in TE and up to 5300m in CXE. However, once established at Mt Everest Base Camp (5300m) the hypoxic exposure of CXE was impossible to standardise. Indeed, 7 of the 16 CXE participants went on to successfully reach the summit of Mt Everest (8850m). These individuals were clearly exposed to more hypoxia than those who remained at EBC. However hypoxia was just one of many issues that the summiteers had to contend with. Life at the very highest altitudes is unpredictable. Weather conditions fluctuate wildly. Illnesses and injuries can strike at random. Levels of physical activity are difficult to control. Dehydration and weight loss are common. Tents fall down, shelters need to be built and the injured need to be evacuated. All of these can impact upon physiological studies. However all three CXE measurements were obtained prior to the summit bid and no differences were observed between EBC residents and those who went higher. Nevertheless, it must be remembered that field studies undertaken over several weeks or months study the impact of the high altitude environment. The effect of hypoxia alone can only be studied in a laboratory setting. Field work like that conducted on TE and CXE provide a springboard for further studies under controlled conditions. The AHS study is an example of this.
-Measurements were obtained at rest in comfortable conditions either in tea houses (TE) or tents (CXE). During CXE the mean temperature during testing was found to be 21.5 degrees C [Levett et al, 2010]. Participants rested comfortably in the horizontal position for 5 minutes prior to testing. All studies were performed in the horizontal position. ECG electrodes were placed on each occasion by the same operator using standard 12 lead ECG placements. Studies were obtained during “rest days”. This ensured that all participants were present. Not only were they well rested but also adequately nourished and hydrated. This was confirmed by plasma osmolarity measurements obtained during CXE which were no different to those obtained at sea level [Levett et al, 2010]. Due to a number of practical constraints, ECG measurement was not possible during submaximal or maximal exercise. The addition of exercise would have revealed further information about changes in the rate, rhythm and morphology of an individual’s ECG on ascending to high altitude.
-The digital electrocardiography equipment had previously undergone field testing on Cho Oyu (8201m) in 2005. This was necessary since such a digital device had never been used before at high altitude. Prior testing ensured that the device and its software were compatible with the laptops used during CXE and TE. The equipment proved robust. Tolerating extremes of barometric pressure, temperature, ultraviolet light and handling without difficulty. Importantly, the device could be used within seconds of being attached to a laptop. More than 30 ECG’s could be obtained every hour. These were easily labelled and stored on the laptop and a portable hard drive. Whilst the ECG’s from CXE and TE provide a picture of electrical conduction changes within the heart it does not provide accurate information about changes in structure or function. Only by combining ECG with tools such as echocardiography or magnetic resonance imaging would this be possible.
-The morphological results from CXE, TE and AHS demonstrate an association between hypoxic exposure and QTc prolongation. However the clinical impact of these findings is unknown. The ICH E14 document issued jointly by the European Medicines Agency and the Food and Drug Administration sets out guidelines for the, “clinical evaluation of QT/QTc interval prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs” [EMA E14, 2005]. ICH E14 urges researchers to adopt the “thorough QT/QTc study” framework when testing the effect of new drugs upon cardiac repolarization. This is now considered to be the “gold standard” of QT measurement and could be applied in future hypoxic research. The “thorough QT/QTc study” framework involves recruiting a large sample, using a positive control group, applying an appropriate heart rate correction, employing a reader that is skilled in measurement of QT and RR intervals and ensuring an assessment of cardiovascular disease risk is made:
Use of a positive control group - Positive control groups contain individuals who are expected to make a significant response to a stimulus. In a “thorough QT/QTc study” this would include studying those with significant cardiovascular disease, electrolyte disturbances and a family history of Long QT Syndrome [ICH E14, 2005]. Negative findings in these populations are an important step in the process of proving the safety of new drugs. Positive control groups were not studied in CXE, TE or AHS since QTc changes had already been observed in healthy individuals. Nevertheless, positive control groups would have proven useful in the understanding of the underlying pathophysiological process. Testing of individuals with congenital LQTS could help identify the pathway responsible for delayed ventricular repolarisation in hypoxia. A more pronounced QTc amongst those with a KCNQ1 gene mutation would imply that changes in IKs activity are responsible for delayed ventricular repolarisation in hypoxia.
Employing a reader that is skilled in the measurement of the QT and RR interval - Unfortunately, the “thorough QT study” guidelines do not, “identify the specific training that is needed”. Nor do they specify the number of readers required to analyze a study [FDA E14, 2012]. Instead the guidelines only ask for, “assessment of intra- and inter-reader variability and suggests that a, “few skilled readers” be used since a large number would increase variability [FDA E14, 2012]. Importantly, bias should be reduced by blinding the reader to the participant’s name, time of recording and the drug they had been exposed to. For the purpose of ascertaining the accuracy of the digital recording in CXE, TE and AHS it was necessary to perform manual measurements of the QT and RR interval. These were performed by a single reader who’d undergone a short period of training at an ECG laboratory. It was not possible to blind the reader. However, the average of two measurements was used for comparison with the digital recording. Nevertheless, the comparison of the manual and digital measurements could have been improved by the blinding of the reader and an increase in the number of readers used.
Adopting an appropriate heart rate correction - The QT interval varies inversely with the heart rate. To determine whether a drug or pathological process has influenced the QT interval it is necessary to correct for heart rate. The method most commonly used in high altitude and hypoxic chamber studies is that described by Bazett [Bazett, 1920]. This is largely because, 
At normal heart rates, this formula is clinically useful, but begins to underestimate and overestimate the duration of cardiac repolarisation at extreme low and high heart rates, respectively.
[Johnson and Ackerman, 2009] 
Since the mean heart rate measurements during CXE and TE ranged from 59.9 to 82.0 beats per minute, this formula was preferred. However, leading experts argue that if the drug has a significant effect upon the heart, “fixed correction methods commonly lead to both false-positive and false–negative conclusions” [Garnett et al, 2012]. Marek Malik, a leading electrocardiologist at St George’s Hospital, cites the example of beta-blockers and their effect upon the patient’s QTc [Malik, 2002] [Malik, 2008]. While increases were observed when the Fridericia formula was applied, more sophisticated techniques were unable to find any effect upon the QTc. These findings have led ICH E14 to conclude,
In adults, Bazett’s correction has been clearly shown to be an inferior method of correcting for differences in heart rate among and within subjects. Therefore, QT interval data corrected using Bazett’s corrections is no longer warranted in all applications unless there is a compelling reason for a comparison to historical Bazett’s corrected QT data.
										[FDA E14, 2012]
Controversy clearly exists. Whilst the extensive use of Bazett’s formula in previous high altitude justifies its use for comparison with the present studies, it is clear from the guidelines that an alternative correction should be sought. Unfortunately there is no single recommended alternative. However, the guidelines state, “presentation of data with a Fridericia correction is likely to be appropriate in most situations” [FDA E14, 2012]. Therefore this was used during CXE, TE and AHS, together with the Hodges and Framingham corrections that had been previously adopted, albeit rarely, in earlier field and chamber studies. Unfortunately, presenting the results of several correction formulae is problematic. Analysis of the same data using different models for correcting QT clearly generates discordant results. Given the narrow range of heart rates obtained during CXE, TE and AHS it was therefore decided that only the results using Bazett’s formula would be highlighted and the remainder included for the sake of completeness.  
In recent years the increasing use of Holter monitoring has given researchers the opportunity to collect vast quantities of ECG data. Using regression modelling this has led to the development of heart rate correction formulae that are specific to each individual. These often differ significantly from pre-existing correction formulae and have led some to conclude, “for detailed precise studies of the QTc interval the individual QT/RR relation has to be taken into account” [Malik et al, 2002]. Provided sufficient data, across a wide range of heart rates, is collected this could be an important step in improving accuracy of future hypoxic studies.
Use a large sample size - In order to identify a significant effect upon the QT interval a large study sample is required. However the exact numbers are not specified in the “thorough QT study” guidelines. Instead it is recommended that any study should be powered to find a 5ms increase, if present, in the positive controls. The number of 12 lead ECG recordings is dependent upon the elimination half life of the drug and the range of doses that need to be tested. According to the guidelines the mean of at least three ECG’s should be obtained for each time point.  In addition, “mechanisms to deal with potential bias, including use of randomization, appropriate blinding and a concurrent placebo control group”, should also be used [ICH E14, 2005]. Unfortunately, the practical limitations of the high altitude environment meant that only a single ECG measurement was obtained at each data collection. Nor was it possible to randomize participants, blind those involved or recruit placebo groups. Introducing these measures in future studies would clearly improve the robustness of the data.
Ensure further assessment of cardiovascular risk is made - The “thorough QT study” highlights the need for careful interpretation of any increase in QTc. Whilst it is widely accepted that a large increase in QTc is of greater concern than a smaller rise, it does not quantify the risk of life threatening arrhythmias that an individual might be exposed to. The role of other electrocardiographic factors may play a crucial part in this:
Rate: PVT tends to occur at low heart rates [Garnett et al, 2012]. Therefore an increase in QTc may carry a significant risk of PVT at 50 or 60 beats per minute, whilst at 70 or 80 beats per minute the effect might be minimal. The increase in heart rate seen on ascent to altitude may therefore offset the risk of PVT caused by QT prolongation.
Rhythm: In some individuals it is not possible to record a stable sinus rhythm. This may be of particular concern at high altitude where newcomers often experience lengthy periods of sinus arrhythmia during sleep. Fluctuations in heart rate lead to changes in the QT interval. Changes in the RR interval may have little effect on ventricular repolarisation for several minutes - “QT-RR hysteresis”. Since the QT interval adapts more slowly to decelerations than accelerations this can lead to the miscalculation of the QTc and an incorrect assessment of ventricular repolarisation [Goldenberg et al, 2006].
Morphology: Limitations in QT interval measurement have led researchers to look for new ways to identify delays in ventricular repolarisation. Beat-to-beat variability of T wave morphology, including area, symmetry and amplitude, are becoming increasingly used [Goldenberg et al, 2006]. These measurements are not only less dependent on heart rate, but have shown promise in predicting clinical outcomes [Zabel et al, 2000] [Zabel et al, 2002].
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